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Abstract 
 
Oral Squamous Cell Carcinomas and their Genetic Variants in Association with 
Extra Capsular Spread 
Priyanka Bhattacharya 
 
Oral squamous cell carcinoma (OSCC) is the sixth most common cancer worldwide with an 
incidence of ~600,000 cases per year and younger age groups, particularly between 40-69 
years, are increasingly becoming affected. OSCC has an overall five-year survival of only ~30% 
when metastatic disease is present. The most adverse prognostic clinical predictor for OSCC is 
extracapsular spread (ECS) from lymph node metastasis. The molecular determinants of ECS 
are undetermined and their characterization could significantly assist patient management, 
identifying those having increased risk and suggesting new possibilities for therapy. The aim of 
this study was to identify genetic variants associated with ECS. Previous work using aCGH had 
found an unexpectedly low frequency of TP53 alteration in OSCCs from a local cohort enriched 
for cases with ECS. SNP genotyping was therefore used to further investigate allelic imbalance 
of TP53 and for comparison CCND1 in primary tumour samples from the series (n=46; 19 node 
negative [N-], 7 [N+ECS-], 20 [N+ECS-]). CCND1 gain and TP53 loss were found to be 
associated with nodal status but not ECS. Five OSCC primary tumour cell lines (2 N- & 3 
N+ECS+) were then screened by whole genome sequencing for genetic variants that may be 
associated with ECS. Variants were found in a broad range of genes but poor coverage (< 5 
fold mean coverage) from some regions of the genome, in particular NOTCH1, suggested that 
there may have been technical limitations. However, pathway analysis implicated the NOTCH 
pathway may have had significance, consistent with literature reports.  Additional next 
generation sequencing assays targeting NOTCH1 were therefore developed and used to 
analyze the gene in these cell lines. High coverage (150-200 fold mean coverage) of NOTCH1 
sequences were achieved and in one of the ECS+ve cell lines (Liv7K), a rare, potentially 
deleterious nonsynonymous polymorphism (rs61751543) was found. Further screening for 
NOTCH1 and TP53 genetic variants associated with ECS was therefore performed for primary 
tumour samples (n=50; 21[N-], 11 [N+ECS-], 18 [N+ECS-]). Sanger resequencing was used for 
independent confirmation of candidate variants identified. Poorly covered samples (n=10) were 
excluded. 7/40 (17.5%) samples showed NOTCH1 variants, with 6/14 (43%) ECS+ samples 
confirmed to have NOTCH1 variants, compared to 1/26 (3.8%) ECS-, Fisher’s exact test p = 
0.0044. None of these samples displayed variants in TP53. Using this approach, comparing the 
frequency of the variants to node status, we produced evidence for a unique subset of ECS 
positive OSCC cases characterized by having disruption of NOTCH1 and absence of TP53 
alteration. The NOTCH1 variants were clustered within the region for the extracellular domain 
(ECD), suggesting that intercellular communication and response could be disrupted. Further 
functional studies using an ECS +ve primary OSCC cell line as well as invasive and non-
invasive controls, showed invasive cell lines demonstrated decreased cell growth and migration 
in response to Notch inhibition by DAPT (25 µM) treatment, with western blotting revealing 
absence of Notch1 and 3 after week three and Notch4 by week four only in Liv7K. These 
findings suggested the importance of further functional studies to assess the effect of Notch 
inhibition on markers of aggressive phenotype. Taken together our observations overall pave 
the way to future studies exploring the downstream effects of NOTCH1 ECD mutations and their 
potential role in OSCC.  
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1.1    The clinical biology of OSCC 
1.1.1    Epidemiology of OSCC 
 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide with an incidence of ~600,000 cases per year [1] and oral squamous cell 
carcinoma (OSCC) which represents 90% of oral cavity tumours [2] is the most common 
subtype. In 2011, there were 6,767 new cases of oral cancer diagnosed in the UK 
(Cancer Research UK, ‘CancerStats’) with a male-female ratio of 3:1 [3]. OSCC refers 
specifically to squamous cell carcinomas arising in the oral cavity or oropharynx (Figure 
1.) [4]. In Western countries, ~50% of all cases of OSCC affect the tongue (20% - 40%) 
and the floor of the mouth (15% - 20%) [5]. The gingivae, palate, retromolar area and 
the buccal and labial mucosa are less frequently affected [6]. The five year overall 
survival (OS) is ~50% [7] but only ~30% when metastatic disease is present [8]. 
Although the incidence of OSCC increases with age, a recent trend of concern is an 
increasing occurrence in younger age groups, particularly in individuals between aged 
40-69 years [3]. Risk factors include alcohol and tobacco use, see 1.1.2.1 below. Given 
the decreasing tobacco use in western countries, a worldwide increase in alcohol 
consumption or Human Papilloma Virus (HPV) infection are possible reasons for the 
increase [9] and the current epidemiological data indicates an increasing demand for 
research to improve the diagnosis and management of this challenging disease [10]. 
 
1.1.2.1 Lifestyle risk factors for OSCC 
 
The chief risk factors for oral carcinogenesis are genetics, tobacco or alcohol use and 
infections [9]. Smoking is linked to an estimated 65% of oral cancer cases in the UK [3]. 
Betel quid, smokeless tobacco, ionising radiation and certain occupational exposures 
are also associated with oral cancer but are less prevalent in the UK [9]. Alcohol has 
been demonstrated to enhance the permeability of the oral epithelium, acts as a solvent 
for tobacco carcinogens, induces basal-cell proliferation, and generates free radicals 
and acetaldehyde, which have the capacity to cause DNA damage [11]. 
3 
 
 
              
Figure 1. Proportions of HNSCC at various head and neck anatomical sites 
relevant to OSCC. OSCCs are found within the oral cavity (the lips, buccal mucosa, 
alveolar ridge, retromolar trigone, floor of mouth, hard palate and oral tongue) and 
oropharynx (base of tongue, soft palate, tonsillar pillar and fossa). OSCC constitutes the 
most common type of HNSCC. 
(Adapted from Head and Neck Tumours May 01, 2014 | JA Ridge, R Mehra, MN Lango, S Feigenberg 
http://www.cancernetwork .com/ cancer-management/head-and-neck-tumours [Accessed September, 
2015]) 
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Alcohol-associated malnutrition and immune suppression may further promote 
carcinogenesis and it may act synergistically with the products of tobacco metabolism in 
the pathogenesis of oral squamous cell carcinoma with smoking increasing 
acetaldehyde exposure time and levels [12]. 
 
1.1.2.2 Human Papilloma Virus in OSCC 
 
In 1983 Syrjanen et al. first reported human papilloma viruses (HPV) to be associated 
with squamous cell lesions at various sites of the body, including the oral cavity [13]. In 
females, HPV infections account for more than 50% of infection-linked cancers 
worldwide, although in males it is only 5% [14]. Estimates of HPV prevalence in OSCC 
vary according to factors that include geographic population differences, specimen type, 
sample preparation methods, and type of HPV detection method [15]. Overall, there is 
evidence that infection with high-risk human papilloma viruses (HPV), particularly HPV-
16, increases the risk of OSCC especially in the oral tongue and oropharyngeal areas 
[16]. The impact of HPV infection may depend on site of infection. HPV expression was 
associated with a favorable outcome in oropharyngeal cancer (OPC) compared to oral 
cavity cancer (OCC) in a single center population-based study [17]. However, 
interpretation of significance is complex, because extracapsular spread from lymph 
nodes (ECS), a poor prognostic indicator in OSCC [18] (see section 1.3) and, was found 
to have no association on disease specific survival in OPC cases, regardless of HPV 
status but was found to be associated with a worse prognosis in OCC cases [19]. Some 
evidence suggests that HPV is associated with cancer in non-smokers and non-
drinkers, however the degree of oral HPV infection may increase with tobacco and/or 
alcohol use with the reason for this remaining unclear [16]. Overall studies suggest that 
HPV positivity is associated with a better prognosis in HNSCC [20, 21].  
 
1.1.2.3 Genetic risk factors for OSCC 
 
Genetic conditions associated with an increased risk of developing OSCC include Li-
Fraumeni Syndrome, Plummer-Vinson Syndrome, Fanconi Anemia (FA),  dyskeratosis 
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congenita, xeroderma pigmentosum and discoid lupus erythematosus [22]. FA is a rare 
autosomal recessive disorder, first described in 1927, can involve the genes BRCA1, 
BRCA2, FANCD2, and FANCG, which are also frequently affected in sporadic OSCC 
[22]. This suggests that the process leading to early occurrence of oral cancer in FA 
patients follows a similar pathway of carcinogenesis to non-FA sporadic cancer patients 
[23].   
 
The clinical behavior of OSCC varies greatly from patient to patient, site to site and 
sometimes even within individual sub sites [22]. Treatment approaches and outcomes 
may vary significantly among the different sub-sites [24].  
 
1.2 The pathology of OSCC 
 
Pathological stage based on the Tumour (T) Node (N) Metastasis (M) (TNM) staging 
method, is widely used for head and neck cancer. Key pathological factors that are 
correlated with poor prognosis in OSCC are summarised in Table 1, [25]; larger tumours 
and presence of metastasis are strongly associated with poor prognosis [26]. 
The presence and nature of cervical nodal metastasis has long been recognized as 
having strong prognostic significance for OSCC, with increased burden having a strong 
correlation with distant metastasis and overall survival [27]. Factors of key relevance; 
are metastatic status (nodal metastasis present versus absent); laterality of positive 
nodes, number of positive nodes; percentage of positive nodes (ratio of positive nodes: 
total number of assessed nodes); number of positive anatomical levels; highest positive 
anatomical level; size of largest metastatic deposit; presence and extent of spread 
outside the nodal capsule (ECS); soft tissue tumour deposits and pN stage [28]. Primary 
tumour histopathology, poorly differentiated tumours [29] and those displaying evidence 
of perineural [30] or perivascular invasion [31] are all also associated with poor 
prognosis predicting cervical metastasis, locoregional recurrence and distant 
metastasis. Prognostic prediction achieved by histopathology and clinical considerations 
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alone is unsatisfactory with a relatively high level of disease recurrence even following 
first-line treatment [8]. 
 
 
Table 1. Summary of key pathological characteristics correlated with poor 
prognosis in OSCC. (EGFR=Epidermal Growth Factor, MVD=Microvessel Density) 
 
Factor Parameter Poor Prognostic 
Characteristic 
References 
Primary Tumour 
Gross 
Characteristics 
Tumour Dimensions 
 
> 2cm [32] 
Tumour Thickness > 5mm [33] 
Total Tumour Volume > 6mm3 [34] 
Margin Status Positive [34] 
Tumour Site 
 
Floor of mouth, tongue, 
soft palate, retromolar 
area, alveolus 
[35] 
Histopathology Malignancy Grading >10 point score [29] 
Pattern of Invasion 
 
Small clusters of 
scattered, dispersed 
cells 
[29] 
Perineural Invasion Present [30] 
Perivascular Invasion Present [31] 
Cervical Lymph 
Node Metastasis 
Number of Metastatic 
Lymph Nodes 
>2 lymph node +ve [27] 
Node Location 
 
Outside lower neck 
involvement 
[27] 
Node Size >2cm [27] 
Extracapsular Spread Macroscopic > 
Microscopic 
[18] 
Molecular Factors p53 Mutation positive [36] 
 
 
Angiogenesis Related 
Factors 
MVD elevated 
Cyclin D1 Positive in primary 
EGFR and TGF Positive in primary 
Human Papilloma 
Virus 
Absence in primary [37] 
 
1.3 Extracapsular Spread (ECS)  
Extranodal extension termed as extracapsular spread (ECS) is defined as invasive 
cancer showing at least penetration of the nodal capsule or extension through the nodal 
capsule into the peri-nodal adipose tissue [38] (Figure 2.). ECS as a pathological entity 
has been extensively characterized over the last few decades. It has been found to be a 
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poor prognostic characteristic having significance in treatment planning for a number of 
different cancers; gastric [39], oesophageal [40], breast [41], cervical [42] as well as 
HNSCC [43-46].  
The presence of ECS was originally documented in most studies as either present or 
absent, however, recent studies suggest that the extent of ECS, similar to growth of the 
primary growth, may also be a key factor for prognostication [18, 47]. The simplest and 
most widely adopted method of characterizing ECS (and the method adopted locally) is 
classification of ECS as macroscopic, tumour extension out of lymph nodes evident on 
dissection, or microscopic, tumour extension only evident on histological assessment. 
As one would intuitively expect, macroscopic ECS has been demonstrated to carry a 
worse prognostic outcome [18], albeit site dependent  [19]. The best means for 
describing the extent of ECS remains controversial, with gross ECS clearly being more 
straightforward to recognize than microscopic ECS. The potential importance of this 
was highlighted by one study proposing a grading system for ECS [47], (summarized in 
Table 2.). They found that only ECS grade 4 (soft tissue metastasis, tumour mass 
without residual nodal tissue or architecture) was associated with poorer outcomes, but 
not independently of T-stage and other variables suggesting standardisation in ECS 
reporting is required. Nevertheless, the presence and degree of ECS is an established 
prognostic indicator for HNSCC.   
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Figure 2. Representative Histopathology of ECS. Haemotoxylin and eosin stained 
sections of lymph nodes from a neck dissection specimen of a patient with metastatic 
OSCC showing A. a section through a lymph node harboring metastatic deposits of 
OSCC (one outlined in black), abutting but not breaching the nodal capsule (designated 
by *) and thus considered as an ECS-ve node and B. section through a node with 
fronds of metastatic OSCC (outlined in red) breaching the capsule and invading into the 
peri-nodal adipose tissue (outlined in green) considered as ECS+ve. 
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Table 2. Comparison of two different methods of ECS classification. Although 
Microscopic ECS in the Woolgar et al. classification broadly equates to grades 2 & 3 in 
the Lewis et al. classification and Macroscopic ECS broadly equates to grade 4 there 
may be considerable overlap in practice, with the extremes of the spectrum more easily 
definable. (Compiled from Lewis et al., Mod Pathol. (2011) Nov; 24(11): 1413–1420 & Woolgar 
et al.,  Eur Arch Otorhinolaryngol (2013) 270:1581–1592) 
                  
 
 
1.3.1 Significance of ECS for OSCC  
ECS is a reliable and significant poor prognostic indicator for OSCC [18]. The 
association of extracapsular extension with poorer outcomes in head and neck 
squamous cell carcinoma was first recognized in the 1970’s [48] and numerous 
subsequent studies further confirmed this association [45, 49]. Studies show that ECS 
from regional lymph nodes is a feature of the group of patients with the worst prognosis 
[50]. The presence of lymph node metastasis alone, is associated with decreased 
survival of ~50% [51, 52]. Surprisingly, even in the light of a wealth of data supporting 
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this prognostic significance, ECS is not considered as part of routine TNM classification 
and must be documented separately on histopathological reporting [53]. The relative 
importance of extracapsular spread (ECS) versus the number of positive nodes remains 
controversial, with studies finding that ECS, not the number of positive nodes, was an 
independent predictor of poor survival [52]. 
 
A research group based in Liverpool, UK, published a cohort of 561 OSCC cases, 
where Cox regression modeling revealed that the single most predictive marker for 
death was extra-capsular spread from cervical lymph nodes (p<0.001) [18]. In the ECS 
group, overall survival at 5 years was about 24%. The study showed that ECS 
associated with a doubling of the incidence of local recurrence and distant metastases, 
but a tripling of regional relapse, even when surgical margins were generous and 
interestingly relapse was more frequently at the primary site. This suggests that the 
aggressive phenotype is expressed not only in the metastatic cells but also within the 
primary tumour. Overall, the study showed that ECS was associated with a doubling of 
the incidence of local recurrence and distant metastasis and that recurrence occurred 
sooner in ECS than in non-ECS cases (206 vs 334 days, p = .04) [18].  
 
Early-to-moderate-stage OSCC (stages I-III) is most often treated surgically and 
radiotherapy [54, 55]. In advanced (stage IV) disease, multidisciplinary non-surgical 
approaches are being used to improve disease control, prolong survival, and maintain 
an acceptable quality of life for patients [56, 57].  The accurate prediction of ECS, prior 
to surgery, could help to better guide management. ECS is frequently present not only 
in patients with advanced nodal metastasis, but is also detected in a small number of 
patients with early-nodal disease and with a clinically negative neck, making ECS 
prediction more difficult [58]. Imaging techniques such as positron emission tomography 
(PET), computed tomography (CT) and magnetic resonance imaging (MRI) may be 
currently used for this purpose but are often not sufficiently sensitive for pre-treatment 
staging of metastasis and ECS [59]. 
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Poor prognostic molecular factors are increasingly being defined in OSCC. For 
instance, a recent multivariate analysis revealed patients with TP53 mutations were 2.4 
times more likely to have loco-regional recurrence evidenced by positive cervical lymph 
nodes being present [36]. Use of such factors could further refine the usefulness of 
histopathological classifications. 
 
1.4 Aggressive molecular markers of OSCC 
Molecular biology advances are providing a wealth of information on genetic 
abnormalities associated with cancer and often aggressive clinical characteristics can 
be predicted on their basis [60]. Adapting the National Cancer Institute definition of a 
biomarker, a biomarker of aggressive phenotype in OSCC would be a biological 
molecule found in blood, other body fluids, or tissues associated with OSCC carrying a 
poor prognosis [61]. Genetic biomarkers in OSCC could either be inherited or somatic 
and identified as mutations in DNA derived from OSCC tumour tissue [62]. Genomic 
instability is an enabling characteristic that is associated with the acquisition of hallmark 
capabilities of oncogenesis. Beroukhim et al., assessed copy number alterations across 
3131 cancer specimens from 26 different cancer types. 158 regions identified were 
significantly amplified in different cancer types and these SCNAs were found to be 
associated with several cancers [63]. Gene rearrangements also have been shown to 
have the ability to trigger a subset of mutational events that result in inactivation of 
tumour suppressor genes [64-66]. The development of aggressive markers of disease 
first requires recognition of an oncogenic genotype, but later stage events are expected 
to drive aggressive behavior. 
1.4.1 The development of an oncogenic phenotype  
 
Current understanding of cancer indicates that a single genetic change is rarely 
responsible for developing malignant tumours, but sequential alterations in several 
genes leads to cancer [67].  This concept was first developed by Fearon and 
Vogelstein, who demonstrated that colorectal cancer cells specific types of genetic 
alterations occur in order of the development of morphological changes from normal to 
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benign tumour (adenoma) through to a malignant tumour or carcinoma [68].  It has been 
suggested that 3-10 genetic events are involved in common adult malignancies in 
humans and indeed mathematical modeling based on age specific tumours suggests 
that 3-7 independent hits are required for tumour formation [69]. The multistep process 
of carcinogenesis reflects a series of genetic alterations that are responsible for the 
transformation to a malignant cell and this concept can be used to better understand the 
specific genetic events responsible for the development of OSCC.   
 
1.4.2 Late genetic events in OSCC development 
 
Loss of heterozygosity (LOH) of chromosomal region 17p and mutation of the TP53 
gene are two key genetic alterations that occur in the later stage of progression from 
dysplasia to invasive squamous carcinoma that may accelerate the rate of genetic 
alterations in oral carcinogenesis. Amplification of 11q13 has been found in 40% of 
cases of oral squamous dysplasia cases [70]. In general, loss of chromosomal material 
at 9p, 3p, and 17p is observed in relatively high proportions of dysplastic lesions 
whereas losses at 13q and 18q are observed more frequently in carcinomas than in 
dysplasia and they are also associated with later stages of carcinogenesis [71].  
1.4.2.1 TP53 and aggressive OSCC phenotypes 
 
The prevalence of mutations in HNSCC varies between 30% -70% depending on the 
type of tumour material, and heterogeneity of tumour sites examined. Most of the 
mutations are found in the conserved regions of TP53 exons 5–8 [72-76]. However, 
some studies have demonstrated that 20% of all TP53 gene mutations occur outside 
exons 5–8 in HNSCC. The pattern of mutations outside and inside exons 5–8 also 
differed. Within exons 5–8 region, the gene alterations were mainly missense mutations, 
however outside exon 5–8 region, the majority of changes were deletions, insertions, or 
nonsense changes [74].  
TP53 has 11 exons, the first is noncoding, and tp53 consists of 393 amino acids divided 
into 4 main regions [77]. The protein contains a critical DNA-binding domain central 
region, a C-terminal domain tetramerisation region, and finally the N-terminal domain 
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harboring a transactivation region [78]. Disruptive TP53 mutations that lead to loss of 
function preferentially affect the DNA-binding domain of the protein (exons 5 to 8) [79]. 
Agrawal et al. found greater than 63% of TP53 mutations to be missense, with the 
remainder predicted to be inactivating (16% insertion or deletion [indel], 16% nonsense, 
8% splice site mutations). Similarly, Stransky et al. reported 50% of TP53 mutations as 
missense, the remainder of which were various predicted inactivating mutations. Some 
studies have demonstrated an association of TP53 mutations with aggressive HNSCC 
behaviour. A multicentre trial analysing 420 patients using a TP53 hybridisation chip 
approach, analysing all known TP53 mutations, showed a decrease in survival by more 
than 1.5-fold in HNSCC patients in the presence of TP53 disrupting mutations [80]. The 
mutation status of TP53 has also been associated with poor response to cisplatin and 
fluorouracil in patients with HNSCC [75]. A prospective trial analysing 106 patients 
showed TP53 mutation status to be an independent predictor of response to fluorouracil 
and cisplatin, with a nonresponse risk 2.7-fold higher than patients with wild-type TP53 
[75]. TP53 mutations are strongly associated with loco regional recurrence following 
primary radiotherapy [81] and in some studies predict loco regional failure in patients 
receiving radiotherapy as adjuvant therapy following surgical resection [82].  
With specific relation to poor OSCC outcome, ultra-deep (>1000×) sequencing of 345 
samples detected that TP53 was the most frequently mutated gene [83] with other 
studies reporting up to 50% of OSCC cases carrying a TP53 mutation [84]. A Dutch 
study revealed 14/31 OSCC samples tested harboured TP53 mutations with five 
missense mutations and nine resulting in a truncated protein. [85]. In a series of 
Taiwanese patients, TP53 mutations were observed in 32.91% of cases and were 
significantly correlated with an advanced form of OSCC leading to poor survival [86], 
whereas in a Mexican cohort of 112 OSCC cases the mutation rate was observed at 
47.3% with a greater frequency of mutation observed with worsening grade [87]. These 
results are further supported by the frequent detection of TP53 mutation in human 
OSCC cell lines [88] as well as experiments using in vitro RNA interference. Irimie et al. 
reported that by inhibiting the expression of mutant p53 they observed a decreased 
proliferation and induction of apoptosis/autophagy in SSC-4 cells. Furthermore, they 
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observed decreased migration and an accompanying decrease in the expression of 
VEGF [89]. Evidence regarding TP53 variants in association with ECS is limited. 
1.4.3 Molecular Characterization of ECS 
 
Researchers have started to molecularly characterize ECS with a recent study profiling 
the DNA methylome in a cohort of OSCC cases local to Liverpool. Differential gene 
methylation levels distinguished OSCC tumour samples from control matched cases 
with putative methylation signatures for ECS and recurrence identified. The data also 
supported the concept of concordant methylation or CpG island methylator phenotype 
(CIMP) in OSCC with an association between 'CIMP-high' and worse prognosis [90]. 
Another study on 127 OSCC patients showed that EGFR copy number aberrations 
significantly associated with ECS [58]. Summarizing our present understanding a 
genetic progression model of multistep oral carcinogenesis is summarized in the Figure 
3. Although some understanding exists already with regard to the multistep process of 
OSCC development, genetic mutations related to aggressive phenotype/ECS are not 
yet fully understood. Evidently, the observations mentioned above indicate that a better 
understanding of the genetic mechanisms of ECS and pretreatment molecular 
classification would be of great help to allow more effective, targeted and potentially 
personalized therapeutic approaches. 
 
1.4.4 The role of cellular diversity   
 
The invasive growth and metastasis ability of cancer cells also depends upon the 
crosstalk between cancer cells and cells of the neoplastic stroma. The stroma of the 
primary tumour provides circulating cancer cells arising from metastatic lesions with a 
favourable site for reseeding and colonization [91]. Traditionally, the cancer cells within 
tumours have been portrayed as reasonably homogeneous cell populations, which can 
initiate tumours and drive tumour progression as a consequence of the oncogenic and 
tumour suppressor mutations that define cancer as a genetic disease. In recent years, 
intratumour heterogeneity and the existence of cancer stem cells (CSCs) has added 
further complexity [92]. Many human tumours are histopathologically diverse, which 
15 
 
reflects clonal heterogeneity. Different regions are demarcated by various degrees of 
differentiation, proliferation, vascularity, inflammation and/or invasiveness. Once primary 
tumours have formed, the CSCs have the capability to self-renew and form the great 
bulk of many tumours [93, 94]. The discovery of CSCs in tumours indicates that a single 
and genetically homogeneous population of cells within a tumour may nevertheless be 
phenotypically heterogeneous due to the presence of cells in distinct states of 
differentiation. With the recent major advances in DNA (and RNA) sequencing 
technology, this is supported by in-depth sequence analysis of tumour cell genomes 
microdissected from different sectors of the same tumour, which has revealed a striking 
intratumoural genetic heterogeneity [95]. 
 
  
Figure 3. Genetic progression model of multistep oral carcinogenesis. 
Transformation of normal epithelium by multiple genetic alterations leads to dyplasia 
and subsequently invasive carcinoma. The key genetic alterations leading to genes 
influencing ECS are yet to be fully determined (highlighted by the red boxes). The final 
image is a haematoxylin and eosin stained cervical lymph node with the arrow indicating 
a capsular breach required for the identification of ECS.(Modified from J dent Res; 2008; 
87;14) 
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1.5 Genomics applied to OSCC 
 
Combining the observations from these studies with previous genomic and functional 
analyses of HNSCC, it is evident that HPV positive and HPV negative HNSCC have 
distinct mutation profiles with key differences, summarized in Table 3. Lack of TP53 
mutations in HPV positive HNSCCs and the loss of CDKN2A/B in HPV negative 
HNSCC are the greatest differentiators [96]. There are a relatively small number of 
oncogenes (PIK3CA was the most frequently mutated oncogene among HPV positive 
patients) affected by activating mutations supporting the role of tumour suppressor 
pathways including p53, Rb/INK4/ARF, and Notch in disease pathogenesis and 
progression [96]. These pathways have roles in key processes like cellular proliferation, 
squamous epithelial differentiation, cell survival, and invasion/metastasis, all of which 
are central to the pathogenesis of HNSCC. Very few large-scale sequencing studies 
investigating mutational profiles of OSCC cases have been performed. One study 
published recently using 345 formalin-fixed paraffin-embedded (FFPE) samples 
obtained from pN+ OSCC patients with advanced stage (mainly stage III/IV) for 
sequencing of the mutational hotspots of 45 cancer-related genes, identified 1269 non-
synonymous mutations in 276 OSCC samples. In their analysis-TP53, PIK3CA, 
CDKN2A, HRAS and BRAF were the most frequently mutated genes [83]. However, 
sub-group analyses examining profiles specifically for oral squamous cell carcinoma 
cases with or without ECS was not performed. 
OSCC genetic profile variation may reflect site-specific impact of various casual agents 
and differences in clinical presentation. For example, tobacco smoke carcinogens, 
increase the prevalence and spectrum of TP53 mutation [97]. Carcinomas in patients 
who have never smoked harbour fewer p53 mutations, typically arise from the tongue, 
more commonly involve women and affect very young or old patients [98]. An important 
causative agent for oropharynx carcinomas is oncogenic human papillomavirus (HPV), 
with more than 50% harbouring integrated HPV DNA [99]. Mechanistically, the E6 and 
E7 viral oncoproteins bind and inactivate TP53 and retinoblastoma gene products 
respectively [100]. These HPV positive oropharyngeal tumours compose a distinct 
pathological entity with its own clinical spectrum and basaloid morphology [99], 
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illustrating the emerging role of genetic characterization as a potential means of 
determining prognosis and influencing management. 
 
Table 3. Comparison of common genomic pathway alterations and specific 
genomic alterations by functional category in HPV-negative versus HPV-positive 
HNSCC.  
(Adapted from Hammerman et al. Cancer Discov. 2015 March; 5(3): 239–244.) 
Genetic Pathways 
and Alterations 
HPV− HPV+ 
RTK Amplification >20% with ERBB family, FGFR, 
INS1R 
Rare 
RTK 
mutations/fusions 
Rare FGFR2/3 mutations in >10%, 
FGFR3-TACC3 fusions 
H/K/NRAS, NF1 5–10%, HRAS may be most 
common 
5–10%, NF1 loss may be more 
common 
PIK3CA 
amplification/mutation 
Common ~30% Very common >50% 
TP53 Genomic loss in nearly all cases HPV-driven loss 
Cell cycle 
deregulation 
Loss of CDKN2A/RB1 by 
multiple mechanisms in nearly 
all cases, CCND1/CDK4/CDK6 
amplification common (30%) 
HPV-driven CDKN2A loss, E2F1 
amplification (20%) 
Oxidative Stress 
Regulation 
Common activation of 
NRF2/KEAP1/CUL3 (25%) 
Rare 
Differentiation Common loss of 
NOTCH1/FAT1/AJUBA, TP63 
gain 
NOTCH1 loss less common, 
TP63 gain more common 
Immune evasion Uncommon HLA mutations, 
<10% 
HLA, B2M mutations & TRAF3 
loss 
 
 
HPV-negative HNSCCs are molecularly diverse, as suggested by expression profiling 
that demonstrates diverse biologic subclasses within HPV-negative disease. These 
studies demonstrate “atypical” HNSCCs constituting 20% of HPV-negative cases and 
the vast majority of HPV-positive HNSCCs and demonstrate lack of EGFR amplification 
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and/or overexpression [101, 102]. An intriguing mutational pattern directly relevant to 
this study was identified by The Cancer Genome Atlas Cancer Network in a subset of 
HPV-negative OSCCs having few to no copy number alterations and statistically 
significant enrichment for HRAS, CASP8 and PIK3CA mutations and lack of TP53 
mutation [21]. 
 
1.5.1 The impact of genomics on treatment strategies 
 
To date, treatment approaches for HNSCC have been dictated by the anatomic site of 
the primary tumour with oral cavity cancers treated primarily with surgical resection and 
pharyngeal and laryngeal tumours with chemoradiation [5]. Although targeted drugs like 
epidermal growth factor receptor (EGFR)-specific antibody, cetuximab, combined with 
radiotherapy are in use, the survival rate has not markedly improved in recent decades 
because of frequent locoregional recurrences, distant metastases and secondary 
tumours. Cetuximab remains the only targeted agent approved for HNSCC in present 
clinical use [96]. The development of targeted therapeutics for HNSCCs has relatively 
slow, due in part to the lack of therapeutic biomarkers and incomplete understanding of 
their genomic landscape. Furthermore, the wide-scale sequencing studies outlined 
previously have revealed predominant changes in tumour suppressor genes without 
numerous oncogene targets. 
If other potential targets for HNSCC are considered, FGFRs, the PI3K/AKT Pathway, 
Cyclin Dependent Kinases and STAT3 are candidates.  FGFR1 amplifications are found 
in HPV-negative patients at a rate of approximately 10% and appear to be enriched in 
non-oropharynx tumours. FGFR2 and FGFR3 mutations and FGFR3-TACC3 fusions 
are of particular interest because they are associated with significant responses to 
FGFR TKIs in pre-clinical models and in early phase clinical settings, including a case 
report of a major response to pazopanib in a patient with a FGFR2 mutated tongue 
cancer [103]. PIK3CA is commonly amplified and/or mutated in patients with HNSCCs 
(37% of cases in TCGA), and PIK3CA alterations are enriched in HPV-positive patients. 
More than 50% of patients with HNSCC have activating somatic alterations in the 
PI3K/AKT/mTOR pathway, stimulating initiatives to develop targeted, small molecule 
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inhibitors. Up to 32% of HNSCCs display an amplification or mutation of CCDN1, CDK4 
or CDK6 with the majority of these alternations found in HPV-negative patients [21]. 
CDK4/6 inhibitors may therefore be effective in-patient cohorts with high rates of 
CCND1 amplification as evidenced by ongoing clinical trials in other cancers and these 
agents are well-tolerated as both single agents and in combination with other therapies 
[96]. Finally, HNSCCs frequently display hyperactivation of STAT3 via a variety of 
mechanisms and STAT3 pathway inhibitors are currently being explored in both pre-
clinical models and in early phase clinical trials. 
 
In summary, the limited information about molecular carcinogenesis of HNSCC as well 
as the genetic and biological heterogeneity of the disease has hampered the 
development of new therapeutic strategies. Further understanding of the specific 
molecular carcinogenesis of OSCC, harboring some distinct genomic characteristics 
when compared to other HNSCCs, will hopefully will lead to novel therapies having 
improved outcomes for every individual patient [104], especially those with the 
aggressive phenotype of ECS.  
 
 
1.6 Summary and study objective 
 
Recent significant broad next generation sequencing studies as well as numerous more 
targeted specific genetic studies suggest that OSCC requiring mutations in a number of 
key genes to develop is no different to other cancers. However, there appear to be 
differences in the spectrum of genes that are involved. Although the key molecular 
determinants of OSCC are becoming more defined our understanding of the molecular 
drivers of aggressive disease, particularly as evidenced by ECS, remains limited.  
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1.7 Overall hypothesis  
 
Significant genetic changes in key genes or gene families drive extracapsular spread of 
OSCC. 
 
1.8 Overall Aim 
 
The overall aim of this study is to elucidate the molecular determinants of OSCC 
associated with ECS. 
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Chapter 2 : Materials and 
Methods 
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2.1 Reagents 
All molecular biology kits and chemicals used in this study are listed along with the 
manufacturer and catalogue number in Appendix A. 
2.2 Clinical series 
OSCC HPV-ve primary tumour samples (n=50) ranging from T1 to T4 stage, with no 
nodal involvement, positive nodes or positive nodes plus ECS were selected from 
Liverpool head and neck tissue bank. The clinical features of the OSCC samples used 
in this study are listed in the table 4. 
 
2.3 ECACC Human Random Control (HRC) DNA 
Control DNA used in this study was obtained from Human Random Control Panel 1 
(HRC1) from Sigma-Aldrich. The purified HRC DNA consists of DNA from 96 random 
individuals with a concentration of 100 ng/μl where the DNA is dissolved in 10mM Tris 
(pH8) and 1mM EDTA.  
2.4 Macromolecule purification from tissues 
 
DNA, RNA and protein were all rapidly isolated from pre-weighed, fresh frozen tissues, 
each sample for all three macromolecules using the AllPrep DNA/RNA/Protein Mini Kit 
(Qiagen, catalogue no: 80004).  Purification was performed according to the 
manufacturer’s protocol. 
 
Table 4. OSCC case series clinical data. (TNM staging, tumour site and survival data)  
FOM = Floor of Mouth 
Patient 
Number 
Pathological Stage T stage ECS Nodal 
status 
Site Death Date of death 
3483 pT2N1M0 2 No pN+ ant pillar fauces no N/A 
3402 pT4N0M0 4 No pN0 FOM no N/A 
3395 pT2N0Mx 2 No pN0 FOM no N/A 
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3385 pT4N0 4 No pN0 retromolar yes 18/10/2009 
3233 pT2N2cM0 2 ECS pN+ FOM yes 08/04/2008 
3465 pT2N2bM0 2 No pN+ tongue no N/A 
3455 pT3N1M0 3 ECS pN+ tongue yes 29/09/2009 
3499 pT4N2cM0 4 ECS pN+ lower alveolus yes 01/04/2010 
3495 pT2N1Mx 2 No pN+ tongue no N/A 
3481 pT2N1Mx 2 No pN+ soft palate no N/A 
3484 pT3N2bM0 3 ECS pN+ tongue yes 02/12/2009 
3270 pT2N2bM0 2 ECS pN+ retromolar yes 08/06/2009 
3286 pT2N2b 2 ECS pN+ FOM yes 21/07/2008 
3230 pT2N1Mx 2 ECS pN+ tongue yes 06/07/2006 
3241 pT2N2bMx 2 ECS pN+ FOM no N/A 
3248 pT2N2bM0 2 ECS pN+ FOM no N/A 
3167 T2N2Mx 2 ECS pN+ FOM yes 24/10/2005 
3366 pT2N2bMx 2 ECS pN+ tongue yes 12/10/2008 
3345 pT2N2cMx 2 ECS pN+ tongue yes 31/12/2007 
3240 pT3N0M0 3 No pN0 max sinus yes 16/12/2006 
3313 pT4aN0Mx 4a No pN0 FOM no N/A 
3261 pT4aN0M0 4a No pN0 mandible no N/A 
3238 pT4N0M0 4 No pN0 mandible no N/A 
3318 pT3N0M0 3 No pN0 tongue no N/A 
       3291 pT2N0M0 2 No pN0 base of tongue    no N/A 
       3258 pT2N0M0 2 No pN0 FOM yes 29/06/2007 
       3383 pT1N0Mx 1 No pN0 supraglottis no N/A 
3251 pT4N1M0 4 ECS pN+ tongue yes 21/07/2006 
3272 pT1N0Mx 1 No pN0 FOM no N/A 
3276 pT2N0Mx 2 No pN0 FOM no N/A 
3288 pT1N0Mx 1 No pN0 tongue no N/A 
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Patient 
Number 
Pathological Stage T stage ECS Nodal 
status 
Site Death Date of death 
3315 pT2N0Mx 2 No pN0 FOM no N/A 
3236 pT2N0Mx 2 No pN0 mandible no N/A 
3242 pT4aN0Mx 4a No pN0 lower alveolus yes 24/12/2007 
3340 pT2N0M0 2 No pN0 tongue no N/A 
3274 pT2N1Mx 2 No pN+ tongue No N/A 
3254 pT2N2cMx 2 No pN+ FOM Yes 22/10/2007 
3277 pT2N2bM0 2 No pN+ ant pillar fauces No N/A 
3289 pT2N1Mx 2 ECS pN+ FOM Yes 15/01/2010 
3237 pT4aN2aMx 4a ECS pN+ mandible Yes 19/10/2007 
3444 pT2N2cMx 2 ECS pN+ tongue No N/A 
3300 pT1N1M0 1 No pN+ tongue No N/A 
3302 pT2N2bM0 2 No pN+ FOM No N/A 
3533 pT2N2bM0 2 ECS pN+ retromolar No N/A 
3301 pT4N0Mx 4 No pN0 maxillary 
alveolus 
No N/A 
3463 pT2N1Mx 2 ECS pN+ tongue/FOM No N/A 
3354 pT2N1Mx 2 No pN+ tongue No N/A 
3461 pT4N2cM0 4 ECS pN+ FOM No N/A 
3464 pT2N2bMx 2 ECS pN+ tongue No N/A 
3480 pT3N2bM0 3 ECS pN+ tongue No N/A 
2.5 DNA analysis 
2.5.1   SNP Genotyping assays  
 
Quantitative PCR (q-PCR) using minor groove binders (MGB) Probes (TaqMan® SNP 
Genotyping Assays ABI, USA) were used for Quantitative PCR (Q-PCR/q-PCR) to 
make allele calls [105]. SNPs from the National Centre for Biotechnology Information 
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(NCBI) dbSNP database were selected on the basis of high level of heterozygosity in 
the European population and are listed in Table 5. 
Table 5. SNP Genotyping assays with their SNP-ID.  
Gene SNP ID 
Level of heterozygocity in 
European population Assay number 
TP53 RS1614984 40% C_8727721_10 
TP53 RS1642785 30% C_2880090_10 
TP53 RS2909430 22% C_26603915_10 
TP53 RS12951053 16% C_2880088_10 
TP53 RS1042522 30% C_2403545_10 
Cyclin D1 RS3212891 43% C_25800715_10 
Cyclin D1 RS649392 43% C_744724_10 
Cyclin D1 RS678653 43% C_744721_10 
 
Reactions were performed in an iCycler thermal cycler (Bio-Rad Laboratories) and 
analysed using the iCycler iQ real time PCR detection system and software 
(version3.0). Samples were diluted to 10ng/µl and 2µl used with 0.5µL probe mix + 4µl 
RT-PCR mix (Taqman assay universal PCR mastermix Amplitaq (R) Gold DNA 
polymerase (Biorad, catalogue number 4304437) + 3.5µL DNase-free, sterile-filtered 
water. Thermal cycling was performed at 95 0C for 3 min for heat activation of the 
enzyme, followed by 50 cycles of 92 0C for 15 sec for denaturation and 60 0C for 1 min 
30 sec for annealing /extension. 
The ∆∆Ct method (input allele1 amount / allele2 amount against those for output allele1 
amount / allele2 amount) was used for allele calls.  
 
2.5.2 Size estimation of DNA 
 
Agarose Gel Electrophoresis: 
1.2% or 0.8% agarose gels according to the expected size of the DNA to be analysed 
were made by combining 1.2g or 0.8g agarose (Fisher scientific, Catalogue number 
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BMA 50002) and 100 ml of 1X TAE buffer. The gel was stained with SYBRsafe 
(Invitrogen, Catalogue no. S33102) at a final concentration of 500ng/ml. Samples were 
loaded with 1 volume of loading dye (containing 3 marker dyes, bromophenol blue, 
xylene cyanol, and orange G) and 5 volumes of each sample and electrophoresis 
performed at 100 volts for 30-60 minutes compared to size markers comprising1kb 
(NEB-catalogue no: N3232S) and 100 base pair (bp) (NEB-Catalogue no: N3231S) 
ladders. Gels were imaged using Typhoon 9400 (Amersham Biosciences) and analysed 
by Image Quant (Molecular Dynamics). 
Agilent Bioanalyser Analysis: 
A DNA 1000 kit (Agilent, catalogue no:50671504) was used for size estimation of DNA 
according to the manufacturer’s instructions. A DNA chip was placed on the chip 
priming station where 9.0 μl of the gel-dye mix were added at the bottom of the well-
marked chip and primed the chip with gel-dye mix. 5 μl of DNA marker was added into 
each well and then 1 μl of DNA ladder and samples loaded into the wells. 1 μl of 
deionized water was added to unused wells. The chip was vortexed for 60 seconds at 
2400 rpm and then the chip was inserted into the Agilent 2100 Bioanalyzer. Agilent 
software was then used for fragment size and library quantification visualized as an 
electrophoregram.  
 
2.6 OSCC cell culture 
2.6.1 Primary OSCC cell culture  
 
Primary OSCC cells were cultured using 10ml medium [90% Dulbecco’s Modified 
Eagle's Medium (Sigma Aldrich, Catalogue no. D5796) + 10% Fetal bovine serum 
(FBS) [pre-warmed to 37°C] per 75cm² flask. The cells were maintained at 37°C with 
5% CO2.  The medium was changed twice a week.  
When sufficient growth occurred (~ 80% confluent), then the cells were released from 
plates by trypsinisation (TrypLE Express,GIBCO, Catalogue no 12406-013). Trypsinised 
cells were harvested by centrifugation at 1200 rpm for 5 minutes. After removal of the 
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supernatant, cells were washed with 6 ml of DMEM medium was added for replating 
and divided between two 75cm² flask. A further 15 ml each of DMEM medium was 
added.  
For storage, cell freezing medium (Sigma- catalogue no. C6295) was added, the cells 
were snap frozen in liquid nitrogen and then and kept at -80°C. 
 
2.6.2 Secondary OSCC cell culture  
 
Secondary cell lines used for this study were: BHY from DSMZ (Braunschweig, 
Germany, Catalogue no: ACC 404), H357 from UK, (Catalogue no: 06092004). These 
cells were cultured in 25cm² flasks using the same medium and conditions as primary 
cell lines. 
  
2.6.3 Cell line authentication 
 
Mycoplasma testing and single tandem repeat (STR) profiling were carried out every 
month to ensure absence of cross-contamination in all cell lines used in the study by 
another fellow lab member who was responsible for maintaining the cell lines. STR 
profiling was performed using the GenePrint 10 system (Promega Catalogue no. 
B9510) and 10 ng of DNA from each cell line used for amplification.  After mixing the 
amplified product with internal lane standard 600 allele ladder, analysis was performed 
by 3130 Genetic Analyzer (Life Technologies) using GeneMapper ID-X software. 
Mycoplasma testing was carried out using e-MycoTM plus Mycoplasma PCR Detection 
Kit (Intron Biotechnology Catalogue no. 17341). 
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2.6.4 Gamma secretase inhibition in OSCC cell lines 
 
DAPT (N-[N-(3,5-difluorophenacetyl)- L-alanyl]-S-phenylglycine t-butyl ester) (Sigma-
Aldrich- Catalogue no: D5942) was used as a gamma secretase inhibitor to investigate 
the effect of the Notch pathway inhibition in different OSCC cell lines especially in 
relation to their invasive properties. 2.7 mg DAPT was dissolved in 250 µl DMSO 
dimethyl sulfoxide (DMSO, Sigma Catalogue no. D2650) and then added to 50 ml of 
media to give a 125 µM Stock solution. Half of the 25cm² flasks were then treated with 
1ml of the DAPT media with 4 ml DMEM normal media to make a final concentration of 
25 µM DAPT and half of the 25cm² flasks were treated with 5 ml standard DMEM 
media. 
 
2.7 DNA Sequencing analysis 
2.7.1 Primer design 
 
Primers were designed Primer3 Input (version 0.4.0), and were purchased from 
Eurogentec (Southampton, UK). The primer sequences and the sizes of the amplified 
products are shown in the Table 6, to 8. 
Table 6. Forward (F) and reverse (R) primer sequences for long range PCR to 
cover all the exon regions for TP53 and NOTCH1 genes. 
 
Gene Exon Sequence PCR product length 
TP53 TP53 _EX_1F GTTTCCATGTACTGAAAGCAA 690 base pair 
  TP53 _EX_1R AAATACACGGAGCCGAGA   
  TP53_EX_2F CTTCTCTGCAGGCCCAGGT 4290 base pair 
  TP53 _EX_9R TGTCTTTGAGGCATCACTGC   
  TP53 _EX_10F CTCCCCCTCCTCTGTTGCTG 3500 base pair  
  TP53 _EX11_R GGAGGCTGTCAGTGGGGAAC   
NOTCH1 NOTCH1_EX1_F CCAGCCGGGGAAGAGAGG 2002 base pair  
  NOTCH1_EX2_R CCCTCGACAAAGCAACAGGT   
  NOTCH1_EX3_F  ACTAACTGCCCTGGCACATC 1330 base pair 
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  NOTCH1_EX4_R ACACGCAGTCTGGGGAACT   
  NOTCH1_EX5_F AGCTGCCGGAACCTCTTAAA 697 base pair 
  NOTCH1_EX5_R CCTCAATGCCAGGACACC   
  NOTCH1_EX6_F  TTAGGGGACAGGGAGCTCAG 3640 base pair 
  NOTCH1_EX12_R  CCTCTGAGCACAGTGCAGTC   
  NOTCH1_EX13_F  GCCCTTAGGGAGCATGTGTA 4980 base pair 
  NOTCH1_EX18_R  GCACACCTCTCTGTGCAGTC   
  NOTCH1_EX19_F CCCTAGGGTTGAGCAGAAGG 3908 base pair 
  NOTCH1_EX25_R CAAGTTCAGGTCCTCCCTCA   
  NOTCH1_EX26_F AGGCCAGCATGCAGTTCTAA 3550 base pair 
  NOTCH1_EX30_R TAGGGGAGAGAGGCAGGTG   
  NOTCH1_EX31_F  CAGACTGAGCACCCGTCTCT 4850 base pair 
  NOTCH1_EX34_R  GAAGGCTTGGGAAAGGAAGC   
 
Table 7. Forward (F) and reverse (R) primer sequences for re-targeting regions in 
NOTCH1 gene.  
Gene Exon Sequence PCR product length 
NOTCH1 EX1_NTCH1_F CTGAGCCTCACTAGTGCCTC 388 base pair 
  EX1_NTCH1_R CCAAAGTTTCCAAAGGGCGC   
  
  
  
  EX2_NTCH1_F CGGGTGAGACTGACCTCTCT 220 base pair 
  EX2_NTCH1_R GGCCATCTCCAGAAGACAAT   
  
  
  
  EX3_NTCH1_F AGCTGTGGCGGGGCCTTC 244 base pair 
  EX3_NTCH1_R GGCAGCGGCACTTGTACT   
  
  
  
  EX4A_NTCH1_F ACCCTCTTGTCCCCTTGTCT 222 base pair 
  EX4A_NTCH1_R GTAGGAGCCGACCTCGTTGT   
  
  
  
  EX4B_NTCH1_F CACTGCCCACCCAGCTTC 238 base pair 
  EX4B_NTCH1_R GCACACTCGTGGGTGACG   
  
 
EX26A_NTCH1_F AGCCCCCTGTACGACCAGTA 240 base pair 
  EX26A_NTCH1_R CACGCTTGAAGACCACGTT   
  
  
  
  EX26B_NTCH1_F GTGGTGGTGGTGCTGATG 238 base pair 
  EX26B_NTCH1_R GTCCATGGGGTCCAGCTC   
  
  
  
  EX27_NTCH1_F CCAGCCCCTCTCTGATTGT 215 base pair 
  EX27_NTCH1_R  CTGCAGGCAGAGCCTGTT   
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  EX28_NTCH1_F CGCAGGTGAGACCGTGGA 260 base pair 
  EX28_NTCH1_R ACCGGGGACCCAGAAGCAG   
  
  
  
  EX29_NTCH1_F CTCACTTCTCGACCCCTCAC 194 base pair 
  EX29_NTCH1_R AGGGAGTGAGCAGAGCCTGT   
  
  
  
  EX30_NTCH1_F GGCTCTGCTCACTCCCTCTA 206 base pair 
  EX30_NTCH1_R GCTGCTGGCACCCTTACC   
  
  
  
 
Table 8A. Primer sequences for Sanger affirmation of TP53 variants.  
 
Table 8B. Primer sequences for Sanger affirmation of NOTCH1 gene variants.  
Oligo name Chemistry Mod5' Mod3' Sequence Bases  
TP53_ EX4F DNA 
 
None 
 
None 
 
GACCTGGTCCTCTGACTGCT 20  
TP53 _EX4R 
 
DNA 
 
None 
 
None 
 
ATGAGACTTCAATGCCTGGC 
 
20 
 
 
TP53_EX5F 
 
DNA None 
 
None 
 
TTCCAGTTGCTTTATCTGTTCA 
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TP53_EX6R 
 
DNA 
 
None 
 
None 
 
TCAGTGGCCCTCCGGGTGAG 
 
20 
 
 
TP53 _EX7F 
 
DNA 
 
None 
 
None 
 
CCTCATCTTGGGCCTGTGTT 
 
20 
 
 
TP53_EX7R 
 
DNA 
 
None 
 
None 
 
TCTTTTCTCTGGCTTTGGGA 
 
20 
 
 
TP53 _EX8F 
 
DNA 
 
None 
 
None 
 
                 CACCTTTCCTTGCCTCTTTCC 
 
21  
TP53_EX8R 
 
DNA 
 
None 
 
None 
 
      AGCTACAACCAGGAGCCATT 
 
20  
Oligo name Chemistry Mod5' Mod3' Sequence Bases 
NTCH1_EX5F 
 
DNA 
 
None 
 
None 
 
ACCTCAGGGAAGAGGCTGAC 
 
20 
 
NTCH1_EX5R 
 
DNA 
 
None 
 
None 
 
TGCCTGTGAGTGCAGTTTAG 
 
20 
 
NTCH1_EX8F 
 
DNA 
 
None 
 
None 
 
GTGGTGTGCAGTGAGGTGTT 
 
20 
 
NTCH1_EX8R 
 
DNA 
 
None 
 
None 
 
AGCCTCGACTCGGTTTCC 
 
18 
 
NTCH1 _EX14F 
 
DNA 
 
None 
 
None 
 
CCATAGGGCATTGCAGACC 
 
19 
 
NTCH1 _EX14R 
 
DNA 
 
None 
 
None 
 
GTCTCCAGCTCCCCAGACTC 
 
20 
 
NTCH1_EX18F 
 
DNA 
 
None 
 
None 
 
ACTCACCCTTCCGTCCTCTC 
 
20 
 
NTCH1_EX18R 
 
DNA 
 
None 
 
None 
 
CCTTCCACGGCCTCACTC 
 
18 
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2.7.2 Polymerase chain reaction (PCR) 
 
Water was used as a negative control and ECACC control panel DNA as a positive 
control. 
2.7.2.1 Long range PCR 
Long range PCRs were performed at 93°C for 3minutes for enzyme activation, followed 
by 35 cycles of 93°C for 15 seconds for denaturation, 62°C for 30 seconds for 
annealing, and 68°C for 1 minute/kb for extension using the Qiagen long range PCR 
protocol with 20 ng of DNA (<=2000 base pair products) or 50 ng (for >=2000 base pair 
NTCH1_EX20F 
 
DNA 
 
None 
 
None 
 
ACCCAGCTGACCCCAATCT 
 
19 
 
NTCH1_EX20R 
 
DNA 
 
None 
 
None 
 
GCCCACAGAGGACCTTGAT 
 
19 
 
NTCH1_EX21F 
 
DNA None None CACCTGTCTACCACCCCATC 20 
NTCH1_EX21R 
 
DNA     None None GGCCACAACCCTTACCCTAG 20 
NTCH1_EX23F 
 
DNA 
 
None 
 
None 
 
GGCCACTGACGAAACCTG 
 
18 
 
NTCH1_EX23R 
 
DNA 
 
None 
 
None 
 
GAGAGGCTCACCCTGCTG 
 
18 
 
NTCH1_EX25F 
 
DNA 
 
None 
 
None 
 
ACCGTCCTGTCTTCCCTCTC 
 
20 
 
NTCH1 _EX25R 
 
DNA 
 
None 
 
None 
 
CAAGTTCAGGTCCTCCCTCA 
 
20 
 
NTCH1_EX31F 
 
DNA 
 
None 
 
None 
 
CACCCGTCTCTGCCTCTG 18 
NTCH1_EX31R 
 
DNA 
 
None 
 
None 
 
CGTAAGCCTGGCCACTGC 18 
NTCH1_EX32F 
 
DNA 
 
None 
 
None 
 
CCTGAGCCTCTCCCTGTTG 19 
NTCH1_EX32R 
 
DNA 
 
None 
 
None 
 
AACCCAGTCCCACCCGTC 18 
NTCH1_EX33F 
 
DNA 
 
None 
 
None 
 
TCTCCAACCTACCCCATCTG 
 
20 
 
NTCH1_EX33R 
 
DNA 
 
None 
 
None 
 
TTTGGCCCTCACTTCTCTGT 
 
20 
 
NTCH1_EX34AF 
 
DNA 
 
None 
 
None 
 
GCTTCCTCTGGTGATGGAAC 
 
20 
 
NTCH1_EX34AR 
 
DNA 
 
None 
 
None 
 
GTGGGCCAGTCTCAAAGG 
 
18 
 
NTCH1_EX34BF 
 
DNA 
 
None 
 
None 
 
AACCACCTGCCTGGGATG 
 
18 
 
NTCH1_EX34BR 
 
DNA 
 
None 
 
None 
 
GCGCCGTTTACTTGAAGG 
 
18 
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length products) in 50 µl reaction volumes. Each reaction contained 5 µl of 10x Long 
Range PCR buffer (Qiagen, catalogue number 206402), 2.5 µl of dNTP mix (final 
concentration: 500µM of each), 2 µl of each forward and reverse primer (from 10 µM 
primer stock concentration) and 2 units Long Range PCR enzyme mix (Qiagen, 
catalogue number 206402). 
 
2.7.2.2 Short range PCR 
 
Short range PCR (~50-1000 base pair targets), were performed at 95 °C / 5 mins for 
enzyme activation, followed by 35 cycles of 94 °C denaturation for 30 sec, 63°C 
annealing for 30sec, and 72°C extension for 1 min followed by 72°C for 10 mins in 20 ul 
reactions containing 20 ng of target DNA, 2 μl of 10x PCR buffer (Qiagen), 2 μl of dNTP 
mix (2 mM), 2 μl of each primer (forward and reverse primer from 10 μM concentration), 
0.8 μl of Mgcl2 from 25m M concentration and 0.2 μl Taq DNA Polymerase (5 units/μl, 
Qiagen, catalogue no. 201203). Tumour DNA, along with random control DNA (positive 
control) was used for PCR amplification. 
 
2.7.3 Purification of PCR products 
 
QIAquick PCR Purification Kit was used (Qaigen, catalogue no: 28104) for purification 
of PCR products according to the manufacturer’s protocol.  
 
2.7.4 Library preparation for next generation sequencing 
2.7.4.1 DNA Shearing 
 
DNA fragments, mean target fragment size and range of 165 bp and 150 to 180 bp, 
respectively were achieved by sonicating input DNA by using a Covaris S2 System 
(Applied Biosystems). 1 μg of DNA diluted in 1X Low TE Buffer were used in a Covaris 
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micro tube was in a total volume of 100 μL for Cycles at 5 °C, with an upper limit of 30 
°C, in Frequency sweeping mode with Water Quality Testing Function, Off and a Duty 
Cycle of 10%, Intensity 5, Cycles/burst 100, and Time 60 seconds. 
 
2.7.4.2 Size estimation of sheared DNA by bioanalyzer 
 
A DNA 1000 kit (Agilent, catalogue no:50671504) was used for size estimation of 
sheared DNA in an Agilent Bioanalyser according to the manufacturer’s instructions as 
described in section 2.5.2.  
 
2.7.4.3 DNA end repair 
 
The ends of sheared DNA (1 μg in a total volume of 100 μl) were polished and 5’ 
phosphorylated using enzymes supplied with the kit. (Applied Biosystems, Catalogue 
no. 4443713). 4 μl of End Polishing Enzyme 1 (10U/ μl ) and 16 μl of End Polishing 
Enzyme 2 (5U / μl), 20 ul 5x end polishing buffer and 8 μl of 10m M dNTP mix in a total 
volume of 200 μl at room temperature for 30 minutes.  
 
2.7.4.4 Adaptor ligation 
5 base unique bar-coded adaptors were designed according to the sequences from Ion 
Xpress™ Plus gDNA and Amplicon Library Preparation user guide (Publication Part 
Number 4471989 Rev. C) and purchased from Eurogentec (Southampton, UK). The 
adaptor sequences are tabulated in table 9A and B. Ligation of adaptors to purified 
sheared DNA was performed using 10 µl of 10X Ligase Buffer, 1.5 µl of DNA Ligase 
enzyme, 22.2 µl of adaptors from 20 µM stock concentration (20 pmolar excess over the 
amount of sheared DNA ends) in a total volume of 100 µl at room temperature 
overnight. 
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Table 9. Forward and Reverse P1 and A adaptor sequences. [A] The table 
summarizes the forward and reverse P1 adaptor sequences. [B] The forward and 
reverse sequences of barcoded A adaptors used in this study. 
9A. 
Oligo name Sequence 
 
P1F 
 
CCA-CTA-CGC-CTC-CGC-TTT-CCT-CTC-TAT-G)GG-CAG-
TCG-GTG-AT 
P1R ATC-ACC-GAC-TGC-CCA-TAG-AGA-GGA-AAG-CGG-AGG-
CGT-AGT-GGT-T 
9B. 
Oligo name Chemistry Mod5' Mod3' Sequence Bases Purification %GC 
A_ITbc_8F DNA   N/A  N/A TTC-CAT-CTC-ATC-CCT-GCG-TGT-CTC-CGA-
CTC-AGA-CTT-GA 
38 HPLC-RP 52.6 
A_ITbc_8R DNA   N/A  N/A TCA-AGT-CTG-AGT-CGG-AGA-CAC-GCA-GGG-
ATG-AGA-TGG-AAT-T 
40 HPLC-RP 50 
A_ITbc_9F DNA   N/A  N/A TTC-CAT-CTC-ATC-CCT-GCG-TGT-CTC-CGA-
CTC-AGG-ATC-AG 
38 HPLC-RP 55.3 
A_ITbc_9R DNA   N/A  N/A CTG-ATC-CTG-AGT-CGG-AGA-CAC-GCA-GGG-
ATG-AGA-TGG-AAT-T 
40 HPLC-RP 52.5 
A_ITbc_11F DNA   N/A  N/A TTC-CAT-CTC-ATC-CCT-GCG-TGT-CTC-CGA-
CTC-AGG-GCT-AC 
38 HPLC-RP 57.9 
A_ITbc_11R DNA   N/A  N/A GTA-GCC-CTG-AGT-CGG-AGA-CAC-GCA-GGG-
ATG-AGA-TGG-AAT-T 
40 HPLC-RP 55 
A_ITbc_12F DNA   N/A  N/A TTC-CAT-CTC-ATC-CCT-GCG-TGT-CTC-CGA-
CTC-AGC-TTG-TA 
38 HPLC-RP 52.6 
A_ITbc_12R DNA   N/A  N/A TAC-AAG-CTG-AGT-CGG-AGA-CAC-GCA-GGG-
ATG-AGA-TGG-AAT-T 
40 HPLC-RP 50 
A_ITbc_13F DNA   N/A  N/A TTC-CAT-CTC-ATC-CCT-GCG-TGT-CTC-CGA-
CTC-AGG-CAC-TA 
38 HPLC-RP 55.3 
A_ITbc_13R DNA   N/A  N/A TAG-TGC-CTG-AGT-CGG-AGA-CAC-GCA-GGG-
ATG-AGA-TGG-AAT-T 
40 HPLC-RP 52.5 
A_ITbc_16F DNA   N/A  N/A TTC-CAT-CTC-ATC-CCT-GCG-TGT-CTC-CGA-
CTC-AGA-CCA-GT 
38 HPLC-RP 55.3 
A_ITbc_16R DNA   N/A  N/A ACT-GGT-CTG-AGT-CGG-AGA-CAC-GCA-GGG-
ATG-AGA-TGG-AAT-T 
40 HPLC-RP 52.5 
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2.7.4.5 Purification of size fractionated DNA 
The adaptor ligated DNA was electrophoresed in an E-Gel (2% agarose, Invitrogen 
catalogue no GG01002) for size selection and DNA in the appropriate size range 
collected using a Gilson pipette.  
 
2.7.4.6 Nick translation 
Nick translation was performed using Hot star Taq plus DNA polymerase enzyme 
(Qiagen, catalogue no. 203605) using 72°C for 30 minutes according to the Short 
Range PCR reaction conditions 2.7.2.2.  
 
2.7.4.7 Emulsion PCR 
 
5 μl of nick translated diluted library (40pM final concentration) was added to 200 μl of 
OneTouch Reagent Mix and 100 μl of OneTouch Enzyme Mix and 595 μl nuclease free 
water in a 1.5-ml LoBind Tube, to make an amplification solution of 900 μl at room 
temperature. 100 μl Ion sphere particles were added and the solution vortexed at 
maximum speed for 5 seconds before microcentrifugation for 2 seconds. The Ion 
OneTouch Template (Life Technologies, Catalogue no. 4468660) containing template 
preparation reagents was used for emulsion PCR according to the manufacturer’s 
instructions.  
 
2.7.4.8 Bead capture 
 
After ePCR, templated beads carrying adaptored library fragment were enriched by 
annealing to the P2 adaptor using the bead Enricher (LifeTechnologies) according to 
the manufacturer’s instructions. 
36 
 
2.7.5 Next Generation Sequence analysis 
2.7.5.1 SOLiD sequencing (set up and parameters) 
 
The quality and quantity of the sequencing beads was determined by a 6 hour work flow 
analysis (WFA) run with a small fraction of the templated beads before actual 
sequencing. 600-700 million optimal beads were sequenced on a full SOLiD 4 slide in 
the order reverse 35 bp read and forward 50 bp read for 12 days on a SOLiD sequencer 
(ABI), according to the SOLiD 4 user guide.  
 
2.7.5.2 Ion TorrentTM sequencing (setup and parameters) 
 
The Ion PGM 200 Sequencing Kit (Life Technologies, Catalogue no. 447400) was used 
for the Ion torrent sequencer. Templated beads were centrifuged for 2 minutes at 
15,500 × g after transferring to a new 0.2-mL PCR tube and adding 100 μl of annealing 
buffer. Supernatant was removed to leave leaving slightly less than 15 μl. 12 μl of 
sequencing primer was added and the pellet disrupted by pipetting. The sequencing 
primer was annealed at 95ºC for 2 minutes and then 37ºC for 2 minutes. 1 μl of 
Sequencing Polymerase enzyme was added and the reaction incubated at room 
temperature for 5 minutes. Enriched beads were loaded onto the Ion 316 Chip 
according to manufacturer’s instruction (Ion Sequencing Kit Quick Reference v2.0, 
Publication Part Number 4469867 Rev.C). 
 
2.7.6 Sanger sequencing 
2.7.6.1 Sample preparation for Sanger sequencing 
 
Dye terminator sequencing reactions were performed using DYEnamic ET dye 
terminator kit (GE healthcare). Forward and reverse primers (Table 8) were used 
separately by setting up two different reactions for each sample for forward and reverse 
sequencing. In each reaction- 4 μl of PCR amplified DNA, 1.5 μl of water, 0.5 μl primer 
(5 μM) and 4 μl DYEnamic ET reagent mix were added. The sample was incubated in a 
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thermal cycler for 25 cycles and the program was 95°C for 20 seconds, 50°C for 15 
seconds, 60°C for 60 seconds. AutoSeq96 plates (Amersham Pharmacia Biotech) were 
used for removal of unincorporated dye labelled terminators and sample preparation for 
Sanger sequencing following manufacturer’s instructions.  
 
2.7.6.2 Analysis of Sanger sequencing reactions 
 
A MegaBACE 1000 detection system (Amersham Biosciences) was used for analysing 
sequencing reactions by capillary electrophoresis. 
 
2.8. Bioinformatic analysis 
2.8.1 Primary sequence analysis by Ion Torrent suite 2.2 software 
 
Primary sequence analysis was performed using the Torrent Suite 2.2. Both SFF 
(Standard Flowgram Format) and FASTQ files were generated. Raw acquisition data 
was converted into base calls and reads, Data was normalized by signal correction. 
After  calculation of an overall quality metric,  low-quality bases were removed from the 
output by either filtering out entire reads or trimming low-quality 3' ends. Adapter 
trimming was also performed.  
2.8.1.1 Data alignment against reference genome 
 
 Reads were aligned using TMAP aligner (The Torrent Mapping Alignment Program for 
Ion Torrent) to reference sequences and alignments converted to BAM (Binary 
Sequence Alignment) files. Genome Reference Consortium Human Build 37 patch 
release 13 was used as the reference genome. 
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2.8.1.2 Coverage analysis 
  
Coverage Analysis was performed to provide a detailed breakdown of the level of 
sequence coverage produced for each targeted genomic region.  
 
2.8.1.3 Variant detection 
 
Torrent Variant Detection Algorithms were used for initial variant calling according to the 
Bayesian method for germ-line SNP detection when coverage was low to medium 
(between 10-50) or the frequentist approach for positions with higher coverage (>60) 
that can be used to detect low frequency variants. Variants were reported with a p 
value. 
  
2.8.1.4 Genome 1000 database to identify known/unknown variants 
 
All the variants generated from samples were then checked as to whether they are 
present in the 1000 genomes database or they were novel variants using the 1000 
genomes project specific version of the Ensembl Browser found at 
http://browser.1000genomes.org. 
  
2.8.2   Bioinformatic analysis of Ion data using Active Perl 
 
Secondary sequence data analysis was performed using a custom designed Active Perl 
script for identifying repeat sequences by RepeatMasker (downloaded from http://www. 
repeatmasker. org), Blast analysis for genome alignment using a local copy of NCBI 
Blast 2.2.28+ (Basic local alignment search tool, download from-
ftp://ftp.ncbi.nlm.nih.gov/blast/ executables /blast+/2.2.28/). The Perl installation was 
ActivePerl (www. activestate. com). Reads were extracted from source (. sff) files 
downloaded from the Ion Torrent server. Two 1 megabase regions were extracted from 
the GRCh37 assembly of the human genome (http://www.ncbi.nlm.nih. 
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gov/projects/genome/assembly/grc/ human /): base 138000000 to base 138999999 of 
chr9 to encompass NOTCH1 and base 7000000 to base 7999999 of chr17 to 
encompass TP53. Coverage data of fifty bases from either side of the amplicon that 
were taken into consideration to ensure sufficient amplicon edge coverage. After 
making sure there is an adequate coverage for each gene, a base-by-base comparison 
of subject (Blast hit) and query (corresponding region of source read) was made for 
each hit. Differences were catalogued by type (query insertion, query deletion, actual 
base change). Known polymorphisms were checked using the UCSC-SNP137 
(University of California Santa Cruz Genome Centre:http:// hgdownloadsoe.ucscedu 
/goldenPath/ hg19/ snp137Mask/) source sequence. This sequence comprises the 
same assembly of the human genome used for Blast (GRCh37).  
 
2.8.3 Bioinformatics analysis of SOLiD data 
 
2.8.3.1 Alignment of reads 
 
The BWA aligner (Burrows Wheeler Aligner)  was used for matching reads to the 
reference genome (hg19) and generate alignments in the SAM (Sequence 
Alignment/Map) format for compatibility with Variant calling and other downstream 
analyses implemented in SAM tools. The software was downloaded from: 
http://sourceforge.net/projects/bio-bwa/files/latest/download?source=files.The 
processing was performed following user instructions. 
2.8.3.2 Variant detection 
 
The Cake software was used for single nucleotide variants detection. Putative raw 
variant calls made by the software algorithm were filtered to identify common variation ( 
variants in 1000 genome project dbSNP) for identification of germ line variants and read 
position filtering (removal of SNPs in read positions where there is a drop in base call 
quality) [106]. The software was downloaded from: http://cakesomatic.sourceforge.net/ 
and applied according to the user manual. 
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For detecting insertions and deletions the Pindel algorithm was used which can detect 
breakpoints of large deletions (1bp-10kb), medium sized insertions (1-20bp), inversions, 
tandem duplications. Pindel only considers perfect matching. [107]. Pindel was 
downloaded from: http://gmt.genome.wustl.edu/pindel/current/ and used according to 
the user instructions. 
 
2.8.3.3 VEP Analysis 
 
The effect of the sequence variants on the 19,135 protein coding genes in the RefSeq 
database [108] was annotated using the Variant Effect Predictor (VEP) [109], which 
predicts the consequence of each sequence variant on all neighbouring RefSeq genes 
based on a set of 35 consequence terms defined by the Sequence Ontology (SO) [110], 
such as loss of function including stop gained/lost variants, frameshift indels, 
donor/acceptor splice and initiator codon variants, missense variants, inframe indels 
and splice region variants, synonymous variants, 3′ and 5′ UTR variants, deep intronic 
and inter-genic variants.  
 
2.8.3.4 Reactome Pathway Analysis 
 
RefSeq variant data generated from SOLiD sequencing was entered into the Reactome 
browser (http://www.reactome.org) to provide a list of significantly down or upregulated 
pathways that would result from any genetic variants detected in the data.  
 
2.8.4 Sanger sequencing data analysis 
 
Sequence analyzer (Amersham Biosciences) and Sequencer (version4.7, Gene Codes 
Corporation) were used to analyse the sequence data. BLAST was used to perform 
searches using the consensus nucleotide sequence generated by the Sequencer to 
confirm the sequence of the PCR products for respective genes.  
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2.9 Statistical analysis 
All the statistical analysis was performed using student’s t-test or Fisher’s exact test 
(SPSS version 16.0). 
 
2.10 Cell functional assays 
2.10.1 Cell viability assay 
 
~3000 OSCC cells were seeded per well of a 96-well Nunclon plate. Serial dilutions of 
DAPT in media were carried out and two concentration ranges were prepared: 50µM to 
0.001µM and 50µM to 0.05µM. Triplicates for each DAPT concentration and two 
controls (0.5% DMSO; no DMSO or DAPT) were set up. For both concentration ranges 
experiments were performed for 24 hours. EZ4U Cell Proliferation and Cytotoxicity 
Assay (Biomedica Gruppe, catalogue number BI-5000) was used according to 
manufacturer’s instructions. Here, 20 μl of dye solution was added to 200 μl sample and 
incubated at 37°C for 3 hours. After incubation, absorbance was measured using 
Modulus Microplate Reader (Turner Biosystems) at 450 nm with 620 nm as a reference. 
The reference absorbance at 620 nm was used to correct for nonspecific background 
values.  
 
2.10.2 Cell growth rates determination by Crystal violet assay 
 
~50,000 OSCC cells were seeded in each 25cm² of flask. Three flasks were treated with 
DAPT (25µM concentration, Sigma-Aldrich- Catalogue no: D5942), while another three 
flasks were left untreated. Subsequently the cells were fixed for 5 minutes with 10% 
formalin and stained for 30 minutes with 0.05% Crystal Violet in distilled water. After that 
the cells were washed 2x with tap water and the flasks drained by inversion for a couple 
of minutes. Then, 1 ml of methanol was added straight to 25cm² of flasks to solubilize 
the dye and 200 μl of the liquid from each flask was then added to 96 well plates for 
reading the plates at 560nm OD. The flasks were also photographed for colony counts. 
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For DAPT inhibition the cells were treated with DAPT inhibitor (25 µM) for four 
consecutive weeks. The proliferation assay procedure was performed every week in 
triplicates (DAPT+/- treated flasks). The number of viable cells was assessed using a 
spectrophotometer measuring absorbance at 560 nm. Background measurements were 
deducted from all recordings. A control measurement of crystal violet dye without any 
cells was measured on each run (mean absorbance 2.5 on all occasions). 
 
2.10.3 Cell migration assay  
 
6 well tissue culture plates were collagen-coated by incubation in 0.2 mg/ml of collagen 
type I solution (Sigma) for 2 h at 37 °C before rinsing with phosphate buffered saline 
(PBS, Invitrogen). Each well was seeded with cells to a final density of 100,000 cells per 
well were maintained at 37 °C and 5% CO2 for 24 h to permit cell adhesion and the 
formation of a confluent monolayer. Confluent monolayers were then scoured with a 
sterile 200 microlitre pipette tip to leave a scratch of approximately 0.4–0.5 mm in width. 
Three wells for each cell line were left untreated, while three were DAPT-treated 
(25μM). After an hour, the plate was set up for phase contrast live imaging. A picture 
was taken for a particular position in each well approximately every 1 hour. The 
experiment was run for 60 hours. The digitized images were then analyzed using 
ImageJ software (https://imagej.en.softonic.com) to measure %coverage of surface over 
time with the experiment repeated in triplicate. 
  
2.11 Protein analysis  
2.11.1 Protein Quantification by Bradford assay 
 
Bradford ULTRA kit (Novexin, catalogue number BFU05L) was utilised for protein 
quantification according to manufacturer’s instructions. A dilution series of protein 
standards was made using the BSA (Bovine serum albumin protein, stock concentration 
2mg/ml) with the dilution range falling within the protein range: 0.1 mg/ml – 1.5 mg/ml. 
Then 20 μl of the samples, standards and a blank (no protein) was mixed with 300 μl 
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BradfordUltra reagent in triplicates and absorbance were read at 595 nm. Absorbance 
was measured using Modulus Microplate Reader, with unknown sample protein 
concentrations determined by comparison to the reference standards.  
 
2.11.2 Western blotting to investigate protein expression 
 
For Western blot (WB) analysis, 50 µg of cell protein lysates were separated on 10% 
precast polyacrylamide gel (Bio-Rad - Catalogue no. 456-1033EDU) and then 
electrically blotted onto PVDF membrane (Bio-Rad) using Trans-Blot® Turbo™ Transfer 
System (Bio-Rad). Membranes were probed for Notch1-4 antibodies. For Notch1 
western blotting, membranes were probed with rabbit monoclonal antibody (Abcam, 
Catalogue no: ab52627), for Notch2 rabbit polyclonal antibody (Abcam, catalogue no 
ab137665), for Notch3 rabbit polyclonal antibody (Abcam, Catalogue no: ab23426) and 
finally for Notch4 mouse monoclonal antibody (Abcam, catalogue no:ab134831) were 
used. All the primary antibodies were used in 1:2000 dilutions. Membranes were then 
washed with washing buffer and probed with secondary antibody. For Notch1-3, 
horseradish peroxidase conjugated rabbit secondary antibody (Amersham, GE 
Healthcare- Catalogue no. NA934) was used in 1:10,000 dilution and for Notch4, 
horseradish peroxidase conjugated mouse secondary antibody (GE Healthcare, 
Catalogue no. NA931) was used in 1:20,000 dilution. For amyloid beta precursor protein 
western blot, anti-amyloid beta precursor protein antibody (Abcam: ab32136) was used. 
β-actin was used for loading control where the membranes were probed with rabbit 
polyclonal antibody to human β-actin (Abcam, Catalogue no: ab8227) diluted in 1:2000 
and with horseradish peroxidase conjugated secondary rabbit antibody diluted in 
1:10,000. The membranes were washed again using washing buffer. The bands were 
visualized using enhanced chemiluminescence (GE Healthcare, Catalogue number 
RPN2108) on X-ray film. The size of protein bands was estimated by running protein 
ladder (Thermo Fisher Scientific; Catalogue number: 26619) parallel where broad 
molecular weight range (10-250 kDa) was covered. All the western blots for Notch1- 4 
protein were performed in triplicate. 
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3.1 Introduction 
German pathologist David von Hansemann reported aberrant mitosis as a feature of 
cancer over 125 years ago in 1890 [111].  By 1914 Theodor Boveri had developed this 
into the hypothesis that chromosomal abnormalities were responsible for the transition 
from normal to malignant proliferation and that the changes were genetic in nature 
[112]. A hundred years of progress, culminating in the use of Next Generation 
Sequencing has led to a detailed description of somatic changes that have arisen in a 
wide variety of epithelial and non-epithelial malignancies. 
3.1.1 Methods for detecting Chromosomal alterations and their significance 
 
The development of methods for cytogenetic analysis was a major breakthrough in the 
study of chromosomal abnormalities in cancer with the discovery in patients with chronic 
myelogenous leukaemia (CML) by Nowell and Hungerford (1960) of the Philadelphia 
chromosome, a region specific, reciprocal translocation between chromosome 9 and 
chromosome 22 [113]. Combining karyotyping with giemsa banding and fluorescence-
in-situ-hybridisation (FISH) allowed further discoveries to be made with increased 
resolution. Kallioniemi and colleagues, in 1992 introduced comparative genomic 
hybridisation (CGH) for detecting DNA amplifications and deletions at higher resolution 
[114]. Ried et al. described in an early study utilising CGH, recurrent alterations in 
sporadic colorectal cancers (CRC) in which genomic gains affecting chromosomes 7, 
8q, 13, and 20q and genomic losses of chromosomes 4, 8p, 17p, and 18q were often 
observed [115]. Increased resolution power became possible through the advent of 
Array based CGH (a-CGH), pioneered by Solinas-Toldo et al. in 1997 and Pinkel et al. 
in 1998, where DNAs from separate genomic regions were spotted out onto an ordered 
array for probing [116, 117]. 
 
The utility of a-CGH was significantly aided by the Human Genome Project allowing the 
creation of a library of cloned DNA fragments throughout the human genome. These 
could then be used as the target region probes on DNA microarrays. The initial 
approaches used arrays with elements from spotting DNA obtained directly from large 
insert genomic clones such as BACs [118]. Such strategies were then largely 
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superseded by oligonucleotide microarrays that were less laborious and provided higher 
genomic resolution. However, other genetic studies have shown that tumour genomes 
have a wide variety of copy-number phenotypes, indicating different types of genetic 
instability. For example, colorectal cancer has different levels and types of genomic 
aberrations, attributable to differences in mismatch-repair competence [119]. The larger 
arm-level somatic copy number aberrations (SCNAs) detected by CGH methods, occur 
30 times more frequently than focal SCNAs when adjusted for size [63]. However, these 
broad regions of gain or loss can include hundreds of genes, several of which are likely 
to be potential ‘driver’ cancer genes [120]. As a result, narrowing the list of potential 
‘drivers’ in large SCNAs has proved difficult [63]. Although large alterations have long 
been associated with poor outcomes, underlying mechanisms and gene-specific 
biomarkers remain elusive [121, 122].  
Recent advances in genomics aided by next generation sequencing used with large 
patient cohorts has provided us with a means of assessing the identity of potential 
drivers within large SCNAs.  Next generation sequencing has also provided a means of 
detecting structural changes accompanied by deep sequencing for the detection of 
variants. In tumours of squamous cell origin, such as head and neck or bladder 
squamous cell carcinoma, the gain of chromosome 3q was found to be the most 
prevalent alteration. Other genomic imbalances commonly observed in these tumour 
subtypes include gains located at chromosome 1, 7, and 20, with losses located at 4, 
11, 16, 17, and 19 [21, 123]. 
 
3.1.2 Allelic Imbalance in OSCC 
 
Patterns of DNA copy number aberration (CNA) including loss of heterozygosity (LOH) 
found in OSCC have been considered to be characteristic for different points in the 
natural history of the disease [124]. PCR for detecting RFLPs and microsatellites was 
initially used for detecting copy number change [125] but thereafter the majority of 
studies used CGH and array-CGH. Oligonucleotide microarray based CGH (a-CGH) 
has been used to score allelic imbalance across the OSCC genome.  Publications for 
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key investigations are listed in Table 10. with the methods used and the regions found 
to be affected.  Huang et al. analysed DNA from primary tumour tissue (n=34 OSCC 
samples of 75 total HNSCC samples) with matching normal tissue controls, and 
observed gains in regions 3q,5p and 8q with loss of 3p for all HNSCC and additional 
gains in 1p and 11q12-13 specific for OSCC [126]. Smeets et al. also used OSCC 
primary tumour tissue samples (n=37) but reference genomic DNA was from a random 
panel of blood donors as controls [127].  Gains and losses, at chromosomes 3q, 8q and 
11q13 and losses of 3p observed were similar but additional losses of 5q, 11q23 and 
18q were found. Oga et al. assessed copy number variation in OSCC primary tumour 
samples (n=17) covering a range of different stages (stage 1-4). Although gains (3q, 8q, 
Xp and Xq) and losses (3p, 4p, 8p, 9p, 13q and 17p) were found in a number of regions, 
the total number of gains and losses was greater in stage III/IV samples (mean 8.11+/-
4.91) compared to stage I/II (mean 1.11 +/-1.49), with 3q gains found more significantly 
in stage III & IV tumours (6/8) v stage I/II (1/9) [128].  
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Table 10. Summary of key publications reporting the use of CGH to investigate 
allelic imbalance in OSCC primary tumour samples. 
Tumour materials  
Control 
samples  
Method /s Observation  References 
OSCC primary 
tumour 
tissue 
(n=17) 
Healthy 
volunteers 
Comparative genomic 
hybridization (CGH) 
Gains in regions 3q, 8q, Xp 
and Xq. Losses detected in 
3p, 4p, 8p, 9p, 13q and 17p. 
Total number of gains 
significantly greater in 
stage III/IV than stage I/II. 3q 
gain in stage III & IV tumours 
(6/8) v stage I/II (1/9). 
[128] 
OSCC  primary 
tumour  tissue (n=34, 
of 75 HNSCC 
samples) 
Matching normal 
tissues 
Comparative genomic 
hybridization (CGH) 
Gains in regions 3q,5p and 8q 
with loss of 3p and 17p for all 
HNSCC. Additional gains in 
1p and 11q12-13 specific for 
OSCC 
[126] 
OSCC  primary 
tumour  tissue 
(n=47) 
Matching normal 
tissues 
Array- comparative 
genomic hybridization 
(CGH) 
Gains in regions 8q, 9q and 
11q, most frequent losses of 
3p, 4q and 17p.  
Deletion of 3p and gain of 11q 
more prevalent with lymph 
node metastasis. 
[129] 
OSCC primary 
tumour tissue 
(n=37) 
Reference 
genomic DNA 
from random 
panel of blood 
donors 
Array- comparative 
genomic hybridization 
(CGH) 
Gains at chromosomes 
3q, 7q, 8q and 11q13 and 
losses at chromosomes 
3p, 5q, 11q23 and 18q. 
 
[127] 
OSCC  primary 
tumour  tissue 
(n=54) 
Marginal normal 
tissues 
Array- comparative 
genomic hybridization 
(CGH) 
Gain of regions including 3q, 
5p, 8q, 9q, 11q, and 20q. 
Loss of 3p, 8p, 9p, 17p and 
18q regions  
[130] 
OSCC  metastatic 
primary tumours with 
paired lymph node 
metastases (n=25) 
Non-metastatic 
primary tumours  
Array-comparative 
genomic hybridization 
(CGH) 
Gain of regions including 3q, 
9q,11q13, 14q, 16p, 18p and 
20q. Loss of 3p, 4q, 8p, 
9p,10p, 13q, 17p, 18q and 
21q regions. 
Gains of 7p, 8q and 17q more 
common with lymph node 
metastasis 
[131] 
OSCC  primary 
tumour  tissue 
(n=205) 
  Array- comparative 
genomic hybridization 
(CGH) coupled with 
whole genome 
sequencing 
Losses of 3p and 8p, and 
gains of 3q, 5p and 8q 
chromosomal regions with 
activating mutations of 
PIK3CA or HRAS, coupled 
with inactivating mutations of 
CASP8, NOTCH1 and TP53 
[21] 
OSCC primary 
tumour tissue  
enriched for ECS 
cases 
(n=65, 22 ECS) 
Normal controls 
(n=6) 
Array- comparative 
genomic hybridization 
(CGH) 
Gain of regions 3q, 5p, 7p, 
8q, 9q, 11q, 14q, 17q, 20p, 
22q. Loss of 3p and 8p 
regions. 
(B. Lloyd 
unpublis-hed 
data) 
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The evidence gained from similar studies has provided some insight into the association 
of allelic imbalance observed with prognosis. Shu-Chun et al. found in their cohort of 
OSCC tumour samples that deletion of 3p (4/23 N0 v 12/24 N+) and gain of 11q (2/23 
N0 v 9/24 N+) were more prevalent in those samples with lymph node metastasis [129]. 
Yoshioka et al., reported gains of 7p (2/10 N0 v 10/15 N+), 8q (5/10 N0 v 14/15 N+) and 
17q (2/10 N0 v 11/15 N+) that were more common with lymph node metastasis in a 
cohort of OSCC samples [131]. As previously discussed (section 1.2), lymph node 
metastasis in OSCC is associated with an aggressive phenotype and is a key poor 
prognostic indicator. However, OSCC patients with lymph node metastasis do not have 
a uniformly poor prognosis [103, 132] with other independent risk factors including 
lymph node metastasis harbouring ECS being a further predictor of poor prognosis 
(section 1.3). Conversely, a powerful a-CGH study combined with whole genome next 
generation sequencing on a large OSCC cohort (n=205) by the Cancer Genome Atlas 
consortium reported that the absence of allelic imbalance in OSCC may be associated 
with good outcomes. A subgroup of oral cavity tumours was identified with favourable 
clinical outcomes displaying infrequent copy number alterations with activating 
mutations of PIK3CA or HRAS, coupled with inactivating mutations of CASP8, NOTCH1 
and TP53 [21]. These data built on a previous study related to the Cancer Genome 
Atlas network that used a-CGH in a more limited number of OSCC cases (n=37) and 
classified samples on the basis of the genetic pattern detected. They concluded that 
three groups were present, one characterized by low level of chromosomal aberration 
(average 2.8 chromosomal breakpoints, n = 8), another by medium level (average 30.0 
chromosomal breakpoints, n = 26) and one with high level (average 52.8 chromosomal 
breakpoints, n = 5) chromosomal aberrations. This classification was significantly (p = 
0.003) associated with survival. In contrast, there was no significant association with 
pathological tumour stage or lymph node status [133]. 
 
Together, these studies suggest that both the level of chromosomal aberration and the 
specific sites of any changes are of relevance. A greater number of chromosomal 
aberrations are clearly more likely to give significant allelic changes. Lymph node 
metastasis and overall survival have been considered but no studies specifically 
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considered ECS. Detailed analysis of TCGA data by Roy et al. linked chromosomal 
aberration to clinical outcome [134]. Specific interrogation of their data with regards to 
outcomes for HNSCC (n=522) reveals that 3q and 8q regions most frequently have 
gains and 3p and 8p regions most frequently have losses. However, gain of 7p is most 
significantly associated with poor survival, suggesting a complex picture. To genetically 
characterise the basis for aggressive phenotype in OSCC, further we conducted an 
investigation of allelic imbalance associated with different histopathological subtypes of 
OSCC, specifically focussing on ECS, the most adverse clinical prognosticator. 
 
3.1.3 Investigation of allelic imbalance in association with ECS: a previous pilot 
study 
 
Previously our laboratory had used aCGH to examine copy number changes in relation 
to ECS.  The series was enriched for cases having associated ECS (20 ECS+ and 26 
ECS- cases, section 2.2). We predicted that particular molecular pathways would be 
altered according to the presence of ECS and this would be reflected in relative 
enrichment of chromosomal gains or losses in the regions where the corresponding 
alleles were located. DNA from fresh frozen primary tumour samples (n=46) had been 
analysed using Nimblegen arrays having 720,000 probes at an average density of 4,260 
probes/µm2.  DNA from each sample was compared to a uniform mixture of DNA from 6 
random, unaffected individuals. The CGH data obtained by this approach revealed a 
number of regions showing amplifications or deletions that had had also been found to 
be affected in other epithelial malignancies (B. Lloyd unpublished data). Significant copy 
number alterations included chromosomal arm amplifications of regions 3q, 5p, 7p, 8q, 
14q, 20p, 22q and chromosomal arm deletions of regions 3p, 8p. This is summarised in 
the ideogram of Figure 4. Considering this data in the context of the established 
literature, discussed previously in section 3.1.2 and summarised in table 10, there was 
overlap but also some differences. Affected chromosomal regions in common were 3q, 
5p, 8q, 9q and 11q for gains (≥3 studies) and for losses (≥3 studies) were 3p, 8p,9p.  
Gains of 14q, 20p, 22q were unique to the literature.  
51 
 
No gains or losses were specifically associated with ECS and therefore genes within the 
segments that showed significant copy number change within our data were subjected 
to hypergeometric analysis in comparison to canonical pathways to determine which 
processes may be enriched. Pathways for multiple processes were implicated, including 
cytoskeletal remodeling: TGF and WNT pathway (p = 7.8 x10-8), keratin filaments (p = 
1.4 x10-7), transcription: receptor mediated HIF regulation (p = 4.1 x 10-7), immune 
response: IL9 signaling pathway (p = 1.1 x 10-6) and chemotaxis (p = 3.8 x 10-6), Notch 
signaling and TNFs/NF-kB/IAP apoptosis for both T4 and T2 tumours (p = 9.7 x10-5 and 
p = 1.0 x10-3, respectively).  More detailed segmentation analysis to narrow down the 
minimal overlapping regions of loss/gain between samples in commonly affected 
regions found complex patterns. The 11q13.2-11q13.3 region was found to have 
aberrations in a large proportion of tumour samples (21/46) with predominant gains 
(20/46) particularly in ECS cases (11/20) (Figure 5.). This 0.514 Mb region contains 5 
key genes: MYEOV, CCND1, FGF19, FGF4 & FGF3, all playing a key role in cell 
proliferation and differentiation. In contrast, some studies of OSCC have reported 
significant loss of 17p13 region (harboring the TP53 gene) [135, 136], loss of 17p13 
was very infrequent in our cohort (1/46 demonstrating a deletion). Significant differences 
between ECS and Non-ECS cases were not found by the study by pathway analysis.  
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Figure 4. Summary ideogram of allelic imbalances found by CGH in our series of 
OSCC cases. Significantly amplified regions are highlighted in green and significant 
deleted regions in pink, with the locations of known cancer related genes listed at their 
appropriate locations next to the ideogram. (B. Lloyd, unpublished) 
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Figure 5. Minimal regions of allelic imbalance found by CGH in our series of 
OSCC cases shown for 11q13.2 – 11q13.3. Red lines signify regions of average gain 
and blue signify regions of average loss of genomic DNA.   [Data courtesy of Dr. Bryony 
Lloyd] 
 
3.1.4 Significance of chromosomal regions 11q13 and 17p13 for OSCC 
 
CCND1 and TP53 are involved with key biological aspects of cancer development, 
regulation of the cell cycle and apoptosis respectively. TP53 and CCND1 both show 
high levels of allelic imbalance in HPV-negative HNSCC [16].  
11q13, the location of the CCND1 gene is frequently amplified in different cancers [137]. 
In the case of OSCC, allelic imbalance is observed for 11q region and high-level 
amplification (>4 copy gains) of CCND1 has been found in up to 22% of cases [136]. 
Over-expression rates of CCND1 was also found for 25-70% of patients with oral 
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cancers [138]. Cyclin D1 protein overexpression was significantly associated with lymph 
node metastasis (p = 0.002). 11q13 and in particular CCND1 may therefore be 
significant drivers of oral cancers. 
TP53 is a well-known and understood tumour suppressor gene, very commonly mutated 
in human cancers (~ 50%); including 25-69% of HPV negative oral cancers [102, 104] 
Loss of the TP53 gene in terms of allelic imbalance, dominates the genomic landscape 
of OSCC in common with many other tumour types [135, 136].  p53 protein 
downregulation occurs in OSCC cases and is associated with poor patient outcome 
[139]. No studies have been conducted so far comparing associations of these two 
genes (CCND1 and TP53) with ECS. 
No regional gain or loss was found to associate with ECS in our a-CGH analysis.   
Similarly, very little is known of any molecular signatures that are associated with ECS.  
However, although our cohort has expected frequencies of 11q13 gain, there appears to 
be a significant deficit of TP53 loss compared to literature reports.  Five studies had 
already found 11q gains in between 25 and 70 % of cases, with two studies reporting 
17p loss in between 50-75% of cases (see Table 10.) whereas we found 43% and 4% 
respectively in our a-CGH study.  A possible explanation is that our samples may be 
genetically different from other cohorts, with a low rate of TP53 change. There may be 
technical explanations, for example admixture of tumour cells and normal cells leading 
to reduced sensitivity of detecting allelic loss [140]. However, pathology reports (not 
shown), suggested that tumour cells comprised average ~70% of our samples (n=46) 
and therefore sensitivity should not have been compromised in this way.  Gains of more 
than 1 copy were observed for 11q13 in our series. We were concerned that our 
approach was underestimating 17p loss and only detecting higher levels of 11q gain.  
Array CGH also leaves open the possibility of balanced allelic loss and gain [141].  I 
therefore decided to examine the validity of our results specifically for candidate regions 
11q13 and 17p by using SNP analysis for detecting actual allelic imbalance, in the 
expectation that this would be more sensitive than aCGH.  
Multiple approaches have been used to detect allelic imbalance using end-point 
readings of PCR [142], but they may not be accurate in quantifying the ratio between 
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the alleles.  The accuracy of SNP analysis can be further improved by quantitative PCR 
(q-PCR), since two or more possible alleles can be labelled with a different flourescent 
dye each, allowing allele calls to be made according to the ratio of possible fluorescent 
probes present. q-PCR also has a greater dynamic range than aCGH, further improving 
the possibility of detecting allelic imbalance.  Chen et al. demonstrated using this 
method that a Pearson Correlation Coefficient (R2) of 0.9798 and 0.9868 when 
compared to a standard curve of fixed ratios with the ability to quantify allelic imbalance 
ranging from 2:1 – 8:1 [143].  
Detection of a clinical association is dependent on study power. We estimated that a 
study performed on TP53 assuming a significance level of 0.05 and a power of 80% 
with an expected frequency of 25-69% for allelic imbalance, requires only 12-52 
samples to demonstrate such a difference at this power. Similarly, for CCND1 the power 
calculation is the same, if similar assumptions were made with a potential frequency of 
25-70% considered. As our available sample set was 46 cases and other gains and 
losses were too infrequent to be useful, CCND1 and TP53 were considered to be the 
most appropriate candidates for testing in our genetically distinct sample set. 
 
3.2 Hypothesis and Aim 
Hypothesis:  Increased copy number change in CCND1 or TP53 is associated with 
ECS, an aggressive phenotype of OSCC.  
Aim: To quantify and compare CCND1 and TP53 gene allelic imbalance in OSCC 
samples of defined histopathological subtypes using single nucleotide polymorphisms 
(SNPs) via a q-PCR method. 
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3.3 Results 
 
3.3.1.1 Establishment and Verification of functioning SNP PCR  
 
Several SNPs were selected to allow for non-informative individual for TP53 (resides in 
17p) and CCND1 (resides in 11q) from the National Centre for Biotechnology 
Information (NCBI) dbSNP database on the basis of a high level of heterozygosity in the 
European population. Predesigned SNP QPCR assays were selected (see section 
2.5.1, Table 5). Standard PCRs were performed (section 2.5.1) and the products 
analysed by agarose gel electrophoresis (reference section 2.5.2) to identify the 
conditions giving the clearest expected bands and therefore greatest specificity.   
Company specified pre-optimised conditions were applied for one TP53 (C-26603915) 
probe targeted against an intronic TP53 SNP (ID: rs2909430, location: Chr.17: 7578645 
on NCBI Build 37) and were then repeated for all other probes of interest. The C-
26603915 assay was performed using DNA from 6 randomly selected samples from the 
human control DNA panel (section 2.3) and 2 negative DNA controls. The presence of 
expected ~120bp bands support successful PCR amplification. 
 
3.3.1.2 Preliminary classification of homozygote and heterozygote samples 
 
Next, 96 samples from the human control DNA panel were screened for candidate 
homozygote and heterozygote samples that could be used to test for the sensitivity and 
specificity of allelic discrimination.  The samples were subject to q-PCR using optimal 
conditions for enzyme activation, template denaturation and annealing/extension (see 
section 2.5.1). CFX managerTM software was used to monitor the q-PCR reaction and 
the baseline and detection threshold were both set for sensitive significant amplification 
detection above background. Duplicate runs were performed for each probe. 
Figure 6. demonstrates RFU values (the increase of fluorescence level) and Ct (PCR 
threshold cycle) values obtained using the C-26603915 TP53 assay. A successfully 
amplified product (∆Ct<50) for both FAM dye (used to detect allele1) & HEX dye (used 
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to detect allele2) probes indicated a heterozygote, whereas an amplified product for 
FAM but not HEX (∆Ct=50), or vice versa, indicated a homozygote for either Allele 1 or 
2 respectively. A negative control was also used with an expected ∆Ct of 50 recorded 
for both FAM and HEX in the absence of DNA. These criteria were applied using the 
data analysis software allowing the cut offs (blue and red lines) to be drawn, 
segregating the samples into these distinct categories. On this basis, the graph shows 
35 samples were classified as heterozygote, with the remainder either homozygote for 
allele 1 (33) or 2 (28). These data confirmed the ability of the method to discriminate 
between the different alleles of a SNP for both genes, allowing for the more detailed 
assessment of sensitivity utilising the homozygote detected samples.  
 
 
Figure 6. Threshold cycle analysis for maximum fluorescence intensity using the 
C-26603915 TP53 assay with human random control DNA samples.  
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3.3.1.3 Specificity of detection of minor alleles 
 
Having identified a number of homozygote and heterozygote samples as outlined in the 
previous section, 2 samples of each homozygote were mixed in different fixed 
proportions and amplified by the C-26603915 TP53 probe to determine minor allele 
detection specificity. The q-PCR was performed in triplicates as previously described 
(see section 2.5.1). Table11. demonstrates the RFU and Ct values for both SNP probes 
generated from the first set of experiments. The lower the Ct value, the higher 
percentage of the respective allele was deemed present. Firstly, the mean Ct values for 
allele 1 (Table 11. pink rows), revealed discernible differences between the different 
samples tested with a mean Ct1 for 100% allele 1 of 23, 90% gave 26 and 50% gave 
28. The mean Ct values for allele 2 (Table 11. white rows) were similar. The negative 
control with no DNA displayed ∆Ct=50 for both fluorescence recordings confirming no or 
little DNA. These observations suggested that the method was sufficiently sensitive 
enough to detect a 10% difference in allele amount. 
Table 11. Fluorescence level in relation to Threshold cycle for human control DNA 
samples mixed in predetermined proportions.   
% allele 1 % allele 2 Mean Fluorescence 
level (RFU) 
Mean PCR threshold 
cycle (Ct) 
Call 
100 0 5005 23 Allele 1 
0 100 5052 23 Allele 2 
90 10 4904 26 Heterozygote 
50 50 4548 28 Heterozygote 
50 50 4488 28 Heterozygote 
10 90 4917 26 Heterozygote 
0 0 3 50 None 
0 0 1 50 None 
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3.3.1.4. Assessment of ability to quantify allelic imbalance 
 
We then went on to vary the overall DNA amount in a further experiment to model a 
situation of allelic imbalance that potentially we could encounter on assessment of 
tumour samples. The method used the previously identified human control samples 
homozygous for allele 1 and 2 (see section 3.3.1.3) and q-PCR performed with the 
same optimised conditions (section 2.5.1). Stock test samples were prepared with a 
total DNA amount of 200 ng and mixture of alleles in a variety of proportions of allele 1: 
allele 2 (200:0, 190:10, 180:20, 160:40, 100:100, 40:160, 20:180, 10:190, 0:200). 5 
subsequent 1 in 5 dilutions were made of these stock test samples, allowing the overall 
DNA amount to be varied from 200ng - 0.064 ng. All samples were analysed in triplicate 
and then used to plot a standard curve. For the TP53 (C_26603915) probe there was a 
correlation observed for both allele 1 and 2 with coefficient of determination values (R2) 
of 0.62 and 0.67 respectively (Fig 7. A & B). A possible reason for R2 being <1 was due 
to variability across samples with low values of DNA (particularly <10ng) for both allele 1 
and 2 being overestimated by this method potentially as a result of non-specific probe 
binding. The amount of over-estimation was different for different probes, with the TP53 
probe illustrated here generally over-estimating at around the same level. 
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A.                                                                                  B. 
  
 
Figure 7.  Allelic amount and allelic imbalance compared to standard (antilog) 
curves from control DNA. A., B. Scatter plots of input amount of DNA v output amount 
(ng) recorded following q-PCR for allele 1 (A.) and allele 2 (B.) Red line = line of best-fit, 
black line = expected standard curve, corresponding R2 values are demonstrated on 
graphs. 
 
Having established that the method lacked sensitivity to accurately quantify differences, 
it was necessary to further clarify the level of allelic imbalance at which a call of 
amplification or deletion could be confidently made. To clarify this level of sensitivity 
further so that a limit of detection (LOD) with regards ∆∆Ct could be identified, above or 
below which samples could reliably be considered to have either a TP53 or CCND1 
deletion or amplification, a further experiment was performed. qPCR was performed 
similarly to previously (see section 2.5.1) using the C_26603915 probe (TP53) with the 
same human control DNA homozygote allele 1 and 2 samples as used previously. A 
DNA amount of 20ng/µl was used initially with both alleles then mixed with less than 4 
fold allelic imbalance differences (20v80, 25v75, 30v70, 70v30, 75v25, 80v20). All 
samples were then further diluted 1 in 10 to give a 2ng/µl total DNA concentration. Each 
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sample was assayed with eight replicates with the ∆∆Ct detected for each sample 
recorded.  
Figure 8. demonstrates the ∆∆Ct values from this experiment using the C_26603915 
TP53 probe. samples mixed as 70v30,75v25 and 80v20 with expected ∆∆Ct values of 
2,3 and 4 respectively, returned mean ∆∆Ct values of 4.18, 6.56 and 6, suggesting 
over-estimation of quantification, but they were all statistically different from the 
reference control on student’s t-test (p<0.05).  Samples mixed in the opposite manner 
as 30v70, 25v75 and 20v80 with expected ∆∆Ct values of 0.5, 0.33 and 0.25 had mean 
∆∆Ct values of 0.61, 0.55 and 0.49 respectively. Only the 20v80 (expected ∆∆Ct = 0.25) 
in the 1 in 10 dilution group sample demonstrated statistical significance compared to 
the reference control (p<0.05) on student’s t-test. The assay limit of detection (LOD) 
was determined on the basis of the samples that remained statistically different from 
reference (1:1) with the lowest detected imbalance above control for amplification and 
the highest detected imbalance below the reference for deletion (see arrows on Figure. 
8 for TP53).  For the TP53 SNP assay this meant cut offs when average values of ∆∆Ct 
detected are >2 or <0.25. Hence, by applying these thresholds to the interpretation of 
subsequent tumour data we could conclude with greater confidence whether allelic 
imbalance was significantly present or not. 
62 
 
 
 
 
 
Figure 8. Mean fold difference for fixed levels of allelic imbalance using the 
C_26603915 TP53 probe. All readings had eight replicates with the findings shown for 
two different DNA amounts (Original dilution=20ng/µl total DNA concentration, Dilution1 
(D1) =2ng/µl total DNA conc.) *=p<0.05 on student’s t-test compared to original dilution 
50v50 control, #=p<0.05 on student’s t-test compared to dilution 1 50v50 control. 
Arrows mark limits of detection of the assay.  
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3.3.1.5 Statistical analysis of allelic discrimination 
 
The optimisation experiments described in sections (3.3.1.2 – 3.3.1.5) were repeated for 
all TP53 and CCND1 SNP probes (Table 5). As the first part of statistical analysis to 
select the best TP53 and CCND1 probes to use on subsequent tumour samples, we 
specifically assessed how sensitive the q-PCR method was to detect heterozygote 
samples for a particular probe, by performing a statistical analysis based on the findings 
from all probes once the experiment described in 3.3.1.3 was replicated with them. The 
triplicate Ct values for both alleles and all probes at a 10% difference sensitivity level 
(100% v 90%) were compared by unpaired t-tests. Table 12. summarises the p values, 
confirming a statistical significance (p<0.05) in all comparisons except C_8727721, 
C_2880090 assay for TP53 and C_744724 for CCND1. The TP53 probe C_26603915, 
previously used as an illustrative example, did show significant difference at 10% 
sensitivity for minor allelic discrimination (allele 1 p=0.010 and allele 2 p=0.024) and is 
highlighted in red. Probes that did not show a significant difference were immediately 
excluded from consideration for use on OSCC tumour samples. 
The remaining probes that were identified as sensitive enough for 10% minor allelic 
difference detection, C_26603915, C_2880088, C_2403545 for TP53 and C_744721, 
C_25800715 CCND1 probes, had their data produced from the 3.3.1.4 set of 
experiments analysed for final probe selection. Table 13. Shows a summary of the 
parameters for allelic discrimination by q-PCR for all these five probes. C_26603915 
and C_744721 probes were the most suitable for tumour sample analysis based on 
their greatest sensitivity for allelic discrimination as well as least levels of over/under 
estimation of ∆∆Ct.  
We can conclude that the q-PCR was not reliable for accurate consistent quantification 
of smaller differences, however, the method can detect allelic imbalances when an LOD 
Ct threshold was applied (≥2 ≤0.25 for TP53 & ≥3 ≤0.5 for CCND1).  
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Table 12. TP53 and CCND1 probe ability to detect a 10% minor allelic difference. 
Student’s t-test results for all TP53 and CCND1 probes comparing Ct values recorded 
by q-PCR between 100% v 90% (i.e. 10% difference) allele groups are displayed.  
 
Gene SNP ID Heterozygocity  Assay number Allele p value 
 
TP53  RS1614984  40%  C_8727721  
1 0.065 
2 0.072 
TP53  RS1642785  30%  C_2880090 
1 0.051 
2 0.076 
TP53  RS2909430  22%  C_26603915  
1 0.010 
2 0.024 
TP53  RS12951053  16%  C_2880088  
1 0.034 
2 0.028 
 
TP53  
 
RS1042522  
 
30%  
 
C_2403545 
1 0.044 
2 0.050 
Cyclin D1  RS3212891  43%  C_25800715  
1 0.012 
2 0.054 
Cyclin D1  RS649392  43%  C_744724  
1 0.089 
2 0.050 
Cyclin D1  RS678653  43%  C_744721  
1 0.005 
2 0.008 
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Summary of optimisation experiments: 
Table 13. Summary of key q-PCR selection parameters for TP53 and CCND1 
allelic discrimination for the 5 assays selected for use with tumour samples. The 
key parameters from experiments described in 3.3.1.1 (Establishment and Verification 
of functioning SNP PCR), 3.3.1.2 (Preliminary classification of homozygote and 
heterozygote samples), 3.3.1.3 (Specificity of detection of minor alleles) and 3.3.1.4 
(Assessment of ability to quantify allelic imbalance) using 3 TP53 SNP probes and 2 
CCND1 probes are described above. Selected probes demonstrating the best levels of 
sensitivity that were used further for allelic imbalance analysis in OSCC samples are 
shown in red. 
 
 C_26603915 
TP53  
probe 
C_2880088 
TP53 probe 
C_2403545 
TP53 probe 
C_744721 
CCND1 
probe 
C_25800715 
CCND1 probe 
100 v 90 p 
value 
Allele 1 
 
0.010 
 
0.034 
 
0.044 
 
0.005 
 
0.012 
100 v 90 p 
value 
Allele 2 
 
0.024 
 
0.028 
 
0.050 
 
0.008 
 
0.054 
R
2 
Allele 1 
 
 
0.62 
 
0.61 
 
0.60 
 
0.96 
 
0.67 
R
2 
Allele 2 
 
 
0.67 
 
0.58 
 
0.62 
 
0.58 
 
0.49 
R
2 
∆∆Ct 
 
 
 
0.64 
 
0.60 
 
0.61 
 
0.51 
 
0.50 
Output 
∆∆Ct  when 
input = 2 
 
4.18 
 
4.30 
 
4.21 
 
1.69 
 
1.53 
Limit of 
Detection 
 
 
≥2 , ≤0.25 
 
≥2 , ≤0.25 
 
≥2 , ≤0.25 
 
≥3 , ≤0.5 
 
≥3 , ≤0.5 
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3.3.2 Allelic imbalance of TP53 and CCND1 loci in OSCC Tumour samples 
 
The specific aim of this part of the study was to test the hypotheses that increased copy 
number change in CCND1 or TP53 gene were associated with ECS, an aggressive 
phenotype of OSCC. Optimisation experiments had determined that allelic imbalances 
could be detected by the method with confidence limits applied. By using an ECS 
enriched sample set of exactly the same samples (n=46) that had previously been 
investigated by CGH, direct comparisons between results obtained by the two assay 
systems could be made.  
q-PCR assay was set up as described (section 2.5.1) and only heterozygote samples 
would be informative for the analysis. For TP53, 22/46 samples were heterozygote, 
whereas for Cyclin D1 37/46 samples were heterozygote, and the homozygote samples 
were excluded from analysis. All mean ∆∆Ct values recorded for the tumour samples 
assessed by q-PCR using both CCND1 and TP53 probes are shown in Figures 9A &B. 
To complete the analysis a student’s t- test comparing the sample mean ∆∆Ct to the 
reference was performed to assess for significant allelic imbalance. For TP53 8/22 
samples overall were found to have allelic imbalance with 6 samples (SP, SY, SR, S9, 
SV, SU) found to have deletions and 2 samples (S11, S8) showed amplification. For 
CCND1, 15/37 samples in total displayed allelic imbalance with 4 samples (S1, S2, S4, 
S18) showing deletion and 11 samples (SW, S16, S15, S21, SY, SX, SI, SR, S19, SF, 
S11) showing amplification. Overall the rates of allelic imbalance for TP53 and CCND1 
were 36.4% and 40.5% respectively, both ~10-20% below levels of allelic imbalance 
reported in the literature for the regions harbouring these genes. These initial 
observations then allowed for further assessments to be performed with regards 
correlation of the findings with the previous CGH data as well as the histopathological 
subtype of the sample. 
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Figure 9. [A]. TP53 allelic imbalance in OSCC tumour samples. [B]. CCND1 allelic 
imbalance in OSCC tumour samples. Bar chart representing mean ∆∆Ct value +/- 
standard error of the mean (5 repeats) for all heterozygote samples.  Limits of detection 
determined from previous optimisation experiments were ∆∆Ct >2 (dashed red line) & 
*p<0.05 v control for amplification, ∆∆Ct <0.25 (dashed blue line) & *p<0.05 v control for 
deletion.      Control ∆∆ct = 1.      ∆∆ct >3 & *p<0.05 v control.       ∆∆ct <0.5 & *p<0.05 v 
control (student’s t-test) 
   
A. 
B. 
68 
 
3.3.3 Comparison of TP53 and CCND1 SNP genotyping data and a-CGH data in 
OSCC samples 
  
To validate our earlier a-CGH observations a direct comparison was required with 
regards to concordance of allelic imbalance detected by both methods and identification 
of any significant differences between both sets of findings. For TP53, of the samples 
identified as heterozygote, 2/22 showed amplification & 6/22 showed deletion, 
compared to 1 amplification and 1 deletion identified by the previous a-CGH study. Both 
these levels of TP53 change were significantly lower than that reported in the literature. 
For Cyclin D1 of the heterozygote samples 11/37 showed amplification and 4/37 
deletion, compared to 20 amplified and 1 deletion in the a-CGH study. If sample-specific 
data was compared across both techniques, overall agreement with the a-CGH data 
was 63.6% for TP53 and 75.7% for CyclinD1 with a free marginal kappa statistic of 0.47 
& 0.53 respectively. Table 14. summarises the contrasting findings from both 
techniques.  
The difference in concordance of both methods and the fewer CCND1 amplifications 
observed by q-PCR along with greater TP53 deletions may be explained by the 
respective technical advantages / disadvantages of both techniques. As only 
heterozygote samples could be considered for the q-PCR, sample size was smaller and 
earlier experimental optimisation had revealed a tendency of the TP53 probe towards 
over-estimating allelic imbalance as well as a tendency of the CCND1 probe used 
towards under-estimation (as previously discussed in section 3.3.1.4). On the other 
hand, lack of probe hybridisation in the a-CGH method can lead to predominant under-
estimation of both amplifications and deletions and is particularly less sensitive than 
PCR based methods in detecting deletions [115].  Although low levels of TP53 allelic 
imbalance were found by both methods, the two sets of findings did not show complete 
concordance and hence the SNP genotyping data produced here could not fully validate 
the earlier a-CGH observations. 
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Table 14. Summary of CCND1 and TP53 allelic imbalance detected by SNP assay 
and a-CGH.  
 
 CCND1  TP53  
Total sample number  46  46  
No. of heterozygote samples  37  22  
No. amplified heterozygote samples  11  2  
No. amplified in CGH data  20  1  
No. deleted heterozygote samples  4  6  
No. deleted CGH data  1  1  
No. of samples specifically concordant with a-CGH data (In only 
heterozygote samples)  
28  14  
% agreement between both techniques  75.7%  63.6%  
% disagreement between both techniques  24.3%  36.4%  
Free-marginal kappa (range -1 to 1)  0.53  0.47  
 
 
 
3.3.4 Correlation of allelic imbalance with histopathological subtype 
 
We went on to assess the proportion of samples showing significant allelic imbalance 
from node positive and ECS positive patients to look for any association with 
pathological stage. The a-CGH study had previously found that TP53 and CCND1 allelic 
imbalance were associated with advanced nodal status but not ECS (see section 3.1.3).  
The number of ECS+ve samples showing allelic imbalance was firstly identified. The 
total number of heterozygote samples for TP53 were 22 where only 2 samples showed 
amplification and 6 samples showed deletion. Out of these 6 samples, 4 samples were 
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node positive ECS-ve samples and only 2 ECS+ve samples showed TP53 deletion. The 
majority of heterozygote tumour samples showed no allelic changes for TP53 gene. On 
the other hand, total numbers of heterozygote samples for CyclinD1 were 37, where 11 
samples showed amplification and only 4 samples showed deletion. The majority of the 
samples showing amplification were ECS+ve samples (8/11, 73%). Table 15. Illustrates 
the precise number of heterozygote tumour samples according to pathological data 
correlated with the q-PCR values.  As there were no other previously reported studies of 
ECS and allelic imbalance we did not have reference levels that this could be compared 
to, however it was in keeping with our previous a-CGH study (see section 3.1.3). To 
specifically assess whether these findings had any significant association with ECS, 
statistical analysis was performed using Fisher's exact test, a statistical test performed 
for contingency tables and appropriate for small sample sizes. ECS positive samples 
were not found to be statistically significantly correlated with TP53 deletion or CCND1 
amplification, whereas, TP53 deletion and CCND1 amplification were found to be 
correlated with nodal status in this data set (TP53 deletion p = 0.040 and CCND1 
amplification p = 0.050) 
In conclusion, both SNP analysis and the previous a-CGH study have similar findings 
when correlated with clinical data, with our study finding only an association of TP53 
deletion and CCND1 amplification with advanced nodal status but not ECS. The fact 
that both methods come to similar conclusions with regards to association with one 
marker of aggressive phenotype (nodal status). The findings indicate our cohort may 
harbour a novel, genetically distinct subset of cases but did not identify a potential 
driver of ECS. As a result a further detailed molecular characterisation of ECS, possibly 
through mutational analysis, was suggested. 
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Table 15. Overall number of OSCC samples demonstrating TP53 or CCND1 allelic 
imbalance detected by q-PCR in relation to Nodal status and ECS.  
 
 
 
Total numbers 
p value (Fisher’s exact 
test) 
N-ve 
N+ve ECS-
ve 
N+ve 
ECS+ 
All 
samples 
Nodal 
status ECS 
Number of samples (%) 19 7 20 46 
 TP53 
Total heterozygote 8 7 7 22 
Amplification 0 (0) 1 (14) 1 (14) 2 (9) 
 
Deletion 0 (0) 4 (57) 2 (29) 6 (27) 0.040 0.651 
 
Unchanged 8 (100) 2 (29) 4 (57) 14 (64) 
 
CCND1 
Total heterozygote 14 5 18 37 
Amplification 1 2 8 11 0.050 0.060 
 
Deletion 2 1 1 4 
 
 
Unchanged 11 2 9 22 
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3.4 Discussion 
3.4.1 The identification of allelic imbalance by q-PCR SNP analysis  
 
SNP analysis by q-PCR is a technique that has some distinct advantages in that it does 
not require labour-intensive DNA processing. It can label probes with two or more 
different fluorophores allowing for allelic qualitative assay in a single tube reaction and it 
also enables the detection of allelic imbalance in any double-stranded DNA sequence. 
Our SNP assay optimization experiments showed in a detailed and robust manner that 
the q-PCR method employed, could detect allelic imbalance when average values of 
∆∆Ct detected by the technique had certain limits of detection thresholds applied (≥3 for 
CCND1 or ≥2 for TP53 amplification or ≤0.5 for CCND1 and ≤0.25 for TP53 deletion). 
However, the method was not sufficiently sensitive to allow confident quantitative 
analysis. 
Although the method has been reported previously in the literature as being able to 
sensitively quantify allelic imbalance [144], the poor performance in quantifying actual 
fold differences in amplification and deletion observed here is most likely due to artefact 
produced from nonspecific probe binding as also previously described [145]. Thus, 
variability may arise due to different test amplification properties and reference loci, as 
well as the differential yield sensitivity of each amplification reaction to the precise 
conditions [146]. The sensitivity of the assay could also have varied because of the 
amplification of normal cell DNA mixed with the tumour sample. When analysing 
heterogeneous tumour tissue, unjustified imbalance calling may occur. As the SNP 
resolution is relatively low, an inconclusive result may be obtained when a substantial 
number of the employed SNPs are homozygous and as a result non-informative. 
However, this issue could be overcome by increasing the number of SNPs to be 
analysed.  
Although the development of genome-wide CNV screening has been used and applied 
to assess allelic imbalance in OSCC samples, including array-CGH and SNP arrays 
(see Table 10), However, q-PCR is a frequent computationally identified loci validation 
method [147]. q-PCR has been used in large-scale CNV analysis in detecting disease 
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associations in OSCC [148]. Thus, findings previously from the literature in combination 
with our own optimisation and understanding of the limitations of the q-PCR method still 
justified the further use of the method for the assessment of CCND1 and TP53 allelic 
imbalance in relation to ECS. 
3.4.2 Allelic imbalance assessment for CCND1 and TP53 in association with ECS 
 
The overall rate of allelic imbalance by the SNP assay was found to be 41% for CCND1 
and 36% for TP53 in heterozygote samples. This compares to previous reports of the 
over-expression rate of CCND1 being 25-70% in patients with oral cancers [138] but for 
TP53 around 50% [149]. One explanation for this along with the overall lack of 
association observed with ECS in this study could be explained by the reduced sample 
size from exclusion of homozygote samples. Indeed, only 22 samples showed 
heterozygosity for TP53 gene whereas 37 samples showed heterozygosity for CCND1 
gene. This has previously been reported as a drawback leading to inconclusive findings 
in other cancer studies [150].  
The SNP assay in both instances found greater numbers of deletions than a-CGH 
(CCND1: 4 in SNP assay /1 in a-CGH, and for TP53: 6 in SNP assay /1 in a-CGH) that 
contribute to the slight difference in overall findings in between techniques. Indeed 
previous studies have shown that a-CGH has the disadvantage of being less sensitive 
in detecting deletions than PCR based methods [141].  Specifically, in the case of TP53, 
optimization experiments for the TP53 probe used in the quantitative PCR had already 
revealed slight over-estimation, which might also explain the difference in the number of 
samples deleted in the q-PCR data compared to the a-CGH data. Along with this, the 
sensitivity of both analyses can be hampered by admixture of tumour with normal 
stromal cells as well as the consideration that tumours can be composed of sub clones 
affecting analysis [151]. The sensitivity of a-CGH depends on visual interpretation and 
although digital image analysis can be applied to improve sensitivity, large copy 
differences are still more readily detected than smaller ones [115]. The difference 
observed in concordance between both techniques (free marginal kappa statistic of 0.47 
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for TP53 and 0.53 for CyclinD1) could also be explained by the q-PCR method suffering 
from nonspecific probe binding that may lead to both over and under estimation.  
In total in our analysis 28.6% node positive ECS+ve samples showed deletion for TP53 
gene and 44.4% ECS+ve samples showed amplification for CCND1 gene. After Fisher's 
exact test was applied, p values correlated with TP53 deletion and CCND1 amplification 
with ECS positive samples did not reach any statistical significance. However, TP53 
deletion and CCND1 amplification were correlated with nodal status (TP53 deletion 
p=0.040, CCND1 amplification p=0.050). Future work increasing the total number of 
samples in different groups especially with regard to ECS cases (20 cases in this 
series) needs to be performed before stronger conclusions can be drawn especially in 
relation to the aggressive phenotype of OSCC, ECS. Furthermore, due to the 
drawbacks of both the a-CGH and SNP assay approaches, a more detailed quantitative 
assessment with re-validation of the findings obtained by this part of the study 
potentially using Multiplex ligation-dependent probe amplification (MLPA) techniques. 
MLPA is a multiplex method that can detect abnormal copy numbers [152]. Using MLPA 
for copy number detection offers some advantages over CGH and FISH techniques; 
because it can identify the frequent, single gene aberrations, it can be used on purified 
DNA and compared to array CGH, MLPA is a cost effective and technically 
uncomplicated method [115].  
3.4.3 Future directions arising from allelic imbalance analysis for ECS biomarker 
discovery  
 
There are several other issues that arise from this part of the study. Firstly, copy 
number changes may not necessarily be reflected in expression so further studies 
clarifying ccnd1 and p53 protein levels may prove useful in interpreting the data. 
Nevertheless, copy number alterations have been published in the literature to be 
associated with a variety of different cancers including head and neck cancer. In a high 
profile study of 279 HNSCC cases, 39 regions of recurrent copy number loss and 23 
regions of recurrent copy number gain were identified [21]. After the start of this study 
there have been papers demonstrating that Cyclin D1 amplification [135, 153] and TP53 
deletion [135] are related to OSCC cases. Amplification of CCND1 gene has been 
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reported in 25-70% of oral cancers premalignant lesions suggesting that cyclin D1 gene 
amplification may be an early event during oral tumourigenesis [70]. Another study on 
164 OSCC cases showed that Cyclin D1 allelic imbalance is an independent predictor 
for worse survival in OSCC in HPV negative cases and a promising biomarker for 
predicting lymph node metastasis in patients with clinically Stage I–II OSCC. [154]. 
The results from our samples found CCND1 amplification and TP53 deletion to be 
correlated with nodal status. This is consistent with another study where frequent gain 
was observed in CCND1, exclusively in OSCC patients with cervical lymph node 
metastasis [130]. Overall, the contradictory results could be because of micro 
metastases present in the samples, which are known to be potentially missed by 
pathologists examining a dissected specimen [18]. Our study did not find many changes 
in TP53 in our subset of OSCC cases. This finding contrasts with other genome wide, 
mutational and genome copy profiling data reported for all head & neck cancers, which 
predominantly report TP53 as a commonly mutated gene (around 50%) [102]. Loss of 
heterozygosity (LOH) was also observed for the TP53 gene in oral cancer series [155]. 
A potential explanation for this could be provided by the Cancer Genome Atlas project 
that assembled the genomic data of 3,299 tumour samples of 12 tumour type and a 
closer inspection of the distribution of data showed a striking inverse relationship 
between copy number alterations and somatic mutations placed at the extremes of 
genomic instability. The data showed that the tumours had either a large number of 
copy number alterations or a large number of somatic mutations, never both. They refer 
to this trend as the cancer genome hyperbola [137]. Keeping that trend in mind, lack of 
TP53 allelic imbalance leads to a possibility of finding mutations in our OSCC series. 
Although many studies have focused on allelic imbalance with relation to HNSCC and in 
particular OSCC, none of these studies have specifically examined any correlation with 
extra capsular spread of OSCC. This suggested a mutational analysis of ECS in OSCC, 
as a further progression of the present study, would be worthwhile with the overall aim 
of better molecular characterisation of this aggressive phenotype in OSCC.   
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Chapter 4 : Screening for 
genomic variants in 
primary OSCC cell lines  
 
 
 
 
 
 
 
 
77 
 
4.1 Introduction 
 
Results in Chapter 3 suggested that although TP53 loss and CCND1 were associated 
with nodal status but not ECS, the low frequency of TP53 change may be associated 
with a previously unidentified subtype of OSCC.  As a result, we initially decided to 
perform a mutational screen on new primary cell lines, of known histopathology, 
obtained through local collection. 
4.1.1 Large scale genome sequencing in cancer  
 
Greenman and co-workers undertook comprehensive Sanger Sequencing of 518 
protein kinase-encoding genes in 210 different cancers including lung, breast, 
colorectal, gastric, testis, renal, ovarian, glioma, melanoma and acute lymphoblastic 
leukaemia for somatic mutation detection in coding exons and splice junctions, reporting 
more than 1,000 somatic mutations overall [156]. Most somatic mutations were deemed 
potential ‘passengers’, not contributing to oncogenesis, whereas 158 predicted ‘driver’ 
mutations were identified on the basis of a statistical model comparing the observed to-
expected ratio of synonymous (no amino-acid change) mutations with that of 
nonsynonymous (altered amino acid) mutations. Most kinase mutations were ‘single 
hits’ [156]. Sjoblom and co-workers used a different strategy, but reached similar 
conclusions. Analysis of 13,023 genes in 11 colorectal and 11 breast cancers revealed 
that individual tumours gather an average of 90 mutant genes with only a subset of 
these genes contributing to the neoplastic process. They identified 1,307 validated 
nucleotide changes in 1,149 genes, of which 189 were significantly mutated. A few 
overlapping driver mutations were identified in the kinase genes analyzed in these two 
studies. [157]. Further whole exome sequencing of a series of glioma, breast, colorectal 
and pancreatic cancers [158-160] had also suggested distinct ‘driver’ and ‘passenger’ 
mutations co-exist in cancers, with driver mutations being key to altering cellular 
pathways associated with the acquisition of aggressive phenotype. Such studies have 
become increasingly comprehensive as Next Generation methods of sequencing have 
been invoked [161-164]. 
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4.1.2 Next generation sequencing applied to HNSCC 
 
Like the cancer studies outlined in 4.1.1, whole exome sequencing has also been 
conducted for HNSCC. Approximately 100 HPV positive and negative HNSCC 
specimens (sites include oral cavity, oropharynx, hypopharynx, larynx, and sinonasal 
cavity) were analysed independently by two groups to understand the pathology of 
HNSCC [101, 102]. One study employed whole exome sequencing analysis (150-fold 
mean sequence coverage of targeted exonic regions) from 74 tumour-normal pairs and 
revealed that frequent mutation occurs in previously known TP53, CDKN2A, PTEN, 
PIK3CA, and HRAS genes. Along with this at least 30% of cases showed mutations in 
NOTCH1, IRF6, and TP63 genes that regulate squamous differentiation implicating its 
deregulation as a major driver of HNSCC carcinogenesis. This analysis identified only 
39 genes with high statistical significance. However, most mutated genes did not reach 
any statistical significance which suggests these could be passenger events. The most 
commonly mutated gene in HNSCC was TP53, whereas around 11% of the HNSCC 
tumours showed NOTCH1 point mutations. In addition, non-synonymous point 
mutations in NOTCH2 or NOTCH3 were also found in 11% of the samples. Recurrent 
mutations were observed in less well characterized genes like SYNE1 and SYNE2 
(20% and 8% of HNSCC samples respectively) along with two apoptosis related genes 
CASP8 (8%) and DDX3X (4%) [102]. 
 
Myers et al. had broadly similar findings employing whole exome sequencing analysis to 
study 32 primary tumours and identified 911 candidate somatic mutations in 725 genes. 
They found recurrent mutations in RIMBP2, PIK3AP1, SI, NRXN2, EPHA7, NRXN3, 
RASA1, HRAS, RXFP3, PIK3CA, TP53, NOTCH1, CDKN2A and FBXW7. They further 
analyzed the sequences of these genes in additional HNSCC cases where somatic 
mutations in TP53, NOTCH1, CDKN2A, PIK3CA, FBXW7 and HRAS were identified in 
47%, 15%, 9%, 6%, 5% and 4% of patients, respectively. The remaining genes were 
not observed to be mutated in more than one of the additional samples analyzed. They 
also found TP53 and NOTCH1 were the most frequently mutated genes in HNSCC 
[101]. If both studies are compared, there was a five-fold difference in the average 
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number of mutations reported per tumour although the two studies analyzed 
etiologically similar cases using related sequencing platforms. One explanation for this 
diversity could be the heterogenous nature of HNSCC or site-specific differences, risk-
factor exposure related differences or indeed differences in aggressive phenotype 
amongst the samples used with limited consideration of detailed histopathological (such 
as ECS) and long term clinical correlates. 
 
Another study highlighted new insights into HNSCC from studying 279 primary tumours 
from HNSCC patients [21]. Whole-exome sequencing identified somatically mutated 
genes which are mainly located in regions of Copy number alterations. 37,061 non-
synonymous somatic variants were detected with 11 statistically enriched genes. TP53 
mutation among HPV negative samples was found at a higher rate (86%) than the 
previously reported papers. Among inactivating mutations, four genes were found 
predominantly in HPV negative tumours. Two of them are CDKN2A and TP53 
associated with cell cycle and survival and the other two were FAT1 and AJUBA, linked 
to Wnt/b-catenin signalling. Apart from this, a frequently mutated novel gene, the 
nuclear receptor binding SET domain protein 1 (NSD1), was identified in 33 HNSCCs. 
Significant inactivating mutations were found in genes linked to squamous differentiation 
including in NOTCH1 (19%), consistent with other reports. Other heavily mutated genes 
were NOTCH2 (9%), and NOTCH3 (5%), and the TP63 target gene ZNF750 (4%). This 
study identified additional mutations in TRAF3, RB1 and NFE2L genes. Of the known 
oncogenes, only PIK3CA achieved statistical significance. These recent studies predict 
that the inactivation of AJUBA, as well as FAT1 and NOTCH1, may converge to 
uncheck Wnt/b-catenin signalling, implicated in deregulation of cell polarity and 
differentiation, then leading to accelerated progression in HNSCC [21].  
 
These studies used fresh, primary tumour tissues. A complimentary follow-up study 
used DNA samples from 252 formalin fixed paraffin-embedded (FFPE) HNSCC tumours 
and gave similar results. In both HPV positive and negative HNSCCs, mutations were 
more commonly identified in tumour suppressor genes compared to oncogenes. The 
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most common altered pathway by mutation was PIK3CA (30%) followed by PTEN 
(15%), AKT1 (5%), RICTOR (4%), mTOR (2%), AKT2 (2%), and PIK3R1 (2%) [80].  
 
The studies differed in a number of ways. Stransky et al. performed whole exome-
sequencing of 74 tumour/normal pairs, with 150-fold mean coverage, while Agrawal et 
al. only sequenced 32 tumour/ normal pairs, with a mean coverage of 77-fold and 
followed up with targeted follow-up sequencing of frequently mutated genes in an 
additional 88 patients. For HPV-negative tumours, Stransky et al. found a mutation rate 
of 4.83 per Mb while Agrawal et al found a mutation rate of 20.6 per Mb. The large 
discrepancy between the two groups may have arisen from differences in bioinformatics 
techniques for mutation calling or differences in coverage of sequencing. Since these 
initial studies, two other groups have determined mutations specifically in OSCC [136, 
165].  
The main observations from these studies are summarized in Table 16. Two of the 
studies required additional sequencing because of mean coverage falling below 100. 
Each study had slightly different patient cohorts and characteristics and different rates 
of significantly mutated genes was observed between studies. Use of formal statistical 
testing also varied. Nevertheless, selecting the most frequently altered genes based on 
high mutational frequency or relation to aggressive phenotype allows useful 
comparisons.TP53, CDKN2A, CASP8, FAT1, NOTCH1, HRAS, PIK3CA, MLL2 and 
FBXW7 were most frequently altered. All studies found TP53 to be the most mutated 
gene, the first two studies found NOTCH1 to be the second most mutated but for the 
more recent studies this was FAT1. FAT1 was not found to be mutated at all by Agrawal 
et al. Pickering et al. had the lowest rate of HPV positivity and found the lowest rate of 
NOTCH1 mutation at 9%. The India ICGC cohort had the highest proportion of smokers 
in their cohort and found significantly greater rates of CASP8 mutation compared to the 
other studies. The comparison suggests that while TP53 may play a consistent central 
role in the pathogenesis of OSCC the other genes that may contribute to and drive 
disease progression with aggressive phenotype may be quite heterogeneous in nature 
and dependent on cohort-specific environmental as well as sequencing method factors. 
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Table 16. Summary of whole exome sequencing studies in HNSCC/OSCC. Sample 
characteristics and mutations observed by four next generation sequencing studies of 
HNSCC and OSCC. OC= oral cavity, OP= oropharynx, H= hypopharynx, L= larynx, SC= 
Sino nasal cavity. 
 
 
 Stransky et 
al. 
 
Agrawal et al. Pickering et al. India ICGC 
 
TCGA 
Total number of 
samples 
74 
 
32 40 50 279 
Sequencing 
Platform 
Illumina Illumina & 
SOLiD 
Illumina & 
SOLiD 
Illumina Illumina 
Disease sites 
 
OC, OP, H, L, 
SC 
OC, OP, L, H OC OC OC, OP, L 
Smokers 
 
89% 75% 78.6% 96% 79% 
HPV positivity 
 
14% 25% 2.5% 26% 13% 
Mean coverage 
 
150 77 119 38 95 
Whole exome 
 
72 32 40 50 279 
Whole genome 
 
2 0 0 0 29 
Additional 
tumours  
NA 88 NA 60 NA 
Significantly 
mutated genes 
39 6 53 10 19 
TP53 
 
62% 47% 66% 62% 72% 
CDKN2A 
 
12% 9.2% 0% 2% 22% 
CASP8 
 
8% 3% 10% 34% 9% 
FAT1 
 
12% 0% 28% 40% 23% 
NOTCH1 
 
14% 15% 9% 16% 19% 
HRAS 
 
5% 4% 9% 12% 4% 
PIK3CA 
 
8% 6% 11% 6% 21% 
MLL2 
 
11% 0% 9.5% 10% 0% 
FBXW7  
 
5.4% 5% 4.7% 2% 5% 
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Although these studies give valuable genomic insights into OSCC, there is no study 
reported so far screening for mutations in OSCC that may be related to ECS. In 
addition, they were performed using either fresh OSCC primary tumour samples or 
FFPE fixed samples, with no possibility of follow up studies in matching OSCC cell 
lines.  
Few studies have characterised OSCC cell lines by focusing on candidate genes. Soichi 
et al. identified mutations in three out of four OSCC cell lines for APC and Axin genes, 
both genes regulating the Wnt pathway and implicating its role in OSCC [166]. Kozaki 
et al. identified PIK3CA missense mutations in 21.4% (3/14) of OSCC primary cell lines 
derived from patients at different stages (I- IV). The highest frequency of PIK3CA 
mutations was observed in stage IV of the disease with a statistically signiﬁcant 
association between the frequency of mutation and stage (P = 0.042, Fisher’s exact 
test) suggesting a role for the PI3K-AKT signaling pathway in OSCC progression [167]. 
The same pathways were implicated by the Exome sequencing studies in OSCC 
tumour samples as previously discussed supporting the value of using primary OSCC 
cell lines as being representative for understanding the pathogenesis of OSCC and 
significance regarding ECS.  
 
4.1.3 Primary cell lines for candidate gene selection in OSCC 
 
In our lab, as a parallel project, five primary keratinocyte cell lines had been cultured 
from fresh oral cancer tissue samples having known histopathology. As a preliminary 
screen for genetic variants that may be associated with aggressive behaviour, low pass 
whole genome SOLiD sequencing was performed on these cell lines. The cell lines 
used and their corresponding nodal status are listed in Table 17.  Cell lines from node 
positive patients but without ECS were not available at this time, reducing the possible 
types of comparison.   
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Table 17. Primary OSCC cell lines used for Low Pass WGS.  
Cell line Phenotype 
Liv4K Node negative 
Liv22K Node negative 
Liv7K Node positive ECS+ 
Liv12K Node positive ECS+ 
Liv26K Node positive ECS+ 
 
 
 
4.2 Hypothesis and aim 
Hypothesis: Specific genetic alterations are associated with ECS in OSCC. 
Aim: Compare primary OSCC cell lines by whole genome sequencing utilising the 
SOLiD platform to identify gene variants that may have a relation to ECS.  
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4.3 Results 
 
4.3.1.1 SOLiD sequencing data acquisition 
 
SOLiD Fragment DNA library preparation was performed initially for a DNA sample from 
the human random control panel and then for each of the cell lines listed in Table 17 
using the standard protocol described in section 2.7.4. Successful ligation of P1 & P2 
adaptors to DNA fragments was confirmed by using agarose gel (1.2%) electrophoresis 
to resolving products. Figure 10. shows addition of adaptors leading to a shift (a~30 bp) 
in the average size of sheared DNA fragments (lane 7) compared to sheared DNA 
without adaptor ligation (lane 5). Purified ligated products were then separated using a 
2% agarose Library Size Selection Egel to select fragments of 200-230bp for further 
nick translation and amplification by PCR. Successful final library preparation was 
confirmed by further agarose gel (1.2%) analysis shown in Figure 11. This shows nick 
translated & amplified libraries of different fragment sizes 200-230bp (lanes 3, 4 and 5) 
compared to a control with no nick translation and absent product (lane 2). Once library 
optimisation was completed using human random control DNA, the same methods 
(section 2.4) were applied to DNA extracted from each cell line described in Section 
4.1.3. 
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Figure 10. Agarose gel showing products of P1 and P2 Adaptors ligated to Human 
Control DNA. Lane key: 1=1 Kb DNA Ladder, 3,10=100bp DNA Ladder, 5=Sheared Control 
DNA, 7= Sheared Control DNA + Adaptor + Ligase, 8=Negative control  
 
 
               
Figure 11. Agarose gel of nick translated and amplified final Human Control DNA 
SOLiD libraries. Lane key: 1=100bp DNA Ladder, 2=No nick translated DNA 3,4,5= 
Nick translated and amplified libraries from 200-230bp in size, 6=Negative control  
 
 
1.          2.        3.          4.        5.         6.          7.         8.          9.         10. 
1.                 2.                   3.                4.                  5.                    6. 
 
 
1000 bp 
500 bp 
 
300 bp 
200 bp 
100 bp 
500 bp 
300 bp 
100 bp 
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4.3.1.2 Quality control of OSCC cell line libraries  
 
The OSCC cell line fragment libraries were analysed for size distribution and quality 
using an Agilent 2100 Bioanalyser, see Figure 12., prior to being pair-end sequenced 
using the SOLiD™ sequencer in the Centre for Genome Research, Liverpool. The 
average sizes of the fragments were 300bp as required for SOLiD sequencing. 
                                                          
                                       
 
 
 
 
Figure 12. Size 
distribution of 
primary OSCC 
cell line SOLiD 
libraries A. 
Bioagilent 
electrophoresis gel 
image of fragment 
size of libraries 
generated from 
different cell lines 
(L=ladder, lane 
1=Liv4K, lane 
2=Liv7K, lane 
3=Liv12K, lane 
4=Liv22K, lane 
5=Liv26K) compared 
to positive control 
DNA libraries (lanes 
6 & 7) and water as a 
negative control 
(lane 8). B. 
Bioagilent 
fluorescence (FU) 
traces of 5 cell line 
libraries compared to 
water and ladder. 
 
A. 
B. 
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4.3.2.1 Overall Coverage generated from OSCC cell lines  
 
Sequences from the libraries were aligned to human genome (HG19) and initial data 
analysis was performed within the Centre for Genomic Research (CGR) using BWA 
(Burrows Wheeler Aligner)  as described in section 2.8.3. Table 18., shows the 
sequence summary for each OSCC sample. The total number of reads ranged from 811 
x 106 - 962 x 106 and percentage of mapped data against HG19 reference data ranged 
from 89.39%-92.86%, indicating that the data was suitable for further analysis. 
However, the mean overall coverage for each sample was low (<10) in unique 
sequences with regions showing 30× average depth ranging from 57.21%-72.63% 
across samples. This suggested that while some conclusions could be confidently made 
from the data, it would be important to assess individual variant coverage before coming 
to firm conclusions. 
 
Table 18. HG19 coverage by sequence data from SOLiD sequencing of OSCC cell 
line samples.   
 
 
Sample Total Reads Mapped HG19 
covered % 
Mean Cov 
(sampling 
every 1k 
bases) 
% sample 
with 30× 
average 
depth 
No.of  
variants 
No. of 
INDELs 
Liv4K 861,811,594 78.48% 89.84% 8.55 66.74% 1,833,275 211,272 
Liv7K 924,316,936 79.15% 89.10% 8.14 62.98% 1,805,627 48,421 
Liv12K 854,142,556 77.06% 92.86% 8.39 65.43% 1,792,593 212,130 
Liv22K 962,374,430 78.27% 90.05% 9.6 72.63% 1,979,526 244,099 
Liv26K 810,808,638 64.60% 89.39% 6.61 57.21% 972,840 98,281 
 
 
 
 
88 
 
4.3.2.2 Analysis of Cross contamination between OSCC samples  
 
To check for cross contamination between samples, specific gene variant profiles were 
considered using haplotype data. The large gene TTN was selected for comparison 
between samples. Although there were a number of common variants observed across 
all the different OSCC cell lines, the majority of variants identified were clearly sample 
specific variants. Furthermore, statistical analysis using a Chi-square test comparing 
two different outcome groups (numbers of homo and heterozygote variants) for each 
cell line combination in turn demonstrated significant differences (p<0.05) between all 
cell line comparisons. This indicated each cell line has their own unique genetic 
landscape of germ line variants. Thus, we concluded that although there was low 
coverage in certain regions, cross-contamination was not present and regions with 
satisfactory coverage around 30 for variant calling, based on the established literature 
[168, 169], could be used to screen for variants in support of further analysis.  
 
4.3.2.3 Identification of novel INDELs 
  
We therefore performed VEP (variant effect predictor) analysis on the SOLiD 
sequencing data. Only variants with coverage 30× average depth were considered for 
further analysis. Table 19. summarises the VEP analysis for each cell line. Of variants 
with potentially deleterious effects (stop gain/loss, start loss, missense variants and 
coding sequence variants), node -ve cell lines displayed marginally a greater number 
(12,582 and 13,525) than ECS+ve cell lines (11,621; 12,025 & 7,243), but small sample 
size precluded any further interpretation. Figure 13. summarises the total for each cell 
line with a breakdown of variants between samples according to ECS status.  
The complete list is tabulated in the supplementary CD (supplementary Table 1). 3313 
INDELs with severe consequences were identified. Furthermore, the affected genes 
harbouring these INDELs were then compared to produce a list of 149 genes affected in 
one or more cell lines. These genes were then arranged in a binary chart to highlight the 
distribution across ECS +ve and -ve cell lines (Figure 14). No novel INDELs were 
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identified for CCND1 and TP53 consistent with the assessment of allelic imbalance in 
the previous chapter 3. No INDELs identified were present in both ECS -ve cell lines, 
however 6 genes were identified with INDELs in two or more ECS +ve cell lines; 
CDK11A (present in all three ECS+ve cell lines tested), FRG1B, TRIT1, MUC17, 
SLC16A7 and ZNF720. If these genes are considered; FRG1B is a pseudogene [170], 
TRIT1 modifies tRNA [171], MUC17 codes for a membrane bound mucin [172], 
SLC16A7 belongs to the monocarboxylate transporter family [173] and ZNF720 codes 
for a zing finger protein involved in nucleic acid binding [174]. 
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Table 19. Types of Variants identified by VEP analysis in Primary OSCC cell lines. 
Variants with potentially deleterious consequences are highlighted in red 
 Liv4k Liv7k Liv12k Liv22k Liv26k Total 
Splice acceptor variant 105 203 209 203 59 779 
Splice donor variant 183 118 114 127 118 660 
Stop gained 103 114 104 115 49 485 
Stop lost 42 31 45 36 22 176 
Start lost 40 17 39 39 17 152 
Missense variant 12393 11458 11835 13314 7154 56154 
Splice region variant 5673 5367 5664 6218 3292 26214 
Incomplete terminal 
codon variant 
2 23 1 1 3 30 
Synonymous variant 14195 13694 14235 15930 8350 66404 
Coding sequence 
variant 
4 1 2 21 1 29 
Mature miRNA variant 14 14 14 3 6 51 
5 prime UTR variant 4909 4618 4782 5719 2874 22902 
3 prime UTR variant 28840 27336 27289 31099 16112 130676 
Noncoding transcript 
exon variant 
37688 35788 36274 41896 21663 173309 
Intron variant 3495332 3405018 3428187 3765968 1934695 16029200 
NMD transcript variant 279527 271680 274004 300717 158166 1284094 
Non coding transcript 
variant 
937624 914838 920450 1008214 519333 4300459 
Upstream gene variant 441876 429659 433067 487939 248765 2041306 
Downstream gene 
variant 
454851 444310 446113 502712 258346 2106332 
TF binding site variant 2462 2418 2415 2896 1524 11715 
Regulatory region 
variant 
233462 223469 228228 252415 135903 1073477 
Intergenic variant 696777 682938 669123 732465 361960 3143263 
Total 6646102 6473112 6502194 7168047 3678412 30467867 
. 
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Figure 13. Summary of total numbers of variants and INDELs with potentially 
severe consequences on the basis of ECS status in each OSCC primary cell line. 
Cell lines are grouped according to ECS status.  
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Of interest 
Figure 14. Summary of 
genes harbouring novel 
INDELs with potential 
severe consequences on 
the basis of ECS status 
in OSCC primary cell 
lines. The Binary chart 
demonstrates the 
presence (red) or absence 
(blue) of gene INDELs 
within each OSCC cell line 
distributed on the basis of 
ECS status. Genes were 
sorted on the basis of 
number of cell lines 
harbouring an INDEL with 
a greater number placed 
superiorly within the chart. 
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Of particular interest is CDK11A, found in all 3 ECS +ve cell lines, coding for a cyclin 
dependant kinase having multiple roles in cell cycle progression, cytokinesis and 
apoptosis [175]. Although the function of CDK11a in OSCC remains unclear, 
translocation or deletion of CDK11 has been reported in neuroblastoma [176].  
 
4.3.2.4 Identification of Novel single nucleotide variants   
 
Novel synonymous/non-synonymous variants with 30× average depth for all the primary 
OSCC cell lines were extracted from the VEP analysis (completely listed in the 
supplementary CD Table 2 and 3).  A total of 4,788 Synonymous variants and 11,099 
Non-synonymous variants were identified with the distribution across all OSCC cell lines 
according to ECS status summarised in Figure 13. The genes affected by non-
synonymous variants with potentially severe consequences (defined as missense, stop 
gain or loss) were identified and analysed across all of the OSCC samples. In total 448 
genes displayed a potentially deleterious variant in one or more cell line, however to 
further focus on key gene variants we produced a list of 27 genes with variants in two or 
more cell lines from which we compiled a binary chart to assess the distribution on the 
basis of ECS status (Figure 15). CDC27 stood out as having variants in all 3 ECS +ve 
cell lines as well as one Node -ve cell line. CDC27 is an anaphase-promoting complex 
(APC) component that as a result may influence the timing of cellular mitosis [177]. 
Overexpression of CDC27 has been observed in colorectal cancer and is significantly 
correlated with tumour progression and poor patient survival [178], however no 
association has been found with head and neck cancer to date. 
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Figure 15. Genes affected by novel non-synonymous variants with potentially 
severe consequences in more than one OSCC primary cell line. 27 genes 
represented in this binary chart were identified from the VEP analysis to have missense, 
stop gain or loss variants identified by WGS. Cell lines are arranged according to ECS 
status and genes have been sorted to demonstrate those with most gene variations 
superiorly. Presence of gene variant shown by red square, absence by blue. 
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4.3.2.5 Pathway analysis for genes having potentially severe functional 
consequences in primary OSCC cell lines  
 
All variants with potentially severe consequences from more than one cell lines were 
identified to produce a list of 176 genes (summarised in supplementary CD Table 4). 
This corresponding Refseq list of genes was used for pathway analysis using 
REACTOME software. 849 pathways were found to be effected (Supplementary CD 
Table 5). Of these, 14 pathways were significant as determined by p values <0.05, listed 
in Table 20. The majority of pathways effected concerned signal transduction. Notably, 
the only other disease pathway affected was Notch pathway signaling within these 
OSCC samples with p values of 0.040 as a result of an FBXW7 potentially deleterious 
variant identified in an ECS+ve (Liv26k) cell line (Table 21.). 
 
 
Table 20. Pathways significantly affected by potentially deleterious gene variants 
identified by SOLiD sequencing of primary OSCC cell lines. 14 signaling pathways 
were identified by Reactome to be significantly effected (p values <0.05) in our primary 
OSCC cell lines.  
Pathway Name p value 
Calmodulin induced events 0.005425621 
CaM pathway 0.005425621 
Ca-dependent events 0.010781121 
Cam-PDE 1 activation 0.012481681 
ABC-family proteins mediated transport 0.018570859 
DAG and IP3 signaling 0.019213819 
Downregulation of ERBB4 signaling 0.022366303 
PLC-gamma1 signaling 0.023612493 
EGFR interacts with phospholipase C-gamma 0.023612493 
PLCG1 events in ERBB2 signaling 0.026052535 
PLC beta mediated events 0.036486897 
G-protein mediated events 0.039389011 
FBXW7 Mutants and NOTCH1 in Cancer 0.040063907 
Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling 0.040063907 
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Table 21. An ECS+ve FBXW7 potentially deleterious single nucleotide variant. A 
missense FBXW7 variant found in a node positive ECS positive cell line (Liv 26K)
Cell line Variant Coverage Consequence Gene 
Liv26K chr4: _153273729_A/G 28.9 Missense variant FBXW7 
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4.3.2.6 Comparison with other sequencing studies 
  
We then compared our variant analysis observations to the established literature, 
particularly the next generation sequencing studies discussed earlier and summarised 
in Table 22 [21, 101, 102, 136, 165]. On specific comparison of our data with the list of 
significantly mutated genes produced from these studies we observed many similarities 
with 7/9 significantly mutated genes also found to have variants in our study. The gene 
with the highest variant frequency was CASP8, found to have variants in three cell lines 
including two ECS+ve cell lines. This was then followed by TP53 and CDKN2A.  
 
 
 Table 22. Presence of significantly mutated genes in OSCC from the literature in 
our WGS data. Variant frequencies of nine key genes are shown for all OSCC cell lines 
along with their ECS status. 
Gene Stransky 
et al. 
  
Agrawal 
et al. 
Pickering 
et al. 
India 
ICGC 
  
TCGA Number of 
cell lines 
with variant 
Phenotype of 
cell line 
TP53 62% 47% 66% 62% 72% 2/5 
N-ve,  
ECS +ve 
CDKN2A 12% 9.20% 0% 2% 22% 2/5 
N-ve,  
ECS +ve 
CASP8 8% 3% 10% 34% 9% 3/5 
N-ve,  
2 x ECS+ve 
FAT1 12% 0% 28% 40% 23% 1/5 ECS +ve 
NOTCH1 14% 15% 9% 16% 19% 0/5 - 
HRAS 5% 4% 9% 12% 4% 1/5 N-ve 
PIK3CA 8% 6% 11% 6% 21% 1/5 N-ve 
MLL2 11% 0% 9.50% 10% 0% 0/5 - 
FBXW7  5.40% 5% 4.70% 2% 5% 1/5 ECS+ve 
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The missense variant in FBXW7 within an ECS+ve cell line (summarized earlier in table 
21), had contributed to our finding on REACTOME analysis that the Notch pathway was 
a key disease pathway altered within our cell lines. However, no NOTCH1 or MLL2 
variants were identified in our sequencing data. Unlike MLL2, with variants absent in 
two sequencing studies [21, 101], NOTCH1 had significant variants identified by all 
sequencing studies. Furthermore, considering our overall aim was to assess 
associations with ECS and aggressive phenotype, NOTCH1 (responsible for cell fate 
determination, proliferation, differentiation and apoptosis) [179] was theoretically a 
stronger candidate to pursue for association than CASP8 (primarily responsible for 
apoptosis) [180] albeit with an absence of variants in our cell lines. Thus, in the light of 
the importance of Notch signalling highlighted by our pathway analysis, the suggested 
importance of the NOTCH pathway from the established literature and the absence of 
NOTCH1 variants within our dataset, we considered whether a NOTCH1 deletion could 
be present in all cell lines or whether there was a technical reason for absence of 
variants.  
 
4.3.2.7 Specific NOTCH1 coverage analysis of OSCC Cell lines 
 
 A more detailed targeted coverage analysis for NOTCH1 was performed. Reduced 
coverage (5× average depth) of NOTCH1 in comparison to the other genes was 
observed suggesting a possible NOTCH1 deletion.  
Table 23. Mean Coverage in our series for genes reported to be significantly 
mutated in the Literature. 
Gene Mean Coverage 
TP53 42 
CDKN2A 8 
CASP8 39 
FAT1 32 
NOTCH1 5 
HRAS 51 
PIK3CA 38 
MLL2 36 
FBXW7  46 
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However, similar observations across all cell lines raised the concern that this could be 
an artefact. Therefore, the data was sent for reanalysis by an independent centre 
(Lifescope). Low NOTCH1 (around 5× average depth) coverage was found in both 
analyses. We assessed whether this could be a gene specific observation related to the 
nature of whole genome sequencing rather than an observation specific to this study by 
comparing NOTCH1 coverage from a complementary parallel project in our lab using 
SOLiD sequencing of CLL (Chronic lymphocytic leukemia) as well as NOTCH1 
coverage downloaded from the Genome 1000 database. Low NOTCH1 coverage 
evidenced by absence of reads on IGV visualization for both the CLL sample and 
genome 1000 downloaded data, similar to our OSCC cell line data. Thus, we can 
conclude that NOTCH1 coverage within the OSCC cell line dataset is low and 
attributable to the SOLiD platform used. As a result, we were unable to call variants for 
NOTCH1 gene based on this data.  
 
4.4 Discussion 
We set out to screen for genetic alterations associated with ECS in OSCC using next 
generation SOLiD sequencing and primary OSCC cell lines so as to produce a list of 
candidate genes that were associated with ECS, a marker of aggressive behaviour in 
OSCC. Production of SOLiD sequence libraries was successfully optimised as 
determined by the sizes of fragments generated from control DNA.  The method was 
used subsequently for DNA from five of our primary OSCC cell lines (2 N-, 3 ECS+). 
SOLiD sequencing of these libraries was performed, Sequence coverage of HG19 was 
reasonable overall but uneven coverage in specific genes of interest was found, in 
particular NOTCH1, which we felt was a candidate for association with ECS on the 
basis of the reported literature and our WGS REACTOME pathway analysis. Although 
the uneven coverage precluded detailed structural rearrangement analysis, haplotype 
analysis did confirm an absence of cross-contamination and adequate coverage (30 × 
average depth) in the majority of regions (58%-73% range in samples) making the data 
amenable to further analysis. A variety of unknown non-synonymous variants and 
INDELs with potentially deleterious effects were detected by VEP analysis across all the 
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cell lines, with a novel FBXW7 variant identified in an ECS+ve cell line. Small numbers 
of samples analysed precluded statistical significance analysis of association of variants 
to histopathological subtypes but key directions with regards to further studies were 
gained.  
4.4.1 Factors affecting sequence coverage by SOLiD 
 
SOLiD next generation sequencing has been widely implemented for cancer genome 
profiling including HNSCC [101] and OSCC [136] and has been found to be comparable 
to other next generation platforms in terms of fidelity and accuracy [181]. Our 
observations revealed key regions of absent/low coverage that were similar using a 
different means of bioinformatics analysis (CGR v LifeScope), type of tumour sample 
(CLL) as well as an easily accessible reference database (Genome 1000). This 
suggested that these regions of poor coverage could have been as a result of technique 
specific drawbacks. 
A range of factors could explain the poor coverage observed here. Biases in sample 
preparation, sequencing, and genomic alignment and assembly can result in regions of 
the genome that lack coverage and in regions with much higher coverage than 
theoretically expected [169]. Coverage with NGS has been described in the literature to 
be poor around areas with high GC content [169]. GC-rich regions, such as CpG 
islands, are particularly prone to low depth of coverage partly because these regions 
remain annealed during amplification [182]. Both NOTCH1 and CDKN2A, that are GC-
rich, were found in our WGS data to have poor coverage, whereas genes with lower GC 
content such as TP53 and HRAS had acceptable coverage. Specifically, the NOTCH1 
gene is known to have a high GC content (17 of 34 exons contain GC> 65% with exon 1 
containing GC >75%). Studies have also shown that despite relatively high read depths 
across most exons, under representation of coverage in several exons (exon 1-26) or 
no coverage (exon1) was common [183]. Other types and causes of sequence errors 
can be diverse with SOLiD sequencing with the in vitro amplification steps potentially 
causing a higher background error rate [184]. Also, beads used in the emulsion PCR 
step of library amplification if they are carrying a mixture of sequences in close proximity 
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to one another can create false reads and low quality bases. Furthermore, signal 
decline, a small regular phasing effect, and incomplete dye removal can result in 
increasing error as the ligation cycles for sequence read out progress [185] and may 
have contributed to our poor sample coverage. 
4.4.2 WGS identified candidate genomic variants and ECS  
 
Our VEP variant analysis alongside REACTOME pathway analysis of our OSCC cell 
line data suggested that the Notch pathway could be potentially affected within our 
samples, being the only disease pathway significantly highlighted in analysis. The 
missense variant in FBXW7 in a node positive ECS positive cell line also further 
supported the potential importance of NOTCH pathway. FBXW7 is part of the F-box 
protein family and constitutes a component of the ubiquitin protein ligase complex [186]. 
It acts as a tumour suppressor in several tumours and a negative regulator of NOTCH1. 
Variants in FBXW7 gene can modulate the Notch pathway [187]. FBXW7 mutations 
have been previously observed in HNSCC samples as summarized in section 4.1.2, 
suggesting the involvement of the NOTCH pathway in head and neck cancer is likely.  
We found that the majority of pathways identified in our pathway analysis were signal 
transduction pathways and this may have great relevance for cancer development. 
Indeed, signal transduction pathways when considered broadly refer to processes by 
which regulatory molecules (e.g., extracellular hormones, growth factors, survival 
cytokines, and specialized proteins) govern the fundamental processes of cell growth, 
differentiation, and communicate within the cell resulting in cell proliferation. The 
ultimate end result of signal transduction networks is to regulate cell growth and division 
[188]. In terms of ECS however, compared to CDK11A (identified from INDEL analysis), 
CDC27 (identified from SNP variant analysis) and CASP8 (identified from key 
comparisons of our data with the literature), NOTCH1 remains a much stronger 
candidate for association based on other factors; the contemporaneous literature, our 
WGS analysis and the known effects of Notch signalling. Arguably we judged that no 
other gene than NOTCH1 was so highly consistently mutated in the literature and 
responsible for a multitude of cellular processes; cell maturation, proliferation, 
102 
 
differentiation and apoptosis, that could prove key to the development of an aggressive 
phenotype required for ECS [189].  
In summary, although we were unable to prove our hypothesis that genetic variants are 
associated with ECS, pathway analysis of variants identified by whole genome 
sequencing (WGS) analysis of primary OSCC cell lines suggested Notch signalling 
could be affected in ECS+ subtypes, however consistent and unexpected deficits of 
sequence coverage in particular of the NOTCH1 gene, indicated that further 
investigation was required to be conclusive.  Whether the deficit was for technical 
reasons or because the gene was preferentially lost was unclear (chapter 4, section 
4.3.2.7).  Comparison to other datasets suggested a technical under-representation but 
other affected genes like FBXW7 implicated the importance of Notch pathway. 
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sequencing of NOTCH1 
from primary OSCC cell 
line 
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5.1 Introduction 
5.1.1 NOTCH signaling in relation to aggressive forms of cancer 
 
In addition to the NOTCH alterations discussed in Section 4.1.2, the literature further 
suggests that NOTCH pathway mutations should be expected Upregulation of Notch1, 
Notch2, , HES1, HEY1 and Jagged1, all genes in the Notch pathway has been reported 
for OSCC cell lines [190]. Pickering et al. discovered changes in gene copy expression 
and number for other NOTCH genes including increased copy number in JAG1, JAG2 
and in NUMB that were associated with elevated mRNA in HNSCC [136].  Our aCGH 
data also showed that copy number change in OSCC tumour samples enriched with 
ECS+ cases (section 2.2) significantly affected Notch signaling (p = 9.7 x10-5) already 
discussed in section 3.1.3. ECS only occurs for 25% of OSCC cases, raising the 
additional possibility that alterations to Notch signaling could be responsible for this 
aggressive subtype.  We therefore decided to further investigate the mutational status of 
the gene in our primary cell lines firstly to determine whether there was a genuine deficit 
in copy number or whether the deficit was more likely to be a technical artifact. This 
would also determine whether Notch mutations were present. 
 
5.1.2 NOTCH1 structure and function 
 
The NOTCH pathway is activated following ligand–receptor binding between two 
neighboring cells [191] (summarized in Figure  16.). In humans, four NOTCH receptors 
(NOTCH1–4) have been identified with five known NOTCH ligands from the Jagged 
family (JAG1 and 2) and Delta family (DLL1, 3 and 4).  
The NOTCH heterodimer consists of an extracellular domain (ECD), a transmembrane 
domain and an intracellular domain (ICD) held together by non-covalent interactions 
that cause auto-inhibition of the protein [192]. In humans, the ECD is involved in Notch 
ligand interactions which contain 29 to 36 EGF-like domains [193]. In Notch1 the 
EGF11–13 region is also capable of binding to its’ ligand in a Ca2+ dependant manner  
[194]. Following the EGF-like domains there are three cysteine-rich Notch repeats 
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(LNRs), followed by a carboxy-terminal hydrophobic region which mediates 
heterodimerisation (HD). LNR repeats and HD form a negative regulatory region (NRR) 
which is situated adjacent to the cell membrane. This NRR prevents ligand-independent 
activation of the Notch receptor [195]. The ICD is composed of conserved protein 
domains: the RBP-Jκ-associated module (RAM) domain, seven ankyrin (ANK) repeats, 
a transcription activation domain (TAD) and the C-terminal PEST domain [196].  
Engagement of the NOTCH receptor with its ligand induces a conformational change, 
facilitating S2 cleavage by tumour necrosis factor-a-converting enzyme (TACE), 
followed by a third cleavage (S3) mediated by the γ-secretase complex. Following this 
final cleavage, the ICD translocates from the plasma membrane to the nucleus. CSL 
(RBP-Jк) complex is then bound and converted from a transcriptional repressor to an 
activator [197] of hairy enhancer of split (HES) and hairy-related transcription factor 
(HEY) families [198, 199]. The pathway is also negatively regulated by Fbxw7 (encoded 
by the FBXW7 gene).  this gene targets NOTCH proteins for proteolytic degradation 
[200]. Multiple laboratories have more recently also reported an alternative non-
canonical role for Notch [201-203] antagonizing Wnt/β-catenin signaling, a critical 
regulator of development and disease, independent of Notch ligand-dependent 
cleavage or nuclear localization.  
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Figure 16. The processing and activation of Notch signaling by ligand binding 
and proteolytic cleavage. The Structure of different human Notch receptors and 
ligands are displayed. Out of five Notch ligands expressed in humans, four (JAG1, 
JAG2, DLL1, and DLL4) can activate Notch receptors. The Ligands have an N-terminal 
DSL domain, variable numbers of EGF repeats and a juxtamembrane cysteine-rich 
domain (CR- only for JAG1 and JAG2).  There are four Notch receptors, Notch1–4, 
involved in Notch pathway, comprised of Notch extracellular (NEC) and transmembrane 
(NTM) subunits. Variable number (29–34) of EGF repeats, 3 Lin12/Notch repeats 
(LNRs), and the N-terminal portion of the juxtamembrane heterodimerization domain 
(HD) is present in NEC. NTM is composed of a RAM domain, 7 ankyrin repeats (ANK) 
repeats and a C-terminal PEST degron domain.  (See inset) 
(Figure adapted from Source: Molecular biology of The Cell, Bruce Alberts et al.) 
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5.1.3 NOTCH1 as a potential ‘driver’ of aggressive phenotype in OSCC 
 
A role for NOTCH signaling in human cancer was first demonstrated for T-cell acute 
lymphoblastic leukaemia, with the identification of a rare t(7:9) (q34:q34.4) translocation 
[204]. Although it is recognized that NOTCH signaling can be oncogenic, growing 
evidence has pointed to a tumour suppressor role of this pathway because deletions 
and inactivating mutations in NOTCH family genes have been identified in a variety of 
tumour types. In solid tumours, there is evidence for growth suppressive functions for 
NOTCH signaling in small cell lung cancer [205] and hepatocellular carcinoma [206]. 
Loss-of-function mutations in NOTCH receptors have also recently been reported in 
HNSCC, cutaneous and lung SCC [101, 102, 136, 207]. 
Thus, the specific role of NOTCH1 in OSCC needs to be further clarified; evidence 
supporting oncogenic and tumour suppressive roles has been published. A cDNA 
microarray study reported overexpression of receptors (NOTCH1, NOTCH2), ligand 
(JAG1) and proteins that modulate NOTCH–ligand interactions (manic fringe, lunatic 
fringe), in microdissected tumour cells from four HNSCC cases [208]. Further reports 
also found increased expression of NOTCH signaling components in HNSCC. 
Significantly increased Jagged1 (encoded by JAG1) expression was found in HNSCC 
compared with dysplasia and normal epithelial tissues [209]. In addition, mRNA levels of 
several NOTCH pathway genes (NOTCH1, NOTCH2, JAG1, HES1 and HEY1) were 
also upregulated in oral squamous cell carcinoma (OSCC) compared to normal tongue 
or oral dysplastic tissues [190, 210].  
Clinical correlation studies using tongue cancer samples demonstrated the levels of 
NOTCH1 protein were positively associated with cervical lymph node metastasis, 
microvessel density (MVD) and depth of tumour invasion [211, 212]. Localization of the 
NOTCH1 protein to the invasive front in OSCC [213], has also been observed, allowing 
for the possibility that NOTCH1 promotes invasion. Additionally, inhibition of the NOTCH 
pathway by a γ-secretase inhibitor or ‘knocking down’ NOTCH1 significantly reduced 
cell proliferation and invasion [190, 213-215]. Chemoresistance conferred by NOTCH 
signaling has been reported for different types of cancer  [216], including HNSCC. High 
expression levels of NOTCH1 protein were found to be strongly associated with 
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cisplatin resistance in cells isolated from patients with HNSCC [217]. Furthermore, 
treatment of OSCC cell lines with the pro-inflammatory cytokine, tumour necrosis factor-
alpha (TNFα), activated NOTCH1 signaling and led to an increase in tumour sphere-
forming ability, stem cell-associated gene expression, chemoresistance and 
tumourigenicity [210]. 
However, next generation sequencing studies in HNSCC have suggested a tumour 
suppressor role for NOTCH signaling, suggesting the NOTCH1 mutations they identified 
in their respective sequencing studies would lead to loss of function phenotypes [101] 
[102]. The NOTCH1 mutations identified in both studies were mainly located at or near 
the epidermal growth factor (EGF)-like ligand-binding domain region within the ECD. 
Similar results were obtained based on The Cancer Genome Atlas (TCGA) data, in 
which NOTCH1 mutations were found in 19.3% of HNSCC cases [218]. A further 
multiplatform analysis revealed the NOTCH1 mutation rate to be 9% but further 
integrative analysis revealed the NOTCH pathway was defective in 66% (23/35) of 
cases with alterations in several members of the NOTCH pathway. These included 
mutations in NOTCH1 and NOTCH2, copy number gains in JAG1, JAG2 and NUMB as 
well as losses in MAML1 and NOTCH2 [136]. Although JAG1 and JAG2 are generally 
known to promote NOTCH signaling, they can also inhibit the pathway through cis-
inhibition [219]. A contrasting study using a single-molecule DNA sequencing platform 
analysing a Chinese population reported 42 NOTCH1 non-synonymous mutations in 
43% of OSCC cases [220].  A relatively high fraction (29%) of these mutations were 
located within the heterodimerisation domain within the ECD, where gain-of-function 
mutations are commonly found. This implies a more complex biological role for 
NOTCH1 mutations in HNSCC/OSCC than simply being either a tumour suppressor or 
oncogene.  Indeed, studies of Drosophila. have demonstrated that the Abruptex region 
of the ECD mediates inhibitory Notch activity and thus mutations specific to these 
regions could result in gains of function [221]. 
One possible reason for the low sequence coverage of NOTCH1 in our data and 
samples from other WGS series could be due to its high GC content (17 of 34 exons 
contain GC> 65% with exon 1 containing GC >75%) of the gene or the large number of 
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EGF repeats in the ECD. Studies have shown that even with relatively high read depths 
across most exons, under representation of coverage in several exons (exon 1-26) or 
no coverage (exon1) was common [183]. We therefore decided to sequence Notch 
following target enrichment of its exons. 
5.1.4 Target enrichment strategies to improve coverage for NOTCH1 Sequencing 
 
Although Sanger sequencing has long been considered the gold standard technique in 
genetic sequencing it has a number of drawbacks, primarily throughput and lack of 
versatility for analyzing genes with complex intron / exon organization like NOTCH1. 
The NOTCH1 gene covers position: base 138000000 to base 138999999 of chr9; 
based on GRCh37 assembly of the human genome) and consists of 34 coding exons. 
Studies of the NOTCH1 gene would also require large amounts of DNA for assessment 
of the entire coding regions [74]. Furthermore, obtaining sufficient amounts of DNA for 
effective sequencing from primary cell line samples can be challenging. 
Shotgun sequencing is widely used to sequence very large regions of DNA (often for 
entire genome) where the DNA is first fragmented into smaller pieces which can be 
sequenced individually. SureselectTM is a further method that can enrich targets of 
interest 300- to 7400-fold dependent upon the size of the targeted region and the 
number of reads per sequencing run (Agilent). However, one of the weaknesses of the 
system is that it performs better with large inputs (>5μg) of genomic DNA for library 
preparation, which is not always available for cancer samples.  
Long-range PCR is a fast, efficient and cost-effective choice for enriching candidate 
genomic region for sequencing, especially when only small sample amounts are 
available. The method can be combined with next-generation sequencing platforms. 
Several long-range DNA polymerases are available, able to amplify up to 15 kb or 
longer genomic DNA [222] with the exons of the NOTCH1 gene comprising ~9.3 kb. 
Typically, larger amounts of DNA are required for longer targets so as a compromise, 
multiplex, long range PCR approach for library preparation that was compatible with the 
next generation Ion TorrentTM sequencing platform, was developed to be applied to 
each of the locally available OSCC primary cell line samples (n=5) Table 17. 
110 
 
 
5.2 Hypothesis and aim 
Hypothesis: Variants in the NOTCH1 gene are associated with ECS in OSCC. 
Aim:  
1) To optimize a target enrichment strategy using long range PCR and next generation 
sequencing to enable sequencing of the exonic regions of NOTCH1 gene. 
2) To use this gene specific variant analysis approach for comparing NOTCH1 variants 
in ECS and non-ECS OSCC primary cell lines for the NOTCH1 gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
111 
 
5.3 Results 
5.3.1 Optimization of long-range PCR for producing NOTCH1 sequence libraries 
for Ion Torrent analysis 
 
Long range PCR was performed using human random control DNA and pre specified 
PCR conditions by Qiagen (see section 2.7.2.1). PCR products (sizes varied between 
600 base pairs to 6 kilobases) were analysed by agarose gel electrophoresis (Section 
2.5.2). Once PCR Library Preparation was optimized using control DNA, the same 
procedure was performed with OSCC cell line DNA (see chapter 4, section 4.1.3).  
A representative gel image of long range amplicons for exons 13-25 generated from a 
random control human DNA sample as well as two primary OSCC cell lines (Liv4K, 
Liv7K), used here as part of optimization, is shown in Figure 17. Expected fragment size 
for exons 13-18 of ~6000 base pairs and exon 19-25 of ~ 5000 base pairs was seen for 
both OSCC cell line samples as well as control DNA sample with absence of PCR 
product in the negative control lane confirming specific amplification and indicating 
adequate PCR optimization.  
The experiments revealed that the primers we had designed for long range PCR were 
able to amplify successfully exonic regions 5-25 and 31-34 of NOTCH1 but there were 
particular regions that failed to amplify in a consistent manner (amplicons targeting 
exons 1-2, 3- 4 and 26-30). The Long Range PCR optimization experiments are 
summarized in Table 24. To maintain full gene coverage, primers for short range PCR 
were also subsequently designed to retarget the NOTCH1 exonic regions 
demonstrating poor coverage by long range PCR. In summary, LR-PCR successfully 
amplified NOTCH1 exon regions 5-25 and 31-34 covered in only 5 amplicons, with 
exons 1-4 and 26-30 subsequently successfully targeted by short range PCR. This 
allowed us to progress on to preparing LR-PCR and SR-PCR amplicon libraries from all 
five OSCC cell lines (Liv4K, Liv 7K, Liv12K, Liv 22K, Liv26K). 
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Figure 17. Long range PCR (LR-PCR) amplification of NOTCH1 exons 13-25. Lanes 
1 & 2 from the left show 1 kilobase and 100 base pair size markers. Bands are visible in 
Lanes 5, 7 & 8 at the expected size of 6000 bp corresponding to exons 13-18 and in 
lanes 11,13 & 14 at the expected size of 5000 bp corresponding to exons 19-25. Lanes 
6 & 12 from the left show negative controls with DNA absent. +ve C = Random human 
control, DNA -ve C = No DNA. 
 
Table 24. Summary of NOTCH1 Long Range PCR optimization. 
 
Amplicon NOTCH1 Exons Size (bp) Long Range PCR Amplification 
1 1,2 2002 X 
2 3,4 1330 X 
3 5 697 ✔ 
4 6,7,8,9,10,11,12 3640 ✔ 
5 13,14,15,16,17,18 5980 ✔ 
6 19,20,21,22,23,24,25 4908 ✔ 
7 26,27,28,29,30 3550 X 
8 31,32,33,34 4850 ✔ 
                               +ve    -ve   primary              +ve  -ve  primary         
                                  C     C    cell Samples          C     C  cell samples     
                                                       Exon 13-18                   Exon 19-25 
1kb   1oo bp                
Ladders 
 
1000 bp 
2000 bp  
3000 bp  
4000 bp  
5000 bp  
 1      2      3     4      5      6       7      8      9     10    11    12    13   14 
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5.3.2 Initial analysis of Ion data using random human control DNA  
 
Ion TorrentTM sequencing of Long and Shorter Range PCR products from the control 
human DNA library was performed according to the standard protocols as described in 
Section 2.7.  Data was processed using Ion Torrent Suite 2.2 software as described in 
Section, 2.8. Sequence reads were aligned against human genome assembly Genome 
Reference Consortium Human Build 37 patch release 13 (GRCh37.p13). The total 
number of reads generated from the control library was 7,691,887 of which 6,278,086 
reads were aligned against chromosome 9; position: 139388896-139440238, which 
contains NOTCH1 and gave an average NOTCH1 target region coverage of 300-fold. 
100 to 200 fold coverage is considered adequate for variant calling. Absence of reads in 
Exon 1 was evident which may have failed to align due to high GC content. 
5.3.3 Variant analysis of NOTCH1 in primary OSCC cell line samples 
 
After confirming adequate coverage for variant calling could be generated from the 
control library, the libraries made from primary OSCC cell line DNA were also 
sequenced (see Section 2.7). Reads were aligned against human genome assembly 
Genome Reference Consortium Human Build 37 patch release 13 (GRCh37.p13). 
Coverage analysis was performed using Ion Torrent Suite 2.2 software.  ~ 77% of the 
total reads were aligned to NOTCH1. Table 25. shows the mean coverage, which for 
each cell line was 150-200 fold; adequate for further variant analysis. 
Table 25. Summary of sequence coverage from OSCC cell line DNA fragment 
libraries.   
Sample name   Type Phenotype Total reads 
GRCh37.p13Cov
ered bases 
against NOTCH1 Mean coverage 
Liv4K 
Primary cell 
line 
Node negative 
3,258,560 2,583,993 164.20 fold 
Liv7K 
Primary cell 
line 
Node negative 
3,354,456 2,698,018 199.46 fold 
Liv12K 
Primary cell 
line 
Node positive 
ECS+ 3,691,887 2,278,086 160.97 fold 
Liv22K 
Primary cell 
line 
Node positive 
ECS+ 4,279,986 3,455,652 198.52 fold 
Liv26K 
Primary cell 
line 
Node positive 
ECS+ 4,564,005 3,662,645 153.89 fold 
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From the exonic/intronic regions of NOTCH1 gene all five cell lines, Ion Torrent Suite 
2.2 software (see section 2.8), identified variants already reported either in the Genome 
1000 or COSMIC databases. The top 10 most frequent, known variants from the cell 
lines are summarized in Table 26. Of these variants, four (highlighted in red) have been 
reported in the literature to be associated with cancer. 
 
 
Table 26. Common SNPs in OSCC cell lines. The 10 most frequently found variants 
and their functional consequences are displayed. 3 synonymous codons and one 
missense variant already described to be associated with cancer are highlighted in red. 
 
SNP-ID No. of Cell lines Functional Consequence 
rs2229974 5 synonymous codon 
rs76371972 5 missense 
rs201968456 5 missense 
rs184874260 5 synonymous codon 
rs114832250 4 missense 
rs10521 4 synonymous codon 
rs199654211 4 missense 
rs35652719 3 missense 
rs200053816 3 missense 
rs2229971 3 synonymous codon 
 
 
No novel variants were found in the five OSCC primary cell lines, in one ECS +ve cell 
line, Liv7K, a rare naturally occuring isogenic NOTCH1 polymorphism was identified in 
the extracellular domain of NOTCH1 (rs61751543, Minor Allele Frequency 0.01) [223]. 
This polymorphism has a single nucleotide variation from C>T in exon 23; 
corresponding to a NOTCH1 extracellular domain variant. The protein residue change 
due to this polymorphism is R [Arg] ⇒ H [His] at position 1279. To assess the potential 
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functional consequence of this coding SNP further we performed an evolutionary 
preservation analysis. NOTCH1 normal protein sequence was used as a control 
followed by the site and nature of amino acid substitution (corresponding to variant) into 
the software tool PANTHER-PSEP for predicting non-synonymous genetic variants that 
may play a causal role in human disease [224]. PSEP (position-specific evolutionary 
preservation) measures the length of time (in millions of years) a position in current 
protein has been preserved by tracing back to its reconstructed direct ancestors. The 
longer a position has been preserved, the more likely that it will have a deleterious 
effect. PSEP analysis results for this variant based on an Exon 23 NOTCH1 
substituition of C>T giving an amino acid change of R64H and a preservation time of 
307 million years. This suggests that this could be a damaging variant (450my > time > 
200my, corresponding to a false positive rate of ~0.4 as tested on HumVar). The 
presence of potentially deleterious variant in the ECS+ cell line, supported further 
investigation of NOTCH1 in relation to ECS.
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5.4 Discussion 
Setting out to genetically characterise the NOTCH1 gene in five OSCC cell lines and 
assess whether variants in the NOTCH1 gene are associated with ECS in OSCC we 
established a target enrichment strategy using long range PCR for next generation 
sequencing allowing the NOTCH1 exons and flanking intronic sequence to be read with 
acceptable coverage for variant analysis. 
5.4.1 A Long range PCR approach for Ion TorrentTM sequencing of NOTCH1  
The key features of an enrichment method have been described as being: enrichment 
factor, specificity, coverage, evenness of target region coverage, method  of 
reproducibility, overall cost per target base of useful sequence data and required 
amount of input DNA [225]. One particular challenge for this was the NOTCH1 gene 
itself. The target region guanine-cytosine (GC) content at extreme values for a target 
region (<25% or >65%) has a significant impact on enrichment efficiency [226]. This can 
adversely affect 5’-UTR/ promoter region enrichment and the first exon of genes, which 
are often GC rich [227]. This was a potential explanation for the poor coverage that we 
faced in the previous whole genome sequencing part of this study (see Chapter 4, 
section 4.3.2.7) as well as exon 1 for targeted sequencing.   
If PCR product sizes fall within the sequencing length of the applied NGS platform (for 
example the maximum read length for Ion Torrent: 400 bp); PCR-based enrichment 
bypasses the need for shot-gun library preparation by using suitably 5’-tailed primers in 
the final amplification steps. Targeting of very large genome sub-regions is challenging 
with this approach however (eg. NOTCH1 gene: ~51kb). Alternatively, Long Range 
PCR has successfully been used to target regions of 5–100 kb [228]. A further 
advantage of using this approach would be that the error rate of standard Taq DNA 
polymerase used in other approaches is 1.1 x 10-4 errors/bp [229], although a variety of 
assay-dependant error rates have been reported. The Long Range PCR Enzyme Mix 
used here is a mixture of thermostable DNA polymerases which provide both very high 
extension rates as well as better proofreading ability, allowing up to 5-fold increased 
fidelity over Taq DNA polymerase [230].  
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In practice, a short range PCR approach had to be applied for some sections of the 
NOTCH1 gene (1-2, 3- 4 and 26-30), maybe as a result of nonspecific primer annealing, 
secondary structures in the DNA template or suboptimal cycling conditions, to maintain 
full coverage. The subsequent steps were all performed successfully for final DNA 
library preparation with confirmation achieved by a variety of methods (Bioagilent trace 
and Ion coverage data generated by Ion Torrent Suite 2.2 software). Specificity was 
confirmed by high coverage of 150-200 fold for the targeted NOTCH1 sequences in the 
control library. A clear benefit of the method was the small amount of DNA required 
from limited supply required to produce results with only 50ng starting amount for long 
range PCR (comparable to Song et al. 2014), but only 20ng required for short range 
PCR amplification. 
That coverage of NOTCH1 sequences was achieved suggests that the poor coverage 
observed with WGS data occurred for technical reasons, rather than genetic events 
leading to reduced copy number.  
5.4.2 NOTCH1 Variant analysis for OSCC primary cell lines  
Variants that had already been reported as polymorphisms in the Genome 1000 or 
COSMIC database and these served as incidental positive controls for variant detection 
by the method. SNPs rs2229974, rs2229971, rs10521, rs76371972) had already 
reported in the literature to be associated with bladder cancer and acute leukemia [231, 
232]. However, there were no unknown non-synonymous variants found in the exonic 
regions of the primary cell lines assessed. This was surprising considering both the 
previously reported higher variant false positive calling rate for the Ion torrent method 
[233] and evidence on 13 HNSCC cell lines that had detected 6 mutations in 4 samples 
with an overall mutation rate of 31% [220]. These differences may be as a result of 
cohort or cell line specific effects as they were detected in a variety of head and neck 
cancers and in a Chinese population. The observation by Pickering et al. that the Notch 
pathway was defective in 66% of cases in their cohort [136] is at odds with the 25% rate 
of ECS observed in OSCC [18]. This may be explained by ECS enrichment of the 
cohort examined by Pickering et al. due to undetected disease in their relatively small 
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cohort (35 cases) or a cohort specific effect where an excess of mutations were 
detected in Notch pathway members with an observed low mutation rate of NOTCH1 
(9%).  
We observed in one node positive ECS positive cell line (Liv7K), a rare NOTCH1 variant 
(rs61751543) was present. The variant is a missense substitution variation and the 
resulting protein change would be from Arginine to Histidine. A previous study first 
reported the rs61751543 NOTCH1 variant, following the profiling of the nonsynonymous 
genomic variation in 158 genes implicated causally in carcinogenesis. Of the 2,688 
allelic variants identified within the cohort, most were very rare, with 75% found in only 
1-2 individuals in the European population. Indeed, the rs61751543 NOTCH1 variant 
allele frequency in the European population has been reported as 0.013% (1000 
Genome Project). The variant has been recently identified following whole exome 
sequencing in two individuals with rectal and one individual with gastric cancer [234]  
however a complex picture was also observed along with 12 other variants so specific 
conclusions were difficult to make. Therefore understanding the significance of this 
finding remains difficult, however generally, it has been observed that only highly 
aggressive cancers can accumulate genetic changes necessary for unlimited growth in 
vitro and spontaneously become continuous cell lines [235]. Liv7K is a continuous cell 
line and the patient from where the tissue was obtained died from the aggressiveness of 
their oral cancer. 
There was a relatively small sample size with an absence of normal control cell lines 
from the same patient to compare to, as well as no Node +ve ECS-ve cell lines 
available for study (2 x Node -ve ECS-ve cell lines were used). In the light of these, the 
biological significance of the identified NOTCH1 rare variant is unknown, but warranted 
further investigation both in terms of functional consequences and as an indicator that 
NOTCH1 variants should be considered in relation to ECS. 
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Chapter 6 : TP53 and 
NOTCH1 Variants in 
relation to ECS in OSCC 
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6.1 Introduction 
Having established the NOTCH1 sequencing protocol and identified a potentially 
deleterious variant in an ECS+ primary cell line, we wished to screen for NOTCH1 
mutations in our clinical series to see if there was an association between NOTCH1 
changes and ECS.  At the same time, we wished to screen for TP53 mutations, to see if 
the low rate of allelic imbalance was matched by low numbers of TP53 mutations in our 
series and whether there was a relationship with ECS. This required a method of TP53 
sequencing to be developed and it was decided to make this compatible with our 
NOTCH1 sequencing method so they could be used together. The background to 
NOTCH1 as a candidate ‘driver’ of ECS has been discussed in the previous chapter 
(see section 5.1.3), and the role of TP53 in the adverse molecular changes responsible 
for OSCC has also been previously outlined (section 1.4.2.1). 
 
6.1.1 Sequencing strategy for NOTCH1 and TP53 
 
Prior to the start of the analysis, a power calculation based on dichotomous endpoints 
(presence or absence of variant) with two independent sample groups was performed 
and as a result some adjustments were made to the test cohort. Assuming a power of 
80%, level of significance of 0.05 and based on the literature expected levels of TP53 
and NOTCH1 mutations in non-ECS groups being ~50% and ~15% respectively, to 
observe an approximate 40% increase in mutational frequency for both genes in ECS 
cases, a minimum overall sample size of 50 would be required. As a result, some 
further OSCC cases were added to the series to increase overall numbers (n=50; 19 N-, 
10 N+ECS-, 21 N+ECS+). The clinical data for these additional samples is shown in 
section 2.2. 
For calling a base change, ≥100 fold coverage was applied, especially as normal tissue 
admixture and the heterogeneity of some cancers can decrease variant allele 
representation [236]. A number of set criteria, established in other studies [237] were 
also used to ensure good quality variant calling: (i) variant location within an exonic or 
splicing region (ii) non-synonymous in nature; (iii) absent from European 1,000 
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genomes variant database (iv) absent from Catalogue of Somatic Mutations in Cancer 
(COSMIC) database  (v) absent from UCSC-SNP137 (University of California Santa 
Cruz Genome Centre) database (vi) the same variant should not be present in more 
than 5 samples otherwise it will be considered as an artefact resulting from the 
sequencing process. 
Considering the drawbacks of the Ion Torrent Suite 2.2 software, a further independent 
bioinformatics analysis of the data was considered necessary. When comparing the Ion 
TorrentTM platform with other NGS platforms, a higher raw error rate (~1.8% v <0.4%) 
has been identified. However, if coverage is sufficient, the representation and ability to 
call SNPs is quite closely matched between these technologies [233, 238]. Along with 
this, the principal error mode associated with Ion data analysis software is miscalling of 
homopolymer lengths, which may lead to insertion or deletion errors [238]. Apart from 
variant detection, haplotype analysis was also necessary to assess for the presence of 
cross contamination between samples and systematic technical errors associated with 
the sequencing approaches, which were challenging to analyse in detail using Ion 
Torrent Suite 2.2 software.  
Hence, a BLAST analysis using an Active PERL script for variant detection was 
performed to reanalyse the Ion TorrentTM platform generated data, allowing for more 
detailed coverage analysis. Use of PERL in conjunction with BLAST allowed precise 
positions of variants to be identified, a confounding factor when they occur in 
homopolymer sequence. The precise methods for the bioinformatics analysis using 
Active PERL script are documented in section 2.8. Detailed coverage analysis was 
performed separately for each sample, for both TP53 and NOTCH1 to ensure sufficient 
read depth both for non-homopolymer and homopolymer regions. This approach was 
used to obtain coverage data for every PCR amplicon, including fifty bases either side 
to ensure sufficient amplicon edge coverage. The presence or absence of cross 
contamination between OSCC samples was verified by haplotype analysis, assessing 
different locations for common SNPs and sample specific SNPs, with the aim of 
assessing the uniqueness of sample identity. Candidate variants were then assessed by 
Sanger sequence to confirm or rule out their presence and produce a final set of 
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variants. Lastly, association of variants to clinical observations was performed as the 
final stage of the experimental strategy to assess for any association with ECS, with the 
detailed clinical data for this set of samples shown in section 2.2.   
 
 
6.2 Hypothesis and aims 
Hypothesis 1: Variants of NOTCH1 in OSCC are associated with ECS. 
Aim: To use a gene specific NGS approach to identify NOTCH1 variants in an ECS 
enriched cohort of primary OSCC tumour samples and test association to ECS 
subtypes.  
Hypothesis 2: Variants in TP53 in OSCC are not associated with ECS.  
Aim: To use a gene specific NGS approach to identify TP53 variants in an ECS 
enriched cohort of primary OSCC tumour samples and test association to ECS 
subtypes. 
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6.3 Results 
6.3.1 Long range PCR Amplicon Library Optimization and preparation for TP53 
and NOTCH1 
 
Optimisation of Long Range PCR for Ion TorrentTM sequencing was performed for 
TP53. Each Long-range PCR primer pair for TP53 was designed to allow coverage of 
the entire exonic region by a minimum number of amplicons and minimal inclusion of 
intronic sequence.  Short introns were included. The PCR product sizes for the TP53 
regions varied between ~700 base pairs to ~4.3 kilobases.  
Long range PCR Ion library preparation was performed using human random control 
DNA for NOTCH1 and TP53 gene outlined in section 2.7. Once PCR Library 
Preparation was optimized using control DNA, the same procedure was performed with 
OSCC primary tumour DNA (n=50).  
 
6.3.2 Coverage analysis on sequenced OSCC tumour samples 
 
The reads generated from tumour samples were mapped against Genome Reference 
Consortium Human Build 37 patch release 13 using TMAP aligner (The Torrent 
Mapping Alignment Program for Ion Torrent). Coverage analysis was performed using 
Torrent Suite 2.2 software. The coverage data generated by the software demonstrated 
that the majority of reads (>85%) were mapped onto chromosome 9 and 17 which 
corresponds to NOTCH1 and TP53 genes respectively (base 138000000 to base 
138999999 of chr9 for NOTCH1 and base 7000000 to base 7999999 of chr17 for TP53; 
based on GRCh37 assembly of the human genome) confirming that the libraries 
generated encompassed the TP53 and NOTCH1 genes as expected. 
When comparing the Ion Torrent platform with other NGS platforms, it is known to have 
a higher raw error rate (~1.8%) than others platforms (<0.4%) due to miscalling within 
homopolymer regions, however if there is sufficient coverage, the representation and 
ability to call variants is quite closely matched between these technologies (Quail et al., 
2012). The, more detailed strict coverage analysis was therefore performed using Active 
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PERL (for full description see Section 2.8). This revealed 40 samples where overall 
average read depth was ≥100. 10 samples showed either very low coverage (where 
mean coverage <50) or low coverage (mean coverage >50 but <100). These 10 
samples were excluded from further analysis to maintain stringency in variant calling.  
Their clinical identity with regards to nodal status is tabulated with sample ID (see Table 
26).   
 
 Table 27. OSCC tumour samples identified by Active PERL script to have poor 
coverage 
Sample Identity Sample ID NOTCH1 mean coverage TP53 mean coverage 
N+ve+ECS+ 3167 43 37 
N+ve+ECS+ 3230 25 28 
N-ve 3240 44 48 
N+ve+ECS+ 3241 49 42 
N-ve 3272 41 40 
N+ve+ECS- 3274 32 29 
N-ve 3315 38 32 
N+ve+ECS- 3481 27 29 
N+ve+ECS+ 3251 77 97 
N+ve+ECS- 3254 85                                         64 
 
 
 
Figure 18A. shows mean coverage data from combined tumour samples (n=40) 
generated by Ion TorrentTM sequencing of NOTCH1 and bioinformatics analysis by 
Active PERL algorithm on the basis of coordinate position with corresponding exonic 
and intronic positions highlighted on the same axis.  From the previous chapter (5) we 
had previously identified that a low read depth was observed in some regions (ex 1-4, 
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26-30) of NOTCH1 using long range PCR amplicons. Therefore, short-range PCR 
primers were used to retargeting those regions.  Using both long and short-range 
amplicons adequate coverage was achieved suitable for variant calling (see chapter 5, 
section 5.3.1). Detailed PERL script coverage analysis generated from each exon 
showed adequate coverage (average read depth 100X) for exonic regions 2-34 of the 
gene (position- chr9: 139,438,476- 139,390,523; based on Genome Reference 
Consortium Human Build 37 patch release 13) but exon 1 of NOTCH1 (position: 
139,440,178- 139,440,238) was missing from our output, as also reported in the results 
to the previous chapter 5 (section 5.3.1). Short range PCR amplicons (exons 2, 3, 4, 5, 
26, 27, 28, 29, 30) produced much greater mean read depth from 300 to 1400 
compared to the long range PCR amplicons, mean read depth ~ 150. 
Figure 18B. shows coverage data of combined tumour samples (n=40) generated from 
TP53 gene based on coordinate position with corresponding exonic and intronic 
positions highlighted on the same axis. Detailed coverage analysis showed adequate 
reads (above 100 mean coverage) for variant calling for all exonic and intronic regions 
(position- chr17: 7,590,694-7,571,719). 
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Figure 18. Mean combined coverage of OSCC tumour samples (n=40) following 
Ion TorrentTM sequencing and ActivePerl Bioinformatic Analysis. 18A. Mean 
Coverage is shown on the basis of coordinate position of NOTCH1 (139390523-
139440238 GRCH 37.13) with precise corresponding exonic and intronic positions 
(exons 1-34) shown on the same axis. Exon 1 showed no coverage. 18B. Mean 
Coverage is shown on the basis of coordinate position of TP53 (7571720-7590868 
GRCH 37.13) with precise corresponding exonic and intronic positions (exons 1-11) 
shown on the same axis. Dashed red line indicates mean coverage above our cut off of 
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6.3.3 Examination of Cross-contamination between OSCC tumour samples 
 
Use of PCR could have resulted in cross-contamination between samples and was 
assessed by comparing the profile of known polymorphisms generated from each 
OSCC tumour sample. The principle used was that if different samples had exactly the 
same known polymorphism profile then the possibility of having cross contamination in 
between these samples was high. Variants identified using the analysis performed by 
ActivePerl algorithm were correlated with the UCSC-SNP137 (University of California 
Santa Cruz Genome Centre: http://hgdownload.soe.ucsc.edu /goldenPath 
/hg19/snp137Mask/) source sequence database to identify known SNPs. A Latin 
Square of samples, versus SNPs, sorted according to SNP frequency in the samples 
overall was created. 3 groups of positive controls were also used in the analysis for 
each gene (1 group of 3 and then 2 groups of 2) where the same samples had been 
intentionally repeated, with a similar SNP profile expected each time the same sample 
was analysed and this was observed, confirming the reproducibility of the results. 
Unique SNP profiles were observed for both NOTCH1 and TP53 in all of the other 
samples, suggesting the absence of cross contamination between tumour samples in 
both cases. Furthermore, statistical analysis using Chi-square tests comparing of 
variants for each sample combination in turn found significant differences (p = 0.001 - 
0.042) between in each case. 
 
6.3.4 NOTCH1 variants in primary OSCC tumour samples 
 
Ion AmpliSeq sequencing data initial variant calling was generated using Torrent Suite 
Software v2.2 with the plug-in “variant caller v2.2” program as described in method 
section 2.8. For unknown exonic variant detection the filtering criteria outlined 
previously in Section 6.1.1 was applied. A total of 9/50 samples were found to have a 
total of 10 NOTCH1 exonic variants (see Table 28.).  All variants were single base 
substitutions with two variants (NOTCH1 Exon 20 139402707 G>C & NOTCH1 Exon 23 
139401209 G>A) observed twice and one sample displayed two variants in both exon 5 
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and exon 20 (sample 3366). The overall variant frequency was 18% (9/50), consistent 
with previously published rates (11-19%).  
Reanalysis of the sequencing data using the Active PERL script was also used to 
identify variants. Their coverage and frequency in the samples was also determined. 10 
sample excluded for poor coverage. Rather than apply cut off filters to set inclusion 
criteria for possible variants, frequency versus coverage was plotted for the entire data 
so that allowance could be made for the context of candidate variants. analysed and 
plotted to allow the identification of significant variants. Previously known SNPs were 
used as controls for positive selection of variants. Homopolymer and non-homopolymer 
regions were considered. This demonstrated that at 10% coverage frequency cut off, 
significant numbers of known SNPs could be missed, thus risking exclusion of novel 
variants. At a 5 % frequency cut off, the majority of known SNPs and therefore novel 
variants were retained. This was accepted as the level that maximised true positives, 
whilst minimising false positives. Other stringent criteria (section 6.1.1) were applied to 
produce a list of unknown variants. 5 novel variants were each detected by both types 
of analysis. 5 detected in the first analysis were undetected in the second analysis and 
the latter gave 9 additional variants (see Table 28). Of the 14 unknown variants that 
were discovered in the second analysis, 13 were in different samples, and 2 variants 
were detected twice within 2 different samples (G>C 139402707 exon 20, G>A 
139401209 exon 23).  One sample displayed two different types of unknown variant 
(sample 3286).  
Sanger revalidation of all identified variants was then performed independently through 
Source Bioscience. Sequence Scanner v2. software was used to examine the 
sequences as chromatograms and the status of the expected novel variants 
determined. All 5 variants detected by both by both methods were validated but only 
5/10 (50%) of the variants from the first analysis and 7/14 (50%) were validated.  
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Table 28. Unknown non-synonymous exonic NOTCH1 variants identified in OSCC tumour cases using Ion Torrent 
Suite 2.2., PERL script and subsequent Sanger validation. All variants along with position and corresponding amino 
acid changes are displayed. Histopathological status of the primary tumour sample is also shown. 5 variants detected by 
both Ion Torrent and PERL analysis were validated by Sanger sequencing, with a further two variants only detected by 
PERL also validated by Sanger (marked by red). 2 variants were detected twice within 2 different samples (G>C 
139402707 exon 20, G>A 139401209 exon 23) and one sample displayed two different types of unknown variant (sample 
3286). 
 
Sample 
Identity  
Clinical 
identity 
Base 
position 
Exon 
position Base change Protein change Protein domain Ion Torrent PERL Sanger 
3366 n+ecs+ 139402707 ex20 TGT>TCT CYSTEINE>SERINE extracellular domain yes yes yes 
3455 n+ecs+ 139402707 ex20 TGT>TCT CYSTEINE>SERINE extracellular domain yes yes yes 
3484 n+ecs+ 139393368 ex33 GAT>TAT 
ASPARTIC 
ACID>TYROSINE transmembramne subunit yes yes yes 
3499 n+ecs+ 139401209 ex23 CGC>CAC ARGININE>HISTADINE extracellular domain yes yes yes 
3270 n+ecs+ 139401209 ex23 CGC>CAC ARGININE>HISTADINE extracellular domain yes yes yes 
3345 n+ecs+ 130404185 ex18 AGG>ATG ARGININE>LYSINE extracellular domain yes no no 
3233 n+ecs+ 139412208 ex8 ATG>ATT METHIONINE>ISOLEUCINE extracellular domain yes no no 
3366 n+ecs+ 139413951 ex5 GGT>GAT GLYCINE>ASP extracellular domain yes no no 
3300 n+ecs- 139400047 ex25 GGT>GTT GLYCINE>VALINE extracellular domain yes no no 
3238 n- 139407961 ex14 AGT>GGT SERINE>GLYCINE extracellular domain yes no no 
3483 n+ ecs- 139400017 ex25 CTG>INSERTION INSERTION extracellular domain no yes yes 
3286 n+ecs+ 139400300 ex25 CGT>AGT ARGININE>SERINE extracellular domain no yes no 
3286 n+ecs+ 139391840 ex34 AAC>AAG ASPARAGINE>LYSINE transmembramne subunit no yes no 
3233 n+ecs+ 139412197 ex8 TCG>TTG SPLICE SITE extracellular domain no yes yes 
3345 n+ecs+ 139395297 ex31 GGC>CGC GLYSINE>ARGININE transmembramne subunit no yes no 
3461 n+ecs+ 139402420 ex21 GGC>INSERTION INSERTION extracellular domain no yes no 
3340 n0 139400300 ex25 CGT>AGT ARGININE>SERINE extracellular domain no yes no 
3242 n0 139399949 ex25 TGC>CGC CYSTEINE>ARGININE extracellular domain no yes no 
3383 n0 139393707 ex32 CTG>INSERTION INSERTION transmembramne subunit no yes no 
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The false positive rate of variant detection for NOTCH1 was unlikely to have been as a 
result of admixture of normal cells with the tumour cells because tumour content had 
been previoiusly been reported by a histopathologist at a high average, typical for this 
type of cancer, of ~70% for our samples and the minimum tumour cellularity required for 
heterozygote variant calling has been reported as ~20% [239]. Technical, algorithmic 
issues reasons are more likely to be the principle source of error because the two 
different methods used were not in agreement and the principal type of error reported is 
miscalling of homopolymer lengths, which may lead to insertion or deletion errors 
(Salipante et al., 2014). Indeed, only one of the three insertions identified was found to 
be validated. Importantly, the use of two different methods is likely to have minimized 
the false negative rate. If the majority of the novel variants found had been validated, 
this would have suggested that the criteria for inclusion were too strict. 
Known base substitution variants already reported either in COSMIC, in UCSC-SNP137 
or in European 1,000 genomes variant database were also identified to obtain a 
complete variant profile for our OSCC cases. A cut off value of base read depth was set 
at ≥100 and variant frequency ≥5%. Table 29. shows the most commonly identified 
known variants present in exonic regions of NOTCH1 and from both homo and non-
homopolymer regions of the gene. The proportion discovered in ECS cases along with 
already known cancer associations, reported in the ClinVar database, are also 
summarised (n=40).  
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Table 29. Most common known exonic SNPs observed in NOTCH1. Assessment 
was made from both homopolymer and nonhomopolymer regions (n=40). The ClinVar 
database was interrogated to assess the presence of any existing cancer associations 
and the proportion of ECS samples identified with the SNP present is also shown. 
SNP Cancer Association Total cases  
/ 40 
ECS cases 
/ 14 
rs201358664 - 39 13 
rs114479009 - 34 12 
rs61751535 - 34 12 
rs2229974 - 31 12 
rs2229971 - 29 8 
rs201968456 - 29 8 
rs184874260 - 25 7 
rs10521 - 25 6 
rs76371972 - 20 5 
 
 
For known INDEL detection, the cut off value for base read depth was also set to ≥100 
with ≥5% variant frequency before identifying any variant as a true INDEL and only 
exonic INDELs were taken into consideration. For NOTCH1, three exonic deletions 
were observed in more than half of the OSCC samples (rs140371192, rs146350322, 
rs41309766). 
 
6.3.5 NOTCH1 variant functional significance 
 
Most of the NOTCH1 mutations identified by the two seminal HNSCC NGS studies 
(Agrawal et al., 2011, Stransky et al., 2011) were observed in the extracellular EGF-like 
repeat domain and are summarized in Figure 19. Mutations within this region could 
potentially have great functional significance as it codes for the EGF-like repeats 10–13 
(coded by exons 6-9) considered to be the ligand binding region of the NOTCH1 
protein. Studies specifically focused on OSCC have demonstrated mutation rates up to 
10% for the ligand binding region of NOTCH1 with a predominance of non-synonymous 
G>A transitions [240].  
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The 7 novel NOTCH1 validated by Sanger sequencing within our ECS enriched OSCC 
cohort were found within exons 8, 20, 23, 25 and 33. Furthermore, if NOTCH1 variants 
found in OSCC cases were structurally distributed and organized by corresponding 
exon and protein domain then most of the identified mutations would be clustered into 
the N-terminal, extracellular EGF like domain, with a few mutations falling within regions 
coding for the transmembrane subunit of NOTCH protein, see Figure 19. While a splice 
site variant was observed in exon 8 and an insertion in exon 25 the remaining 5 variants 
were all single base substitutions (G>C, G>T, G>A) with 2 variants (exon 20 G>C, exon 
23 G>A) identified in two different samples. To assess the functional consequences of 
these coding SNPs further we performed an evolutionary preservation analysis entering 
normal protein sequence as a control followed by site and nature of amino acid 
substitution (corresponding to variant) into PANTHER-PSEP [224]. PSEP analysis 
results for three different coding SNP variants are summarised in the Table 30. 
 
Table 30. Summary of NOTCH1 coding SNP PSEP analysis results. All three 
NOTCH1 variants were found likely to have potentially deleterious effects on PSEP 
analysis. my=million years, Interpretation thresholds: "probably damaging" (time > 
450my, corresponding to a false positive rate of ~0.2 as tested on HumVar database), 
"possibly damaging" (450my > time > 200my, corresponding to a false positive rate of 
~0.4) and "probably benign" (time < 200my). 
Variant Substitution Preservation Time / my Interpretation 
Exon 20 G>C C446 1036 probably damaging 
Exon 23 G>A R72H 307 possibly damaging 
Exon 33 G>T D27Y 797 probably damaging 
 
This analysis revealed that these three coding SNPs, were likely to have significant 
functional consequences and alongside the other variants identified we can hypothesize 
that all the variants identified would lead to impaired NOTCH signaling either as a result 
of impaired ligand binding (Exon 8-25 variants) or intracellular NOTCH pathway 
activation (Exon 33 variant) and this would certainly warrant further investigation with 
more specific functional studies.  
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Figure 19. Structural distribution of NOTCH1 variants found in OSCC cases 
organized by corresponding exon and protein domain. All NGS ActivePerl algorithm 
identified variants (pink) and Sanger validated variants (red) are shown in relation to 
coding exon position and corresponding NOTCH1 protein domian. Sites of mutations 
found from two seminal HNSCC sequencing studies (Agrawal et al, 2011 and Stransky 
et al. 2011) are shown for comparison (dark and light blue circles). HD = 
Heterodimerization domain (N and C terminus), PEST = Peptide sequence rich in 
Proline, Glutamate, Serine and Threonine amino acids, NEC= Extracellular domain, NTM 
=Transmembrane subunit, RAM = RBP-Jkappa-associated module, TAD = Trans-
activating domain , LNR = Lin-12/Notch repeat  domain, ICN = intracellular Notch 
domain  
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6.3.6 Novel NOTCH1 variants in association with OSCC histopathological status 
 
Histopathological sample identity with regards to nodal status and presence of ECS was 
correlated with the presence of validated NOTCH1 variants in 2 x 2 contigency tables 
with ECS+ve and ECS-ve (N- & N+ve ECS-ve) groups or N-ve and N+ve (N+ve ECS-ve 
& N+ve ECS+ve) and significance determined by a two-tailed Fisher’s exact test. The 
resulting p values are summarised in Table 31. A significant association (p=0.0109) was 
observed between the presence of NOTCH1 variants and nodal status.  NOTCH1 
variants also had a significant association (p=0.0044) with the presence of ECS. The 
validated NOTCH1 variant frequency of 17.5% (7/40) corresponded to mutational 
frequencies observed in the literature (Agrawal et al. 2011, Stransky et al. 2011) and the 
association of NOTCH1 variants with poor histopathological prognostic indicators in 
OSCC also corresponded with previous evidence showing NOTCH1 mutations to be 
associated with significantly shorter overall and disease-free survivals (Song et al., 
2014). Our observation of a significant association of NOTCH1 variants with ECS was a 
novel finding and taken in conjunction with the potential deleterious functional effects of 
the NOTCH1 variants described earlier, our results suggest NOTCH1 may be a ‘driver’ 
of clinically aggressive forms of OSCC. 
Table 31. Summary of NOTCH1 variants according to histopathological subtype. 
Fisher’s exact test was performed comparing NOTCH1 variants in ECS +ve to ECS-ve 
cases with p values shown, demonstrating a significant association between NOTCH1 
gene variants and ECS status.   
 NOTCH1 mutation 
Discovery 
(By Ion software) 
Discovery 
(By ActivePerl 
Algorithm) 
Sanger 
Validation 
N-ve 18 1 3 0 
N+ve ECS- 8 1 1 1 
N+ve ECS+ 14 7 9 6 
p value N+ vs N- 0.0266 0.0896 0.0109 
p value ECS+ vs ECS-  0.0044 0.0036 0.0044 
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6.3.7 TP53 variants in primary OSCC tumour samples 
 
TP53 sequences from our OSCC tumour samples were analysed as above, Section 
6.3.4.  The coverage versus frequency graphs for each position as for NOTCH1 showed 
that at a cut off level of 5% variant frequency level, false positive variants were 
minimised whilst candidate, novel variants were retained.  
Table 32. shows the unknown variants (insertions, deletions and SNPs) identified using 
this method in both homopolymer and non-homoplymer regions for TP53. 7 variants, 
were identified including 5 previously identified by Ion Torrent analysis alone and only 
the 5 variants found by both methods were confirmed by Sanger sequencing. The table 
also summarises TP53 non-synonymous exonic variants along with the expected 
resulting conformational change. A total of 5/50 samples were found to have TP53 
exonic variants with the majority (3/10) found within Node -ve cases. Four of the 
variants were single base substitutions (TP53 Exon 4 7579370 G>T, TP53 Exon 4 
7579473 C>G, TP53 Exon 5 7578473 C>G) with one insertion also identified (TP53 
Exon 6 7578185 G>GCT). 
Table 32. Validated, unknown non-synonymous exonic TP53 variants identified in 
OSCC tumour cases. All variants along with position and corresponding amino acid 
changes are displayed. Histopathological status of the primary tumour sample is also 
shown. 5 variants detected by both Ion Torrent and PERL analysis were validated by 
Sanger sequencing (marked by red), with a further two variants only detected by PERL 
script. 
Sample 
Identity 
Clinical 
identity 
Base 
position 
Exon 
position 
Base 
change Protein change 
Ion 
Torrent PERL Sanger 
3345 n+ecs+ 7578473 Ex4 CCC>GCC PROLINE>ALANINE yes yes yes 
3300 n+ecs- 7579473 ex3 CCC>CGC PROLINE>ARGININE yes yes yes 
3258 n- 7579370 ex3 AGC>ATC SERINE>ISOLEUCINE yes yes yes 
3461 n- 7578185 ex5 G>GCT INSERTION yes yes yes 
3242 n- 7576855 ex8 CAG>TAG 
GLUTAMINE>STOP 
CODON yes yes yes 
3533 n+ecs+ 7577105 ex7 CCT>CTT PROLINE>LEUCINE no yes no 
3483 n+ecs- 7577563 ex6 T->- DELETION no yes no 
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6.3.8 Functional Significance of TP53 variants  
 
p53 protein is active as a homotetramer, comprising 4 × 393 amino acid residues, 
functioning primarily as a transcription factor. Functionally, mutations in different regions 
of the gene would potentially have differential effects; exons 2 and 3 affecting 
transactivation and the interaction of p53 with CBP, CREB, MDM2 and p300, exons 5 to 
8 affecting DNA binding and exons 9 and 10 affecting oligomerization. The five TP53 
validated by Sanger sequencing within our OSCC cohort were found within exons 3, 4, 
5 and 8. The variants discovered in DNA binding domain coding region exon 5 was an 
insertion and exon 8 a single base substitution resulting in a stop codon, both likely to 
profoundly affect protein structure and function (i.e. frameshift mutation and truncated 
protein). The two single base substitutions (both C>G) observed in transactivation 
domain coding exon 3 as well as a single base substitution (G>T) in exon 4, while not in 
the commonly mutated DNA binding domain, may still have had detrimental effects on 
protein function and were similar to those previously described in OSCC [241, 242]. To 
assess the functional consequences of these three coding SNPs further we performed 
PANTHER-PSEP analysis. PSEP analysis results for the three variants are summarised 
in the Table 33.  
Table 33. Summary of TP53 coding SNP PSEP analysis results. All three TP53 
variants were found likely to not have deleterious effects on PSEP analysis. my=million 
years, Interpretation thresholds: "probably damaging" (time > 450my, corresponding to 
a false positive rate of ~0.2 as tested on HumVar database), "possibly damaging" 
(450my > time > 200my, corresponding to a false positive rate of ~0.4) and "probably 
benign" (time < 200my). 
Variant Substitution Preservation Time / my Interpretation 
Exon 3 C>G P40R 176 Probably benign 
Exon 3 G>T S74I 91 Probably benign 
Exon 4 C>G P28A 176 Probably benign 
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This revealed that these three coding SNPs were less likely to have significant 
functional consequences compared to the other two variants detected, again 
highlighting the seemingly low level of TP53 abnormalities in our cohort.  
 
6.3.9 Association of novel TP53 variants with histopathological status 
 
Histopathological subtypes with regards to nodal status and presence of ECS were 
assessed for the presence of TP53 variants. 2 x 2 contigency tables were compiled and 
analysed for significance by two-tailed Fisher’s exact test (Table 34.). No association of 
TP53 variants was observed with either nodal status or ECS. The low TP53 variant 
rates (Sanger validated 12.5% (5/40)) compared to the literature ~50% (Agrawal et al. 
2011, Stransky et al., 2011) within our ECS enriched cohort is a factor. Lack of 
association with both nodal status and ECS agrees with the negative results observed 
previously in this study with regards to a-CGH and SNP genotyping for TP53 allelic 
imbalance (see chapter 3, section 3.3.4). 
 
Table 34. Summary of TP53 variants in association with histopathological 
subtype. Variant numbers validated by Sanger Sequencing are shown. Fisher’s exact p 
values are shown and no significant associations were found.      
 
 TP53 variant 
Discovery  
(By Ion software) 
Discovery 
(By ActivePerl 
Algorithm) 
Sanger 
Validation 
N-ve  18  3  3 3 
N+ve ECS-  8  1  2 1  
N+ve ECS+  14  1 2 1 
p value N+ vs N- 0.6419 1.0000 0.6419 
p value ECS+ vs ECS-  0.6404 1.0000 0.6404 
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6.3.10 Known TP53 variants in association with OSCC histopathological status 
 
The very low frequency of TP53 alterations found in our study compared to published 
studies raises the significance of possibly deleterious known variants because these 
could make up the difference compared to other studies. Known variants were identified 
for TP53 gene in the cases, using the same criteria as above. Table 35. summarises the 
known SNPs, found in the exonic regions of TP53 gene both homo and non-
homopolymer regions of the genes. The proportion discovered in ECS cases along with 
already known cancer associations, reported in the ClinVar database, is also 
summarised. Similarly, for INDEL detection, the cut off value of read depth of the base 
was set to ≥100 with a variant frequency ≥5%.  Only one TP53 exonic insertion 
(rs397516437) was observed. 
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Table 35. Common known exonic SNPs observed in TP53. Assessment was made 
from both homopolymer and nonhomopolymer regions (n=40). The ClinVar database 
was interrogated to assess the presence of any existing cancer associations. Number of 
cases harbouring the variant on the basis of ECS is shown, and the fisher’s exact test p 
value comparing variant levels between ECS +ve and ECS -ve groups are shown. No 
differences between ECS -ve and ECS +ve levels of known potentially deleterious 
variants was observed. 
SNP Existing Cancer Association ECS -
ve 
cases 
/ 26 
ECS 
+ve 
cases 
/ 14 
Fisher’s 
exact p 
ECS+ v ECS-  
rs1042522 Li-Fraumeni syndrome 25 12 0.2763 
rs28934874 Liver, Malignant melanoma, Multiple 
myeloma, HNSCC, Adenocarcinoma of lung, 
Li-Fraumeni syndrome,  
Squamous cell carcinoma of lung, Brain, 
Breast, Pancreatic adenocarcinoma, Bladder 
TCC, Oesophageal, Colorectal, Stomach, 
Ovarian ,Uterine 
20 8 0.2808 
rs72661119 Li Fraumeni syndrome 12 4 0.0958 
rs141402957 Hereditary cancer predisposing syndrome 12 5 0.7385 
rs56275308 Li Fraumeni syndrome, Hereditary cancer 
predisposing syndrome 
12 5 0.7385 
rs144340710 Li Fraumeni syndrome, Hereditary cancer 
predisposing syndrome, 
Rhabdomyosarcoma 
11 4 0.5024 
rs11540652 Liver, CLL, Medulloblastoma,  
Malignant melanoma, Multiple myeloma, 
HNSCC, Small cell lung cancer, 
Adenocarcinoma of lung, Li-Fraumeni 
syndrome, Squamous cell carcinoma of 
lung, AML, Myelodysplastic syndrome,  
Brain, Breast, Glioblastoma, Pancreatic 
adenocarcinoma, Skin SCC, Bladder TCC, 
Glioma, Oesophagus, Colorectal, Stomach, 
Ovary, Uterus, Prostate 
9 3 0.2992 
rs56184981 Li Fraumeni syndrome 9 2 0.0897 
rs121912651 Liver, CLL, Medulloblastoma,  
Malignant melanoma, Multiple myeloma, 
HNSCC, Small cell lung cancer, 
Adenocarcinoma of lung, Squamous cell 
carcinoma of lung, AML, Myelodysplastic 
syndrome, Brain, Breast, Glioblastoma,  
Pancreatic adenocarcinoma, Skin SCC, 
Bladder TCC, Brainstem glioma, 
Oesophagus, Colorectal, Stomach, Ovary, 
Uterus, Prostate 
8 2 0.1570 
rs28934875 Li-Fraumeni syndrome 7 3 1.000 
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Analysis of known deleterious variants revealed that a significant excess of these 
variants within ECS cases did not exist. Hence, these variants could not explain the 
shortfall in the overall low rate of TP53 variation observed in our cohort of cases. This 
implied that we may genuinely have a subset of cases with lower than reported TP53 
variation but carrying NOTCH1 mutations as summarized in Table 36. Only one of the 
cases was ECS -ve. This sample was from the oropharynx and had been identified as 
having mutant TP53 by initial NGS analysis but this was not confirmed by Sanger 
sequencing. The remaining samples were all from the oral cavity with wild type TP53. 
 
Table 36. Samples with Sanger validated NOTCH1 mutants and their TP53 status. 
 OC=Oral cavity, OP=Oropharynx, WT=Wild type  
 
 
To investigate this further we re-assessed the literature to see whether a similar subset 
of cases with low TP53 variation and NOTCH1 mutations had been observed in other 
studies, specifically in OSCC cases. Table 37 summarizes all the OSCC cases 
discovered by Agrawal et al. displaying NOTCH1 mutations with their TP53 status, HPV 
status, Site and Type of mutation shown. 
 
 
 
 
Sample Site TP53 status HPV 
Status 
ECS 
Status 
Mutation type 
3366 OC WT - + Nonsense 
3455 OC WT - + Nonsense 
3484 OC WT - + Indel,Missense 
3499 OC WT - + Missense 
3270 OC WT - + Missense 
3483 OP WT (Mutant in PERL) - - Missense 
3233 OC WT - + Missense 
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Table 37. OSCC Samples with NOTCH1 mutations in Agrawal et al. and TP53 
status. 
WT=wildtype, OC=oral cavity, OP=Oropharynx, +=HPV present, -=HPV absent, u= HPV 
unknown   
Sample Site TP53 
status 
HPV 
Status 
Amino acid Mutation type 
HN12PT OC WT - p.W1843X Nonsense 
600 OC WT u Q290X Nonsense 
HN 105 PT OC WT - fs, p.G812W Indel,Missense 
478 OC WT - p.G484V Missense 
HN 102 PT OC WT - p.E450K Missense 
HN 117 PT OC WT - p.G310R, p.C456R Missense 
HN 208 PT OC Mutant - p.R365C, p.R1280C Missense 
385 OC Mutant - p.R1984X Nonsense 
HN 107 PT OC Mutant - p.S402X Nonsense 
HN 115 PT OC Mutant - fs,p.G1340A Indel,Missense 
HN 183 PT OC Mutant - p.Q1958X Nonsense 
HN 194 PT OC Mutant - fs Indel 
HN14PT OC Mutant - p.P391S Missense 
HN 245 PT OP WT + fs Indel 
HN 142 PT OP WT + p.R353H, p.M2011R Missense 
HN 251 PT OP WT + p.F1292L p.V2039L Missense 
HN 255 PT OP WT u p.V2039E Missense 
HN 148 PT OP Mutant u p.G1638V, p.P2272S Missense 
HN 139 PT OP Mutant u p.C554X Nonsense 
 
Interrogation of the data revealed 19 samples with NOTCH1 mutants that were OSCC 
cases. Of these 10 had wildtype TP53 and 9 had mutant TP53. Most NOTCH1 mutant 
samples identified by Agrawal et al. were from the oral cavity (13/19) with the HPV 
staus either +ve or unknown for all oropharynx samples. Considering the oral cavity 
samples we then considered the 12/13 samples that were confirmed as HPV -ve, to 
draw an appropriate comparison with our study of HPV -ve cases. Of these 6/12 
displayed wildtype TP53, suggesting our subset could be similar in nature to these 
samples. Of note, the ECS status of the samples identified by Agrawal et al. was not 
documented for comparison.  
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6.4 Discussion 
 
Assessing the hypotheses that variants in NOTCH1 but not TP53 were associated with 
ECS in OSCC by using a gene specific NGS mutational analysis approach in an ECS 
enriched cohort of primary OSCC tumour samples, genetic characterisation was 
performed after optimising Ion TorrentTM sequencing for TP53 having previously 
optimised the method for NOTCH1 sequencing. Through this approach we identified 
both known and unknown variants in both genes with a significant association of 
NOTCH1 detected unknown variants with ECS, but no association of TP53 variants 
found. The benefits and drawbacks of the method used are discussed, followed by the 
significance of known and unknown variants for both genes, focussing on potential 
functional consequences. 
 
6.4.1 Long range PCR for NOTCH1 and TP53 Ion TorrentTM sequencing target 
enrichment  
 
Long range PCR followed by Ion amplicon library preparation for both NOTCH1 and 
TP53 were initially optimized using random control DNA samples in a manner similar to 
that previously discussed in Chapter 5, Section 5.3. This approach allowed for full 
exonic coverage of both genes and minimised use of limited quantities of tumour DNA. 
We were aware that although analysis by Ion torrent software 2.2 was able to identify 
variants, the Ion torrent sequencer has been previously reported as being prone to 
miscounting the number of bases in homopolymer reads potentially due to both 
software and hardware/chemistry concerns [238] and the possibility of strand-specific 
errors remained after initial bioinformatics analysis. In the light of this, to further improve 
the confidence of variant calling we performed and independent form of bioinformatic 
analysis using an ActivePerl script that called Blast to identify sequence alignments and 
then, located the actual position of variants within alignments, allowing for errors like 
homolymer misreads. This analysis demonstrated persistent poor coverage in 10 
samples that were then excluded from analysis as a result. The analysis also confirmed 
the absence of cross-contamination between samples for both genes and detected 9 
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NOTCH1 and 2 aTP53 variants, that had been missed by the Ion Torrent Suite. Variants 
called originally by the Ion Torrent Suite were also found. This confirmed the benefit of 
performing such an analysis while demonstrating the limitations of the Ion Torrent Suite 
Software. 
 
However, only 46% of total variants identified by either Ion software or ActivePerl (or 
both) were confirmed by Sanger Sequencing. Although a number of studies have used 
the Ion torrent platform for sequencing samples, some studies have reported that its 
specificity may be low due to a high false positive rate, especially for INDEL detection 
[243, 244]. Due to the nature of the sequencing chemistry involved with the Ion Torrent 
platform, homopolymer regions have a greater indel calling error rate than other 
genomic regions. The literature suggests that it remains challenging to eliminate these 
false positives by defining a threshold based on mutation frequency [244] indicating the 
importance of using other methods for re-validation. 
 
Furthermore, cancer specimens from biopsy specimens may contain significant 
proportions of normal tissue; blood cells, stromal components, and inflammatory cells 
[239]. This would result in dilution of tumour DNA with normal DNA. Somatic mutations 
may therefore only be at low frequencies.  High coverage by Next Generation 
Sequencing can nevertheless detect such variants (<10% allelic frequency) [245, 246] 
but they are less easily detected by Sanger sequencing which relies on the rationing of 
electropherograms. We therefore used a cut off of 5% for either allele for variant calling 
on the basis of a 10% cut off excluding a significant number of variants (see section 
6.3.4). In practice, the percentage of tumour cells was estimated by pathologists on 
hematoxylin and eosin (H&E)-stained slides with the samples used for this analysis 
demonstrating an average 70% tumour to normal tissue ratio based on histopathological 
reports as previously described in Chapter 3. This would be considered a high ratio 
compared to most standards [239]. However, evidence suggests that this means of 
assessment may be prone to bias and over-estimation [247] with significant inter-
pathologist variation reported. More sophisticated methods have been described 
utilizing transcriptomic expression data [248] or copy number data [249] neither of which 
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was available as would be required for our samples. Furthermore, PurityEst has been 
described as a means of using next generation sequencing data to infer tumour purity 
level from the allelic differential representation of heterozygous loci with somatic 
mutations in human tumour samples but requires matched normal tissue which was not 
available in this instance [250]. Future studies evaluating genetic drivers of aggressive 
phenotype in OSCC would significantly benefit from the inclusion of such matched 
controls. 
 
6.4.2 Low levels of TP53 nonsynonymous variants in OSCC ECS 
 
Our study revealed 5 Sanger validated TP53 variants spread across the three 
histopathological subtype groups assessed (3 N-, 1 N+ECS-, 1 N+ECS+) with no 
significant associations found with either nodal status or ECS. 2 of the variants were in 
the DNA binding domain coding region of the p53 protein suggesting potential 
deleterious effects, however, three of the variants were coding SNPs that were deemed 
‘probably benign’ after PSEP functional analysis. Indeed, an overall particularly low rate 
of TP53 variance of 12.5% (5/40) of Sanger validated variants was found that seems at 
odds with the reported HNSCC/OSCC literature with recent NGS studies finding 47-
66% [21]. Multiple explanations for this difference are possible. 
That our careful analysis detected more variants than were validated supports an 
excess of false positive variants rather than significant numbers of false negatives. It 
remains possible that sample admixture with a significant proportion of normal cellular 
DNA in relation to tumour DNA in certain samples, may have contributed to the low 
identified TP53 variant rate. However, if these technical drawbacks were prevalent and 
consistent, one would expect a similar effect on NOTCH1 variant frequency, which in 
contrast was actually found to reflect the rate from previous studies published in the 
literature. Also in support of this being a novel result was the earlier observation from 
the same sample cohort with regards allelic imbalance and a lack of copy number 
change associated with TP53. Therefore, an alternative explanation was considered. 
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The shortfall in detected TP53 variation could be due to selection of a genetically 
predisposed group, by assessing known variants within our cohort. Of the known SNPs 
already reported in the literature we identified a number that had been previously 
described associated with a range of cancers; stomach, colon, glioma and breast 
cancer [251-254]. The most commonly identified TP53 SNP, rs1042522, a missense 
polymorphism found to be present in 37 OSCC samples, has previously been reported 
to be associated with numerous cancers [255-257]. The SNP corresponds to exon 4 of 
TP53 causing an arginine to proline substitution at position 72 which resides in the SH3 
binding domain of the p53 protein and could bear functional significance [258]. 
Following assessment of the most commonly identified variants, the distribution of 
deleterious variants across cases and any statistical significance associated with 
histopathological status was assessed. No association was found with ECS, confirming 
the presence of a subset of cases with low TP53 variation and NOTCH1 mutations. 
Assessment of the findings of Agrawal et al. suggested that a significant number of 
cases existed in their series with NOTCH1 mutations but wildtype TP53 [101]. As 
correlation of histopathological status with these samples was not discussed, we can 
speculate that on the basis of our findings that a significant number of these samples 
may have been from ECS +ve cases. Of note when considering our subset of cases 
with wildtype TP53 and mutant NOTCH1, other studies have demonstrated that in the 
presence of wildtype TP53, Notch1 activation increased the invasiveness of 
hepatocellular carcinoma cells and was correlated with advanced grade III HCC  [259]. 
Low TP53 mutation rates have previously been reported in the literature to be 
associated with a number of tumour-specific, demographic or environmental factors. It 
has been previously reported that in HPV positive HNSCC TP53 mutation is uncommon 
with one study reporting only a 7% TP53 mutation rate amongst HPV+ve OSCC 
samples [260]. Furthermore, a recent meta-analysis found that the TP53 codon 72 
polymorphism (rs1042522), found in 25/40 of our OSCC cases, was associated with 
HPV-related OSCC susceptibility cases but there was no association between this 
polymorphism and non-HPV OSCC cases, suggesting that the polymorphism may be a 
marker of HPV-related OSCC [261]. Our samples were all considered to be HPV-ve as 
detected by routine PCR from the regional clinical pathology laboratories but on the 
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basis of the discussion above, one theory to explain the low TP53 rate could be 
undetected HPV infection. However, HPV-DNA PCR remains the most accurate method 
for detection at present [262] bar specific HPV genotyping and sequencing. 
Other possible factors that may have interplayed to create the low TP53 rate could be 
patient demographics, tumour site and smoking habits. Asian populations have been 
previously reported to demonstrate low TP53 mutation rates (Zannaruddin et al., 2013), 
with a mutation rate of 27% in a Malaysian cohort but with similar mutational 
frequencies of PIK3CA and HRAS to Caucasian populations [263]. A Taiwanese study 
similarly revealed a frequency of 32%. In contrast, other Asian cohort studies of TP53 
mutational frequency have revealed higher rates akin to Caucasian reported rates [165] 
suggesting that demographic effects alone will not suffice to explain the low rates, 
particularly for our own Caucasian cohort. Site may influence TP53 mutation rate with 
another study on an Asian cohort revealing a 10.6% TP53 mutational frequency 
specifically in Tongue OSCC [264]. A further interplay with environmental factors is 
suggested by evidence that amongst an American cohort of never-smoker tongue 
OSCC showed a TP53 mutation rate of 19.6% [265]. There were 20 out of 50 samples 
in our cohort originating from the tongue but smoking data was unavailable at the time 
of analysis and may have provided further insight into possible reasons for the low level 
of TP53 variation observed. The possibility remains that a yet undetermined cohort 
specific factor/s may also have contributed. Further detailed multivariate clinical analysis 
with a larger sample size would be required to fully determine the factors involved. 
6.4.3 NOTCH1 nonsynonymous variants associated with ECS  
 
NOTCH1 variants ((7/40) *100=17% of overall cases) discovered by this study following 
both bioinformatics and sequencing validation were significantly associated with ECS 
(p=0.0044). Our reported rates of NOTCH1 variants are consistent with the recent 
literature for HNSCC / OSCC with rates reported from 9-16% [101, 102]. Furthermore, 
on detailed assessment of Agrawal et al., the potential for a similar subset of OSCC 
cases carrying wildtype TP53 but mutant NOTCH1 was identified.  
147 
 
The 7 NOTCH1 variants were located within exons 8, 20, 23, 25 and 33 with all bar the 
exon 33 variant being clustered within the N-terminal, extracellular EGF like domain in a 
similar manner to previous observations described for HNSCC (See Figure 19.). 
PANTHER-PSEP analysis of the 5 coding SNP variants, with 4 within these EGF like 
domains and one within the NICD portion of the protein, suggested likely deleterious 
effects on protein function. A further insertion was observed in exon 25 and a splice site 
nonsynonymous variant that was observed in a region specifically coding for the ligand 
binding domain (exons 8-11) of the EGF like repeats. 3 of our detected variants 
corresponded to the Abruptex region (exons 19–23) of EGF like repeats. Although little 
is known about EGF repeat contribution to NOTCH1 function, it has been shown that 
the integrity of the Abruptex region (EGF repeats 24–29) is required for suppression of 
NOTCH1 activity [221] and that variants within this region enhance NOTCH1 signaling 
[266]. Although EGF repeats facilitate ligand-mediated receptor activation, variants in 
the Lin-12/Notch repeat domain (LNR) coded by exon 25 in which we discovered 2 
variants can lead to ligand-independent activity [267]. 
A large number of known single base substitutions and indels were identified in our 
cohort of OSCC samples for both genes. For NOTCH1, the most frequently identified 
SNP was rs201358664 that was found in 39 / 40 samples. Of note however, there were 
other SNPs (e.g. rs2229974, rs2229971, rs10521, rs76371972) found in the present 
OSCC case series, that although were not reported in ClinVar, have been reported in 
the literature to be associated with bladder cancer and acute leukemia [231, 232] but 
have not been described to be associated with OSCC. Although the majority of these 
SNPs correspond to missense substitutions, there were exonic known NOTCH1 
deletions identified, such as; rs140371192, rs146350322 and rs41309766, potentially 
bearing significant functional consequences.  
Our observations should be considered in the context of the spectrum 
of NOTCH1 mutations observed in HNSCC by NGS studies, which have been 
fundamentally different from those identified in haematopoietic tumours [268], as the 
majority have been (including our study) in the N-terminal EGF-like ligand binding 
domain and were predicted to alter the protein N-terminal to the transmembrane region. 
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The location and nature of these alterations suggests that NOTCH1 may be acting as a 
tumour suppressor in HNSCC. Although subsequent studies confirmed NOTCH1 
inactivating mutations and showed NOTCH1 tumour-suppressor activity in OSCC cell 
lines [136], NOTCH1 dysregulation is likely to be more complex than simple loss-of-
function [215]. Furthermore, approximately one third of HNSCCs displayed evidence of 
increased NOTCH1 pathway activation as compared with normal mucosa [215].  
Rettig et al. were able to provide a further interesting insight into the potential role of 
NOTCH1 in OSCC by demonstrating that cleaved NOTCH1 expression (NICD 
immunohistochemistry) patterns correlated with NOTCH1 mutations and ECS in a 
cohort of HNSCC samples but interestingly did not observe a significant association 
between NOTCH1 mutation and ECS itself [269]. It is already established from a 
considerable body of evidence that Notch signalling is likely to be linked to the 
progression and maintenance of a tumour; however, Notch signalling alone is unlikely to 
directly cause the cellular processes that take place within a tumour without crosstalk 
between Notch signalling and other signals.   
 
6.4.4 The Putative role of Notch in ECS 
 
Key supporting evidence for either role of NOTCH1 in OSCC as a tumour suppressor or 
oncogene is summarised in Table 38. In the present study, our results of an association 
of NOTCH1 variants with ECS as well as the knowledge that significant copy number 
aberrations of NOTCH1 observed in the CGH data obtained earlier in our group 
(unpublished data, Lloyd B.), would suggest that NOTCH1 is acting as an oncogene in 
the ECS-enriched cohort of samples analysed. Some available evidence from the 
literature would also support this role. Yoshida et al. demonstrated that Notch1 
expression correlated with both the T-stage and the clinical stage in OSCC, with loss of 
Notch1 expression correlated with the inhibition of cell proliferation and TNF-α-
dependent invasiveness in an OSCC cell line and a γ-secretase inhibitor prevented cell 
proliferation and TNF-α-dependent invasion of OSCC cells in vitro [270]. 
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Table 38. Evidence supporting contrasting roles for NOTCH in OSCC. Literature 
exist to support both a tumour suppressor and oncogene role in OSCC. Our results 
support a more oncogenic role for NOTCH1 being a potential driver for ECS in OSCC. A 
dual role may be possible considering tumour heterogeneity and the complexity of 
Notch signalling and interaction with parallel signalling pathways within the tumour cell. 
 
Oncogene Tumour Suppressor 
 NOTCH1 variants predominantly in the extracellular domain and may inhibit either 
trans-activation or cis-inhibitory ligand binding (present study) 
 aCGH analysis showing NOTCH1 
amplification in our OSCC cohort 
(B.Lloyd unpublished data) 
 WGS studies in HNSCC finding 
similar extracellular location to the 
majority of NOTCH1 mutations 
 NOTCH1 variants significantly 
associated with ECS (Present study) 
 NOTCH1 expression inhibited cell 
growth (Pickering et al., 2013) 
 EGFR, inhibitory to Notch signalling, 
copy number loss in our a-CGH data 
(B. Lloyd unpublished) 
 EGFR, inhibitory to Notch signalling, 
amplification associated with ECS 
(Michikawa et al., 2011) 
 Notch1 expression correlates with 
advanced stage and inhibition 
prevented cell proliferation (Yoshida 
et al., 2013) 
 NOTCH1 mutations not associated 
with ECS (Rettig et al., 2015) 
 Intracellular domain of the Notch1 
(NICD1) expression associated with 
ECS (Rettig et al., 2015) 
 
 
Rettig et al. found that intracellular domain of the Notch1 (NICD1) expression was 
associated with ECS in OSCC, supporting a more oncogenic role for NOTCH1 and 
Notch signalling [269].  
 
Supporting a tumour suppressive role, Pickering et al. expressed the cleaved/activated 
form of NOTCH1 (ICN1) in five cell lines that harbour missense or truncating NOTCH1 
mutations [136]. They found the relative fraction of ICN1-expressing cells decreased to 
less than 40% of its original value in 16 days. Furthermore, by using mouse xenografts 
in an orthotopic tongue cancer model they demonstrated both ICN1 and full-length 
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Notch (NFL) caused a dramatic reduction in tumour size compared with the vector 
control. Although Rettig et al. reported NICD1 expression to be associated with ECS, 
however did not find any association of NOTCH1 mutation with ECS in a cohort of 
OSCC cases suggesting a tumour suppressive or dual functional role for NOTCH1 
variation [269].  
 
Further insights have been gained from EGFR signalling. Notch signalling does promote 
terminal differentiation of keratinocytes and is negatively regulated by the EGFR 
pathway [271]. The epidermal growth factor receptor (EGFR) is a transmembrane 
tyrosine kinase receptor belonging to the HER/erbB family and is overexpressed in up 
to 90% of HNSCC [31]. High EGFR gene copy number has been reported in 10% to 
58% of HNSCC [135]. In HNSCC activating EGFR mutations are rare [21]. 
Overexpression of EGFR and high EGFR gene copy number are associated with poor 
prognosis and radio resistance [272] .  Importantly a study demonstrated EGFR copy 
number aberration to be associated with ECS [58]. These observations would support 
NOTCH1 acting as a tumour suppressor gene in certain circumstances. However, on 
retrospective analysis of the a-CGH data from our cohort (chapter 3, Figure 4.) EGFR 
was observed to be within a region of loss with no variants with severe consequences 
also observed within the gene in our whole genome sequencing OSCC cell line 
analysis. Bearing in mind our results and the other conflicting evidence that exists, a 
dual role may be possible.  
 
Finally, evidence suggests that the four Notch proteins that have been identified have 
distinct activities and outcomes depending on cellular context, although it is thought that 
the mechanistic details of action are similar [273]. As the majority of the variants we 
found in OSCC as well as in previously published studies, were in the extracellular 
domain of NOTCH1 [101], more detailed investigation of the functional effect of 
extracellular domain variant in oral cancer needs to be performed. These studies would 
focus on the possible impact of perturbations in structure at this site on function and 
may provide more evidence as to whether Notch is acting as a tumour suppressor or 
oncogene in contributing to the formation of aggressive phenotype. 
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7.1 Introduction 
Notch signaling has been discussed previously in this study (see section 5.1.2); given 
our detection of NOTCH1 ECD variants associated with ECS in OSCC (see section 
6.3.6), as well as considering their predicted protein structural effects (see section 
6.3.5), a number of other aspects are worthy of consideration.  1. What role do 
NOTCH1 ECD variants have to play in the pathogenesis of ECS in OSCC? 2. Could 
inhibitory Notch signaling affect key aggressive cellular characteristics and be of 
potential therapeutic use in OSCC? and 3. The Notch family of proteins consists of 4 
transmembrane proteins (NOTCH1, NOTCH2, NOTCH3, & NOTCH4) and each could 
have an impact on tumourigenesis [274] through changes at different levels of NOTCH 
signaling; their ligands, the receptors themselves or their downstream targets. Evidence 
suggests that the biologic effects of Notch signaling vary in cell type–dependent 
fashions [275]. Furthermore, microarray analysis of Notch signaling pathway member 
expression amongst a wide variety of tumours has revealed potentially differential roles 
for each Notch pathway member [276]. Could differential effects exist in OSCC?  
Considering these points as well as technical drawbacks at this stage of the study, as 
the detailed characterization of the role of ECD variants would require larger genetic 
characterization studies of multiple cell lines alongside comprehensive ligand-receptor 
binding studies, we elected to focus on the latter two points. We set out to perform an 
initial screen of the functional effect of NOTCH1 inhibition in oral cancer to better 
understand the biology of aggressive phenotype in OSCC by assessing key in vitro 
markers (proliferation, migration and Notch expression) using both invasive and non-
invasive OSCC cell lines and pharmacological inhibition of Notch signaling.  
7.1.1 Notch pathway inhibition in HNSCC/OSCC 
 
Notch Signaling has been previously demonstrated to be associated with an aggressive 
metastatic phenotype in vitro cancer models [277, 278]. Yoshida et al.  reported Notch1 
and intracellular Notch domain (NICD) upregulation in OSCCs and that expression was 
characteristically localized at the invasive tumour front [213]. They also demonstrated 
that γ-secretase inhibitor (GSI) prevented cell proliferation and TNF-α-dependent 
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invasion of OSCC cells in vitro. Furthermore, on clinicopathological analysis, Notch1 
expression correlated with both the T-stage and the clinical stage [213]. In addition, 
Weaver et al. reported a gene expression RNA analysis of 19 OSCC samples and 
demonstrated that Notch pathway upregulation was significantly correlated with patient 
mortality status and with expression of the pro-invasive gene FGF1. Furthermore, they 
demonstrated that in vitro HNSCC cell Notch activation increased FGF1 transcription 
and induced an increase in cell migration and invasion, abrogated by FGF1 knockdown 
[279]. 
Some further insight can be gained from the consideration of cancer stem-like cells 
(CSCs) that are likely to play a role in tumour recurrence and confer resistance to anti-
cancer therapy treatment [280]. Examining isolated CSCs (oralspheres) from HNSCC 
cells for tumourigenicity and in immunodeficient mice, aggressive tumour growth and 
higher expression of Notch1 protein was observed as compared to parental cells [281]. 
7.1.2 Genetic manipulation of Notch pathway signaling  
 
Sun et al. in 2014 performed an integrated analysis on a cohort of HNSCC tumours 
assessing expression, copy number, methylation, and mutation analyses. They 
observed copy number levels of JAG1 and JAG2 ligands and the NOTCH3 receptor 
were significantly increased in HNSCC, and that no NOTCH pathway gene promoters 
were significantly hypomethylated in HNSCC tumours compared with normal mucosa. 
To assess overall NOTCH pathway activation, they analyzed downstream effectors 
HES1 and HEY1 finding ~32% of HNSCC tumours showed HES1 and/or HEY1 
expression  consistent with NOTCH activation. On performing exonic sequencing on 
these HNSCC tumours, 5 novel inactivating NOTCH1 mutations in 4 of the 37 tumours 
analyzed were identified, but none of the mutations were associated with HES1 or 
HEY1 activation and thus they were able to characterize a subset of wild-type NOTCH1 
HNSCC tumours with increased HES1/HEY1 expression. The authors suggested a 
bimodal NOTCH pathway pattern of HNSCC alterations, with a small subset harbouring 
inactivating NOTCH1-specific mutations, and a larger subset having other NOTCH 
pathway alterations, including increased receptor or ligand expression or gene copy 
number, as well as downstream pathway activation [215]. They went on to demonstrate 
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that in NOTCH1 wild-type HNSCC cells, siRNA NOTCH1 or HEY1 inhibition significantly 
decreased cell growth. Furthermore, application of GSI-XXI, a NOTCH pathway 
inhibitor, to HNSCC cells also inhibited cell growth quantified by a CCK-8 colorometric 
assay. Consistent with this study, Pickering and colleagues discovered other NOTCH 
pathway gene changes in copy number and expression, including increased NOTCH 
receptor ligand JAG1, JAG2 and MUMB copy number changes that were associated 
with elevated mRNA levels [136] although overall protein levels were not assessed in 
the study.  
Wang et al. demonstrated in pancreatic cancer cell lines that down-regulation of Notch-
1 expression by siRNA inhibited cell growth, induced apoptosis and induced cell cycle 
arrest in G0-G1 phase, while overexpression of Notch 1 by cDNA transfection promoted 
cell growth and inhibited apoptosis [282]. NOTCH1 and NOTCH2 siRNA mediated 
knockdown in AML cell lines resulted in a suppression of proliferation, induction of 
apoptosis and a reduction of mTOR protein with similar findings observed in T-ALL cell 
lines [283].  siRNA NOTCH1 knockdown in glioma stem cells (GSCs) as part of an 
investigation of glioblastoma multiforme, demonstrated inhibitory effects on proliferation. 
Furthermore, Notch-1 silenced GSCs engrafted on Balb/c nude mice showed a 
reduction in oncogenicity, with direct intratumoural injections of Notch-1-siRNA 
significantly delaying the growth of pre-established tumours in nude mice [284].  
7.1.3 Pharmacological inhibition of Notch pathway signaling 
 
Methods of chemical inhibition target essential Notch pathway signaling steps: 
expression of ligands, ligand ubiquitination and trans-endocytosis, expression of Notch 
receptors, ligand-receptor binding, heterodimer dissociation during Notch activation,  
ADAM-mediated cleavage of Notch, subsequent ubiquitination and endocytosis of the γ-
secretase substrate, γ-secretase-mediated cleavage of Notch, assembly of the 
coactivator complex with Notch and CSL, heterodimerization of Notch transcriptional 
complexes, Notch post-translational modifications and finally expression of Notch 
targets [285]. Gamma-secretase inhibitors are commonly employed in vitro and in vivo 
preventing the release of the notch intracellular domain (NICD) [286]. Monoclonal 
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antibodies directed against Notch receptors or their ligands, Notch receptor or ligand 
decoys and blocking peptides inhibit Notch mediated transcription have also been used.  
7.1.4 γ-secretase inhibitors 
 
γ-secretase acts upon a variety of substrates including amyloid precursor protein (APP) 
[287]. γ-secretase is a high molecular weight protein complex found on the cell 
membrane with a varying estimated size between 250 and 2000 kDa, including 
presenilin (PS), nicastrin, Aph-1, and Pen-2 parts [288]. Increasing evidence suggests 
that assembly of the active PS / γ-secretase complex takes place in a chronologic order. 
Firstly, Aph-1 and nicastrin forms an intermediate complex. After that, Aph-1 and Pen-2, 
in turn, function as chaperones assisting in PS / γ-secretase complex assembly, 
trafficking and PS endoproteolysis [289]. PS contains the catalytic site of the PS / γ–
secretase complex and has two forms, namely PS1 and PS2, encoded by two different 
genes, PSEN1 and PSEN2, where Presenilin 1 plays an important role in proteolytic 
processing [290]. PS is endoproteolyzed into two subunits- N-terminal fragment (NTF) 
and C-terminal fragment (CTF), and these fragments are believed to represent the 
active form of PS [288]. Presenilin appears to be required for the transmembrane 
cleavage of Drosophila Notch and biochemical studies suggest similar for mammalian 
Notch proteins [291]. Knockout of presenilin-1 in mice reduces proteolysis of the Notch 
transmembrane region. Presenilins auto cleave to form the active site of γ-secretase 
[292]. 
Chemical inhibitors of γ-secretase (GSIs) mostly interact with the active site of the 
protease GSIs are classified into two types,: (1) aspartyl proteinase transition-state 
analogs as peptide isosteres mimicing the transition state of substrate cleavage by γ-
secretase binding competitively to presenilin catalytic active sites; and (2) small 
molecule non-transition-state inhibitors with a different binding site from the active site, 
possibly at the interface of the γ-secretase complex dimer [293]. [223] and have been 
explored as therapies for diseases including: Alzheimer’s disease [294] and  leukemias 
[295] [296]. Gamma-secretase (γ-secretase) inhibitors are able to inhibit cell growth and 
induce cell apoptosis [297].  
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7.1.5 Notch pathway inhibition in OSCC 
 
DAPT, N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester, is a widely 
used non-transition state analog, dipeptide inhibitor of the benzodiazepine type [298],     
reducing proliferation with an ADAM cleavage site dependency [299]. For Head and 
Neck cancers, DAPT inhibited the growth of human tongue carcinoma, human 
nasopharyngeal carcinoma drug-resistant cell line (CNE2) and Tca8113 cells by 
inducing G0-G1 cell cycle arrest and apoptosis [300] and enhanced cisplatin-sensitivity 
of Tb3.1 cells [301]. Notch signalling in NPC cells is down-regulated by DAPT 
increasing radio sensitization, [302]., DAPT reduces head and neck cancer stem cell 
(CSC) populations and tumour self-renewal in vitro and in vivo [303]. Given the 
complexities of NOTCH signaling both within and between cells, the observation of 
unexpected or adverse outcomes is unsurprising. Off-target Notch-associated effects in 
the early GSI trials for Alzheimer’s disease led to widespread gastrointestinal toxicity 
[304]. Nevertheless, DAPT holds great utility in the laboratory setting. 
The primary OSCC cell lines used previously, particularly including ECS positive lines, 
provided opportunities to investigate the biology of aggressive subtypes of OSCC. NGS 
studies of NOTCH1 on these cell lines had demonstrated one particular primary node+ 
ECS+ cell line containing the rs61751543 SNP. This is a rare non synonymous 
NOTCH1 extra cellular domain (NECD) polymorphism previously reported to be 
associated with other cancers [234] and found to be ‘possibly damaging’ on our earlier 
evolutionary functional analysis (section 5.3.3). This cell line (Liv7K) was chosen to 
examine further with regards its cellular biology related to aggressive behavior including 
cellular migration and proliferation. DAPT was chosen as a means of NOTCH pathway 
inhibition due to its ready availability with extensive supporting data in the literature. 
7.2 Hypotheses and aim 
Hypothesis: Inhibition of the Notch pathway by DAPT, a γ-secretase inhibitor, 
would result in decreased cell proliferation and migration in an ECS +ve cell line. 
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Aim: The aim was to assess whether Notch pathway interference mediated by γ-
secretase inhibition impedes cell growth and migration in both invasive and non-
invasive OSCC cell lines. 
 
7.3 Results 
7.3.1 Measurement of DAPT toxicity on OSCC cell lines 
 
Inhibitory concentration 50 (IC50) experiments to determine specific DAPT cell line 
toxicity was carried out as described in section 2.10.1 using the Liv7K cell line and 
DAPT incubation for either 24 hours or 72 hours with concentrations ranging from 10nM 
to 50μM in DMSO (DAPT solvent) at 0.5%. Absorbance values were then recorded 
using a spectrophotometer to assess cell viability. Figure 20. demonstrates the mean % 
absorbance compared to DMSO control readings from three repeats with standard 
deviation bars also shown. All concentrations of DAPT tested, over both time periods, 
provided absorbance readings that were not significantly different from each other with 
overall reading variation likely to be introduced by experimental error from preparation 
of serial dilutions. Cell cytotoxicity would have led to significant drops in recorded 
absorbance which was not observed. The mean absorbance for all obtained values for 
the 24-hour treatment was lower compared to the 72 hour treatment, consistent with a 
higher level of growth and proliferation with time giving a higher absorbance rate.  
7.3.2 The effect of DAPT on OSCC Cell proliferation 
 
Based on IC50 values and evidence from the literature of DAPT gamma secretase 
inhibitory efficacy over a prolonged period [305], a crystal violet cell proliferation assay 
was set up over 4 weeks with or without a DAPT concentration of 25 μM (in culture 
media that was replaced weekly) on OSCC cell lines. The optical density at 560nm was 
recorded each week (week 0, 1, 2, 3, 4) in triplicates (standard error of the mean 
shown), following adjustment for background, as a measure of cell proliferation being 
directly proportional to the number of viable cells at each time point.  Experiments were 
performed in triplicate with mean optical densities calculated for each time point. Figure 
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21. demonstrates that both invasive cell lines (BHY and Liv7K) showed impaired 
proliferation when incubated with DAPT from 2 weeks with final optical densities after 4 
weeks of 1.98 and 1.92 respectively (compared to controls of 2.33 and 2.32). On the 
other hand, H357, the non-invasive cell line, showed no significant difference compared 
to control at 4 weeks (2.32 v 2.31). 
 
 
Figure 20. Liv7K Cell Viability following exposure to varying concentrations of 
DAPT over different time periods. Graph represents values of DAPT concentration 
(µM) against mean % absorbance of DMSO control values obtained following 24 hour 
incubation (black) and 72 hour incubation (red). Concentration values from left to right 
correspond to 50, 10, 5, 1, 0.5, 0.1, 0.05 and 0.01 μM DAPT dissolved in 0.5% DMSO.  
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Figure 21. BHY(invasive), H357 (non-invasive) and Liv7k cell proliferation in the 
absence or presence of DAPT. The graphs illustrate crystal violet proliferation assay 
results following incubation of BHY cells for 4 weeks in the presence or absence of 
25μM DAPT (replenished on a weekly basis). Optical density at 560 nm readings were 
taken in triplicate and the mean (+/-SEM) is displayed. Recordings made with DAPT 
incubation are shown by the red line and control by black.  
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     7.3.3 The effect of DAPT treatment on NOTCH receptor expression  
 
To explore the effects of Notch inhibition on Notch receptor expression on OSCC 
cell lines, western blots were performed for Notch1-4 (method described on section 
2.11.2), extracted from the 3 cell line lysates (BHY, Liv7k and H357) on a weekly 
basis for 4 weeks, in the presence or absence of prolonged DAPT treatment (25 μM) 
administered weekly.  
 
Western blots for Notch1-4 on control cell lysates without DAPT treatment 
demonstrated the presence of NOTCH 1(size 125 kDa),3 (size 244 kDa) & 4 (size 
210 kDa) in BHY, Liv7K and only 3 & 4 in H357 lysates, but a complete absence of 
NOTCH 2 in all three cell lines (Fig. 22). In the light of this surprising finding, an 
instant blue stain was performed on the polyacrylamide electrophoresis gel prior to 
membrane transfer confirming presence of adequate separated protein products as 
well as a Ponceau Red stain of PVDF membrane confirming adequate and uniform 
protein transfer across different cell lines. To test NOTCH2 antibody functionality, 
HELA cell lysates in two different dilutions (1/500 and 1/1000) were used as a 
control alongside lysates from all 3 cell lines in the same experiment, confirming the 
ability of the antibody to detect NOTCH2 (Figure 23.). This suggested a possible 
deletion of NOTCH 2 in all cell lines examined. Of the detected Notch proteins (1, 3 
& 4) in these control conditions, no variation was observed in expression with time 
over the four-week period.  
 
Following DAPT treatment however, western blots for Notch1-4 on OSCC cell line 
lysates revealed a response only in invasive cell lines. A decrease in expression of 
NOTCH 1, 3 & 4 was observed in Liv7K cells, evidenced by absence of NOTCH1 
and 3 bands by week 3 and NOTCH 4 by week4 (Figure 22.). BHY cell lysates 
revealed an absence of NOTCH 4 expression by week 2 but no significant change in 
NOTCH 1 or 3 (Figure 22.). The non-invasive cell line H357 showed no difference in 
NOTCH 3 or 4 protein expression following DAPT treatment (Figure 22.). 
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Figure 22. Western blot of NOTCH 1–4 in A. BHY cell line B. H357 C. Liv7K cell 
line in relation to the presence/absence of DAPT. Western blots were performed on 
cell lysates in a conventional manner (section 2.11.2). Protein lysates were extracted 
weekly for upto 4 weeks duration with the cells either incubated with or without DAPT 
(25 µM). Experiments were performed in triplicate with representative blots shown 
above. β-actin was used as a loading control. 
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Figure 23. Western blot of NOTCH 2 in HELA cells and OSCC cell lines at differing 
antibody dilutions.  Experiments were performed in triplicate with representative blots 
shown above. β-actin was used as a loading control. 
 
 
These results demonstrate that DAPT inhibits NOTCH expression in invasive OSCC cell 
lines so it was assessed whether this was taking place through the expected inhibitory 
effects on the у-secretase. Western blots were performed in a similar manner to 
previously on all OSCC cell line lysates over 4 weeks but also over the shorter time 
frame of 24 hours, in the presence or absence of DAPT but using antibodies against 
amyloid precursor protein (APP). APP is an alternative protein target cleaved by у-
secretase (described previously in section 7.1.4. and expected to increase in expression 
if DAPT was exerting its inhibitory effects on NOTCH through у-secretase. APP western 
blot results for protein lysates from Liv7K cells are shown in Figure 24. as a 
representative example. Control HELA cell lysates confirmed the detection of APP at 
the expected fragment sizes (95 & 110 kDa fragments). Liv7K protein lysates in control 
conditions in the absence of DAPT showed no change in APP levels with time. DAPT 
treated cells also showed no difference in APP expression over 24 hours incubation, 
however a gradual APP increase did occur from weeks 2 - 4 compared to control. This 
supports the conclusion that the effects of the DAPT inhibitor observed on the Notch 
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pathway in earlier experiments are likely to be as a result of an inhibitory action on у-
secretase. 
 
 
Figure 24. Western blot of amyloid precursor protein (APP) on protein lysates 
from Liv7K cells in the presence or absence of DAPT. A. Western blots of Liv7K cell 
protein lysates (+/- DAPT 25 µM incubation) performed in a standard manner on lysates 
extracted from 0, 6, 12, 24 hour time points. Hela cells were used here as a positive 
control. B. Western blots of Liv7K cell protein lysates (+/- DAPT 25 µM incubation) 
performed in a standard manner on lysates extracted from weekly time points up to 4 
weeks. β-actin was used as a loading control for both blots. 
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7.3.4 The effect of DAPT on OSCC Cell line migration 
 
To assess the effect of NOTCH variation and pharmacological NOTCH inhibition on cell 
migration, a cell motility / migration assay was set up in the standard manner using a 
‘scratch assay’ monitored by phase contrast live imaging as previously described in 
section 2.10.6. BHY, H357 and Liv7K cells were assessed over a 60-hour period, either 
in the presence or absence of incubation with 25μM DAPT. Images were taken at 1-
hour intervals and initially inspected to assess qualitative differences. Images from the 
start of the experiment and end were then assessed by ImageJ software analysis for 
quantification of the extent of migration by calculating the mean % wound closure 
(triplicate experiments) for each cell line, in DAPT present and absent conditions (Figure 
25.). Liv7K showed the greatest final migration (80.4 %), followed by BHY (39.8%), 
(both invasive cell lines), followed by the non-invasive cell line H357 (9.1%). Liv7K cells 
were able to nearly completely close the ‘wound’ at the end of the 60-hour course of 
imaging, however a substantial decrease in cell migration was observed following DAPT 
incubation (Figure 25.) of Liv7K. Indeed, quantification of the effect of DAPT incubation 
on Liv7K migration revealed significant migratory inhibition (30.2% v 80.4%; p<0.05 on 
student’s t-test) but no significant difference was observed with DAPT on BHY or H357 
cells.  
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Figure 25. Migration assay observations for OSCC cell lines in the presence or 
absence of DAPT. Mean % wound closure with both treated (DAPT in 25 µM 
concentration) and untreated OSCC cell line cells (BHY, H357 and Liv7k) from 0 to 60 
hours is demonstrated. ImageJ quantification of % wound closure was performed on 
images recorded from all groups over 1 hour time points. Mean % wound coverage +/- 
SEM shown from 3 replicates. * = p<0.05 on Student’s t test compared to Liv7K without 
DAPT. 
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7.4 Discussion 
We compared invasive (BHY), non-invasive (H357) primary OSCC cell lines and a 
primary OSCC cell line with representative histopathology (node positive ECS positive) 
found previously by this study to have a rare form of extra cellular domain non-
synonymous polymorphism (rs61751543). The main aim was to assess whether Notch 
signaling inactivation, mediated by γ-secretase inhibition, impedes cell growth and 
migration by invasive and non-invasive OSCC cell lines and how Notch may thus play a 
role in the development of aggressive phenotype. Previous animal studies 
demonstrated that continued DAPT treatment at a concentration of 10µM maximally 
blocked Notch signalling after 28 days [305]. Pilot studies in our lab showed that DAPT 
at a 25 µM concentration for 72 hours did not significantly inhibit Notch activation in 
OSCC cell lines. Therefore, DAPT was administered here at 25 µM concentration for 28 
days. Insufficient opportunity was available for investigating the exact role of NOTCH1 
variants. However, OSCC cell proliferation, migration and Notch receptor expression 
following notch inhibition with DAPT, only decreased in invasive cell lines, suggesting 
the importance of Notch pathway activation for their behaviour. 
 
7.4.1 NOTCH1 variation and aggressive OSCC 
 
Proliferation assays in standard cell culture conditions (-DAPT) and for the time period 
examined, revealed no significant differences between BHY, Liv7K and H357 cells with 
all cell lines proliferating to the same level after a 4-week period. Migration was 
significantly different between the cell lines however with Liv7K displaying a significantly 
greater rate of migration compared to BHY, which was in turn greater than H357. Liv7K 
was already known to be associated with more aggressive behavior using migration 
assays [306]. As DAPT had no effect on BHY cell line migration, we speculated that this 
could either be due to the absence of NOTCH1 variants within the cell line or that the 
cell line may have been from an ECS-ve patient. The Notch genetic profile of BHY was 
undetermined and future studies sequencing NOTCH1 in both these cell lines would 
allow more definitive comparisons to be drawn. Western blot analysis in the absence of 
DAPT also revealed differential NOTCH receptor profiles between invasive and non-
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invasive cell lines with Liv7K and BHY demonstrating NOTCH 1, 3 and 4 expression but 
H357, although a non-invasive cell line, demonstrating an absence of NOTCH1, with 
NOTCH 2 absent from all cell lines. The absence of NOTCH1 within our negative 
controls confounded further interpretation of the effect of NOTCH1 variants. The 
absence of NOTCH1 from H357 that we detected would be in keeping with the literature 
as Yap et al. demonstrated a frameshift mutation in H357 which causes an eight-
nucleotide deletion, making NOTCH1 undetectable [189]. Given the phenotypic 
difference between H357 and Liv7K, there may be other pathways that contribute to 
their contrasting phenotypes.  
 
Surprisingly, Notch2 protein was absent from all of our cell lines. Protein lysate 
generated from Hela cells and the three cells were used for western blot using different 
NOTCH 2 antibody concentrations. Previous published studies with the same Notch2 
antibody had found normal detection by the antibody in Hela cells [307].  A strong band 
of Notch2 protein was produced from Hela cells using two different concentrations 
confirming absence of Notch2 from the oral cancer cell lines. Further investigation, such 
as by investigating whether NOTCH2 deletion is present within the DNA of these cell 
lines to account for the lack of Notch 2 protein observed, would need to be performed 
before coming to a definite conclusion. Interestingly, studies in the literature further 
highlight the possibility of opposing functions of NOTCH1 and NOTCH2. Using a Kras-
driven endogenous non-small cell lung cancer mouse model demonstrating NOTCH1 
deficiency led to a reduced early tumour formation and lower activity of MAPK 
compared with the controls but unexpectedly, NOTCH2 deletion resulted in dramatically 
increased carcinogenesis and increased MAPK activity [106]. A complex balance may 
exist in terms of differential Notch signalling in OSCC.  
The data here does not conclusively demonstrate the effects of NOTCH1 but provides a 
basis for further work. Rettig et al. combined genetic and expression analysis of HNSCC 
demonstrated three distinct staining patterns when using an antibody specific for Notch 
intracellular domain 1 (NICD1): positive/peripheral (47%), positive/nonperipheral (34%), 
and negative (19%) and NICD1 expression was found to be associated with NOTCH1 
mutation status (P < 0.001). Most NOTCH1-wild-type tumours were peripheral (55%), 
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whereas mutated NOTCH1 tumours were most commonly negative (47%). Interestingly 
nonperipheral tumours were more likely than peripheral tumours to have extracapsular 
spread. A further study of NICD1 by IHC in our ECS enriched OSCC cohort may prove 
useful in understanding any functional effects of NOTCH1 genetic variation in OSCC. 
 
7.4.2 Relation of Notch signalling to aggressive phenotype 
 
The importance of Notch signaling in contributing to an aggressive phenotype was 
supported by our experiments inhibiting Notch signaling with DAPT. Proliferation assays 
revealed a substantial decrease of both Liv7K and BHY cell growth by treatment with 
DAPT (25 µM) for four weeks compared to their respective control non-treated cell lines. 
Migration assays also showed differences with Liv7K cells (derived from an ECS +ve 
patient) displaying significant decreased cell migration as a result of DAPT treatment. 
However, BHY, an invasive cell line, was not affected. Furthermore, western blot 
analysis of NOTCH 1-4 following DAPT incubation revealed decreased expression of 
Notch 1 and 3 by week 3 and Notch 4 by week 4 in Liv7K cells but only Notch 4 by 
week 2 in BHY cells (H357 revealing no change in Notch receptor expression from 
DAPT). The differential findings between the two invasive cell lines, BHY and Liv7K, 
with regards both proliferation and Notch receptor expression could be due to either the 
level of Notch pathway activation within the cell line itself and/or the efficacy of the 
DAPT administered to actually inhibit Notch signaling. DAPT may not have worked as 
well on BHY cells.  As discussed earlier, H357 demonstrated an absence of NOTCH1 
on western blot analysis, potentially meaning DAPT may not have been able to display 
its full inhibitory effect on phenotypic assays (even in the light of NOTCH3 and 4 still 
being present).  
To conclude that DAPT was having its observed effects through the γ -secretase 
pathway and that our observed phenotypic effects were as a result of Notch signaling 
inhibition would require further experiments. Inhibition of γ –secretase activity, by DAPT 
was assessed by western blots analysis with an antibody directed against APP at two 
different time points. No significant differences between treated and untreated cells 
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were observed at early times but there was an increase in APP protein in treated cells 
by week 2 onwards suggesting successful γ-secretase inhibition by DAPT at this time 
point, corresponding to when effects were observed with regards proliferation and Notch 
receptor expression. Although there are previous studies which suggest that DAPT 
inhibition requires a prolonged time course of incubation, such as 28 days [308], other 
studies report a more rapid time frame for efficacy with one study reporting a 15 minute 
10µM incubation of DAPT in primary rat peritoneal mesothelial cells blocking 
transforming growth factor (TGF)-β1 induced Notch signaling activation [309]. In our 
study, inhibitory DAPT activity may have still been present in the early stages of DAPT 
incubation to explain our migratory assay observations (significant difference at 
60hours) but may have simply been of too low a magnitude to quantify by the resolution 
of western blotting.    
In summary, these experiments support but do not conclusively prove our original 
hypothesis that inhibition of the Notch pathway by a γ-secretase inhibitor would result in 
decreased cell proliferation and migration and support a role for Notch signaling in 
producing aggressive forms of OSCC. Although some studies suggest that when DAPT 
is administered in high concentration, cell death results [308] this was not our 
experience. Other studies have also previously revealed that down-regulation of Notch1 
expression by DAPT substantially inhibited cell growth, induced G1 cell cycle arrest and 
induced apoptosis in an ovarian cancer and lung squamous cell carcinoma cell lines in 
a dose and time dependent manner [216, 310]. This raises the question of whether cell 
cycle arrest was related to the cell growth inhibition observed in the OSCC cell lines in 
the present study and to address this question further, studies need to be performed, 
possibly using flow cytometry for cell cycle analysis, as well as potentially TUNEL assay 
to explore the mechanisms of apoptosis induced by DAPT in OSCC cell lines further.  
 
7.4.3 Future directions related to Notch 
 
Future studies would potentially benefit from the availability of more primary OSCC cell 
lines and their genetic characterization. Alternative inhibitory strategy to GSIs i.e. siRNA 
knockdown or monoclonal antibodies, to rule out off-target gamma secretase inhibitory 
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effects could also be performed. As downstream Notch receptor signaling targets have 
been demonstrated to be differentially expressed in HNSCC [136] and only Notch 
receptor expression levels were assessed here a valuable extension to the study could 
be Real-time PCR performed on the downstream NOTCH1 genes, HES1 and HEY1, as 
further markers of Notch pathway activation. This could be of particular significance as a 
recent study demonstrated that HES1 and HEY1 were overexpressed in HNSCCs 
(~31.8% cases) in comparison to expression levels in normal mucosa [215].  
Rather than being an exhaustive assessment of the relation of NOTCH1 to aggressive 
phenotype, our study was primarily a genomic study that explored the functional 
consequences of Notch signalling inhibition following the identification of a significantly 
greater number of NOTCH1 variants amongst an ECS-enriched cohort. Further 
transcriptomic, epigenetic and proteomic analysis of the same sample cohort could 
allow a wider ranging integrative means of analysis to better understand the role of 
Notch variants in ECS but also identify other potential drivers of aggressive phenotype 
in OSCC. These other drivers could either interact with Notch signalling or be 
independent of it. 
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8. Overview  
 
Extra-capsular spread from lymph nodes is a poor prognostic factor and one of the key 
hallmarks of aggressive phenotype in OSCC. Our SNP genotyping study in an ECS-
enriched local cohort found an association of TP53 and CCND1 allelic imbalance with 
nodal status but not ECS. With overall allelic imbalance rates being comparable with the 
literature for CCND1 (41%) but not TP53 (36%) which was lower than expected, 
suggesting the possibility of a unique subset of cases with cohort specific effects and 
the need for further mutational assessment. This was initiated by whole genome 
sequencing on primary OSCC cell lines which identified a number of key genes found to 
be significantly mutated within these samples (CDK11A, CDC27, CASP8). However, 
some uneven coverage in certain key gene areas (NOTCH1) was also observed. 
Contemporaneous sequencing studies as well as evidence that notch signaling may 
play a key role in the characteristics required for aggressive phenotype alongside our 
own WGS data pathway analysis, suggested NOTCH1 may be of importance. 
Furthermore, detection of a potentially deleterious FBXW7 missense variant suggested 
that Notch signalling was significantly affected in the cell lines assessed. Specific Ion 
TorrentTM sequencing for NOTCH1 and TP53 variants in primary OSCC tumour 
samples revealed 7 NOTCH1 novel nonsynonymous variants and 5 TP53 variants with 
overall mutational frequencies for NOTCH1 (17.5%) but not TP53 (12.5%) comparable 
with the literature. Furthermore, NOTCH1 variants were significantly associated with 
ECS (p<0.05) and the majority of variants corresponded to the ECD region of the 
NOTCH1 protein. Preliminary functional characterization showed that migration, 
proliferation and NOTCH isoform expression in an ECS+ve cell line, was significantly 
decreased by gamma secretase Notch pathway inhibition. 
 
8.1. Importance of CCND1 for ECS 
 
Frequent gain of CCND1 has been observed exclusively in OSCC patients with cervical 
lymph node metastasis [130]. A study of 164 OSCC cases showed that CCND1 allelic 
imbalance is an independent predictor for worse survival in OSCC in HPV negative 
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cases and a promising biomarker for predicting lymph node metastasis in patients with 
clinically Stage I–II OSCC. [154]. However, a study using FISH to assess CCND1 and 
EGFR copy number aberration in 127 primary OSCC cases demonstrated EGFR copy 
number aberration, but not CCND1, to be associated with ECS [58]. Other studies have 
demonstrated CCND1 amplification detected by q-PCR to be present in 50% of OSCC 
samples but not associated with lymph node metastasis [153]. In our study, we did 
observe an association with nodal status but not ECS.  
 
One explanation for lack of association with ECS could be as a result of undetected 
micro metastases present in node negative samples [311]. Alternatively, as CCND1 is 
required for progression through the G1 phase of the cell cycle [312] and predominantly 
affects cellular proliferation it may be less vital to drive invasion. CCND1 amplification is 
likely to be an early event in oncogenesis with a FISH study on OSCC tumour samples, 
lymph node metastases, oral leukoplakia (OLK) and oral lichen planus (OLP), finding 
CCND1 amplification in a higher proportion of OSCC and lymph node samples than in 
OLK and OLP samples, but no significant difference between OSCC & lymph node 
samples [135].  
 
8.2 Importance of TP53 for ECS 
 
TP53 copy number alteration was associated with nodal status of OSCC, but next 
generation sequencing demonstrated that TP53 genetic variants are rare in our subset 
of OSCC cases in contrast to the literature. TP53 deletion [135] and loss of 
heterozygosity (LOH) [155] have been previously reported to be prevalent in OSCC with 
NGS studies revealing it to be consistently the most heavily mutated gene in OSCC 
[21]. OSCC patients carrying TP53 mutations have reduced survival compared to those 
with a wild-type status [263, 313] and furthermore the carriage of missense mutations in 
the TP53 DNA binding domain was associated with decreased disease-specific survival 
compared with wild-type TP53 in a cohort of 345 OSCC patients [314]. Our lack of TP53 
variation was borne out through analysis of both known and unknown TP53 variants 
and further study of the existing literature supports the possibility of a genuine subset of 
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NOTCH1 mutant TP53 wild-type cases as observed within our ECS enriched cohort. 
Indeed, a recent systematic review of TP53 as a prognostic factor in HNSCC’s four 
main anatomical subsites (larynx, oropharynx, hypopharynx, oral cavity) demonstrated 
large heterogeneity in study-level and patient-level characteristics, making it difficult to 
ascertain a clear picture [315]. The significance of the low level of TP53 variation 
amongst our cohort of ECS-enriched cases remains unclear and further sequencing 
studies with larger sample sizes may shed further light. 
 
8.3 Importance of Notch for ECS 
 
We found significant association of Notch pathway signaling by WGS of primary OSCC 
cell lines alongside significantly greater NOTCH1 variants associated with ECS. 
Variants were predominantly clustered in regions coding for the extracellular domain of 
the NOTCH1 gene. This finding was initially observed on the basis of Ion TorrentTM 
sequencing but was further confirmed by bioinformatics re-analysis and validation of 
detected variants by Sanger sequencing, suggesting that Notch could be having a key 
role in the development of ECS. DAPT inhibition of proliferation, migration and 
differential Notch protein expression suggested that Notch signaling may be important 
for the behavior of these cells. Our observations indicate that NOTCH1 is more likely to 
be acting as an oncogene in our patient cohort, but further studies to elucidate the 
functional effects of NOTCH1 ECD variants are required. 
 
The majority of variants identified in this study were found within the EGF repeat 
domain, as already evidenced in other squamous cell carcinoma settings in the 
literature [102, 268], and have been predicted to be mostly inactivating by disruption of 
ligand binding. However, insights gained on Notch-ligand interactions from drosophila 
studies may help explain our oncogenic findings. Studies support contrasting canonical 
Notch–ligand interaction modes. Trans ligand-receptor binding may occur to initiate 
Notch signaling [316]. Alternatively, cis inhibitory ligand-receptor binding as a result of 
ligand expression on the same cell surface as the receptor may limit Notch activity 
[317]. Although these differing modes of interaction are established, the molecular basis 
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for activating and inhibitory complexes is poorly understood. Notch EGF 11–12 and the 
DSL domain residues interact to promote Notch trans-activation, however, the 
molecular requirements for cis-inhibitory interactions are less clear. Early studies 
proposed that the Abruptex region of the Notch receptor (EGF24–29) might be involved 
in cis interactions [221], but a further study demonstrated that the Notch EGF 10–12 
region is also required for cis-inhibition [318]. Three of our variants fell within exonic 
regions encoding these protein domians of the Notch receptor so it remains possible 
that our ECD detected variants may have interfered with Notch-ligand cis-inhibition in a 
manner that allowed the predominant activation of Notch signaling. 
 
There remains a need for improved patient prognostication and assessment for OSCC 
management. Treatment for OSCC depends on the location of the primary tumour, the 
stage of the disease, and the expected oncological and functional outcomes [24]. Early-
stage (I/II) HNSCC only requires single-modality therapy (i.e. surgery or radiotherapy), 
whereas locally advanced disease (AJCC stage III/IV) requires various combinations of 
radiotherapy, surgery, and chemotherapy or cetuximab [4]. Present survival rates for all 
patients with HNSCC are approximately 40% to 60% at 5 years [319] and there remains 
a significant under staging of disease by current imaging modalities [306]. Notch 
analysis may help as a biomarker for prognostication, with patients detected to have 
Notch mutations undergoing more stringent and multi-modal imaging assessment as 
well as further genetic characterisation, such as TP53. 
 
Activating mutations in classic oncogenes are relatively rare in OSCC, most genetic 
alterations occurring in tumour suppressor genes, limiting opportunities for targeted 
therapies and restoring the activity of altered tumour suppressor genes like p53 or 
CDKN2A is extremely challenging [320]. While studies directly inhibiting Notch signaling 
in OSCC e.g. by GSIs remain to be reported, targeting non-canonical Notch signaling 
may hold great promise for novel treatment strategies. A US group are presently 
conducting (NIH National Cancer Institute NCT02649530) a Phase II clinical trial of 
WNT974 in patients with recurrent, metastatic or advanced stage HNSCC, with one of 
the tertiary objectives being to explore the response to therapy based on NOTCH 
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receptor mutational status, as well as assess expression of NOTCH and WNT pathway 
gene sets prior to therapy. As previous studies have demonstrated an enriched rate of 
response to WNT974 in cell lines harboring a NOTCH1 mutation. Thus, selection of 
appropriate management strategies on the basis of NOTCH variant status may 
potentially benefit treatment options in a number of ways. Only a minority of patients 
benefit from anti-EGFR monoclonal antibodies, and the objective response rate in 
monotherapy is between 6% and 13% [321]. Due to the negative regulation of Notch 
signalling by EGFR, cetuximab may show greater response in tumours carrying NOTCH 
variants associated with poor outcome. Alternatively, combination treatments of 
cetuximab with targeted Notch therapy may improve survival. Finally, information 
provided by both TP53 and NOTCH variant status may allow the more effective use of 
combinations of multi-modal therapy or more aggressive single mode therapy for cases 
of disease that would have otherwise been undertreated without genomic information 
predicting ECS and aggressive phenotype. 
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8.4 Limitations and Future Directions 
 
Our initial sample size was determined by the availability of samples locally and power 
calculations based on expected mutational frequencies from the literature, however our 
study would benefit from increased sample size and specifically the inclusion of more 
node positive ECS negative cases. In our assessment of allelic imbalance, 24 samples 
for TP53 and 9 samples for CCND1 had to be excluded because of homozygosity and 
10 samples were excluded from NGS analysis of NOTCH1 and TP53 due to resultant 
low sequence coverage. Additional samples may potentially indicate differences 
between all 3 histopathological subgroups, increase significance of notch to ECS and 
identify whether there are extracellular domain hotspots of mutation. Matched normal 
DNA would provide the required information to call ‘mutations’ as opposed to ‘variants’. 
Our analysis would also have benefited from more primary OSCC cell lines with a 
greater variety of novel ECD variants as well as further node negative and node positive 
control cell lines to compare.  
Ligand binding assays and/or co-immunoprecipitation assays on OSCC cell lines with 
known NOTCH1 ECD variants would allow a further understanding of the mechanistic 
changes that variants could have on the notch receptor-ligand interaction. Transfection 
studies of wild type or mutant NOTCH1 (carrying an ECD variant) into primary OSCC 
cell lines would be beneficial to demonstrate the functional effects of variants. 
Specifically, co-expression of mutant and wild type notch with N or C terminal 
fluorescent protein tags in the same cell in vivo could be used to compare rates of 
processing. 
8.5 Conclusion 
Extracapsular spread from lymph nodes is a key poor prognostic marker in OSCC and 
present imaging modalities are too poor to identify it reliably pre-operatively. This study 
has identified a unique subset of ECS positive OSCC cases harboring a low rate of 
TP53 mutation along with significantly elevated levels of NOTCH1 variants within the 
extracellular domain. Our findings suggest that the downstream effects of NOTCH1 
ECD mutations and their potential role in OSCC should be further explored as Notch 
may be a key driver of ECS in OSCC.   
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Appendix 1: 
Abstract arising from this thesis presented at the National Cancer Research Institute 
Conference, Liverpool, November 2016  
& also published in the European Journal of Surgical Oncology (November 2016 
edition) 
 
NOTCH1 Mutations and Extracapsular Spread from Oral Squamous Cell 
Carcinoma Lymph Node Metastasis  
Bhattacharya P. 1, Risk J.M. 1, Dhanda J. 1, Shaw R.J. 1,2, Lloyd B.1, Sibson R.1 
1Dept Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of 
Liverpool, Liverpool, L69 3GA. U.K.; 2 Regional Maxillofacial Unit, Aintree University Hospitals 
NHS Foundation Trust, Liverpool,UK  
 
Background: The most adverse prognostic predictor for Oral Squamous Cell 
Carcinoma (OSCC) is Extracapsular Spread (ECS)) from lymph node metastasis, which 
needs further molecular characterization. 
Methods: Next Generation Sequencing compared TP53 and NOTCH1 mutations in 
OSCC primary tumour samples (n=50; 21 node negative [N-], 11 [N+ECS-], 18 [N+ECS-
]).  Sanger Sequencing independently validated candidate variants. Primary OSCC cell 
lines were chosen according to NOTCH1 variant status.  Their cell growth and migration 
were compared following treatment with the γ-secretase inhibitor DAPT (N-[N-(3,5-
difluorophenacetyl)- L-alanyl]-S-phenylglycine t-butyl ester), used for Notch inhibition. 
Results: Data from 40/50 OSCC samples was included following quality control 
screening for average coverage. Known intronic and exonic variants (1000 Genomes) 
were found plus 14 NOTCH1 non-synonymous variants in 13 OSCC samples and 7 
non-synonymous TP53 variants. 9/14 [N+ECS+] samples had NOTCH1 variants, 
compared to TP53 (2/14 of [N+ECS+] samples). Sanger Sequencing confirmed 57% of 
all variants with a rate of 7/40 (17.5%) for NOTCH1. 6/14 (43%) ECS+ samples had 
confirmed NOTCH1 variants compared to 1/26 (3.8%) ECS-, Fisher’s exact test p = 
0.0044.  Variants clustered in the N-terminal, extracellular EGF-like repeat region.  
In vitro, decreased cell growth and migration was observed after DAPT (25 µM) 
treatment for four weeks compared to controls. Western blot analysis for Notch proteins 
revealed absence of Notch1 and 3 after 3 weeks and Notch4 by week four. 
Conclusion: Overall rates of NOTCH1 mutations in our OSCC cohort were consistent 
with recent literature and NOTCH1 may be a key driver of ECS in OSCC.   
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Supplementary 
data CD 
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INDELs with potential 
functional effects 
2 Complete list for unknown 
synonymous variants 
3 Complete list of Unknown 
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4 Complete list of genes for 
pathway analysis 
5 Pathway analysis data 
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Appendix 3: 
Reagent / Kit Manufacturer Catalogue Number 
AllPrep DNA/RNA/Protein Mini 
Kit 
Qiagen 80004 
QIAquick PCR Purification Kit  Qiagen 28104 
Agarose Seakem LE Fisher Scientific BMA 50002 
SYBRsafe Invitrogen S33102 
1kb Ladder  NEB N3232S 
100 bp Ladder NEB N3231S 
DNA 1000 kit  Agilent 50671504 
Taqman assay universal PCR 
mastermix Amplitaq (R) Gold 
DNA polymerase 
Biorad 4304437 
Dulbecco’s Modified Eagle's 
Medium  
Sigma Aldrich D5796 
TrypLE Express GIBCO 12406-013 
Cell freezing medium  Sigma C6295 
DAPT (N-[N-(3,5-
difluorophenacetyl)- L-alanyl]-S-
phenylglycine t-butyl ester)  
Sigma-Aldrich D5942 
Phosphate buffered saline  Sigma D8537 
Long Range PCR kit Qiagen 206402 
Ion shear plus reagents -  Life Technologies 4471248 
Hot star Taq plus DNA 
polymerase enzyme  
Qiagen 203605 
Platinum PCR Super mix high 
fidelity 
Invitrogen  12532-016 
OneTouch Reagent Mix Life Technologies 4468660 
The Ion PGM 200 Sequencing 
Kit  
Life Technologies 447400 
EXOSAP-IT  Usb 78200 
DYEnamic ET dye terminator kit  GE healthcare  
SOLiD Fragment Library 
Construction Reagents  
Applied Biosystems 4443713 
Egel  Invitrogen G661002 
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Reagent / Kit Manufacturer Catalogue Number 
EZ4U Cell Proliferation and 
Cytotoxicity Assay 
Biomedica Gruppe BI-5000 
Halt Protease Inhibitor cocktail  Thermo Fisher Scientific JI120584 
Bradford ULTRA  Novexin BFU05L 
10% precast polyacrylamide gel  Bio-Rad 456-1033EDU 
NOTCH1 primary antibody  Abcam ab52627 
NOTCH2 primary antibody Abcam ab137665 
NOTCH3 primary antibody Abcam ab23426 
NOTCH4 primary antibody Abcam ab134831 
Horseradish peroxidase 
conjugated rabbit secondary 
antibody  
Amersham, GE Healthcare NA934 
Horseradish peroxidase 
conjugated mouse secondary 
antibody  
Amersham, GE Healthcare NA931 
Amyloid beta precursor protein 
antibody  
Abcam ab32136 
β-actin antibody  Abcam ab8227 
Chemiluminescence  GE Healthcare RPN2108 
 
 
